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Abstract  
RNA-binding proteins (RBPs) are a highly regulated, evolutionarily conserved and 
functionally distinct family of proteins involved in key RNA metabolic processes. The 
RNA-binding motif protein RBM5 is an anti-proliferative, pro-apoptotic, putative tumor 
suppressor. A paralogue of RBM5, RBM10, which shares 50% identity with RBM5, 
functions in development. RBM5 and RBM10 are spliceosomal components involved in 
alternative splicing. RBM5 and RBM10 are ubiquitously expressed with higher levels in 
muscle (heart and skeletal) and pancreas. Most of the studies on RBM5 and RBM10 have 
been focused on cancer cells. Several factors such as 1) abundance in muscle, 2) 
developmental and temporal regulation, 3) alternative splicing activity and 4) association 
with functional events related to muscle development led us to hypothesize that both 
RBM5 and RBM10 are involved in skeletal muscle differentiation. The mechanism of 
action through which these two RBPs effect differentiation is hypothesized to involve 
alternative splicing of muscle differentiation-specific mRNAs. RBM5 and RBM10 
expression and intracellular distribution was analyzed during muscle differentiation in the 
C2C12 murine model using qPCR, end-point PCR, immunoblotting and confocal 
microscopy. Also, RBM5 and RBM10 levels were transiently down-regulated using 
siRNA either separately and/or together and the associated changes in cell phenotype, 
expression of myogenic proteins plus a few alternative splicing events were analyzed. We 
observed a decrease in RBM5 and RBM10 protein expression levels in the differentiated 
myotubes compared to the myoblasts and myocytes, which indicates a time-dependent 
potential regulatory role during differentiation. Further, changes in RBM5 and RBM10 
protein expression without modulating the levels of mRNA variants suggests post-
transcriptional and/or post-translational regulation. Stage-specific differential localization 
suggests multiple functions related to mRNA biogenesis. RBM5-depleted cells showed a 
reduction in the total cell number during differentiation, and exhibited a delay in 
differentiation, fusion and maturation with down-regulated expression of myogenin and 
myosin heavy chain (MyHC). This implies that RBM5 is necessary to maintain the cell 
population to execute the myogenic differentiation process in a timely manner. RBM10-
depleted cells showed an increase in total cell number immediately after transfection, and 
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exhibited a delay in differentiation with a decrease in inclusion of exon 11 in Dtna 
mRNA. This indicates that RBM10 is required to maintain the necessary cell population 
before induction and acts as a splicing regulator during differentiation. RBM5- and 
RBM10- depleted cells differentiated and matured slowly, and had an increase in Mef2c γ 
exon inclusion. Therefore, these two RBPs are associated with the alternative splicing of 
Mef2cγ during differentiation. This is the first study to analyze the expression and the 
function of these two RBPs in a murine skeletal muscle differentiation model, and has 
implicated them in myogenesis, paving a way for further characterization. Future studies 
can investigate the involvement of RBM5 and RBM10 in disease states such as muscular 
dystrophy and rhabdomyosarcomas, given the known functions of RBPs in tumorigenesis 
in other cell types. 
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Chapter 1  
  
1 Introduction  
1.1 RNA-Binding Proteins 
During RNA biogenesis, multiple factors are involved in regulating all of the steps from 
generation to degradation of mature mRNA transcripts. One of the major factors involved 
in this control are the RNA-binding proteins (RBPs). RBPs bind to nascent transcripts to 
form ribonucleoprotein complexes (RNPs). These RNPs are essential components in many 
RNA metabolic processes including splicing, capping, polyadenylation, transport, 
localization, stability and translation (Glisovic et al., 2008). The predominant mechanisms 
of RNP activity are post-transcriptional control, which is accomplished by (a) binding of 
RBPs to the 3’ or 5’ untranslated regions (UTR) of RNA leading to transcriptional 
repression or activation, and (b) RBPs acting as splicing factors leading to alternative 
splicing of mRNAs, thereby resulting in expression changes of important genes (Kishore et 
al., 2010). Thus, RBPs play an important role in RNA metabolism by regulating a number 
of gene expression changes in a cell.  
RBPs are highly significant, evolutionarily conserved and functionally relevant amongst 
species. Most of the functions of RBPs are in developmental processes, specifically, in 
germ-line and early embryo development (Naryzhny et al., 2006, Colegrove-Otero et al., 
2005). They are also involved in the development of neuron, muscle, hypodermis and 
excretory cells and determine the timing of development (Lee and Schedl, 2006). 
Additional associated functions of RBPs are in cell attachment, cell migration, cell cycle 
checkpoint control, DNA damage responses and miRNA biogenesis (Lunde et al., 2007). 
Because RBPs are implicated in multiple cellular events, it is not surprising that their 
expression is highly regulated. It is worth highlighting that altered expression, mutation and 
improper functioning of RBPs can cause cancer (Kim et al., 2009, Wurth, 2012), muscular 
atrophies (Lukong et al., 2008), cardiovascular diseases (Musunuru, 2003) and 
neurodegenerative diseases (Lukong et al., 2008). 
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There are close to 860 RBPs in humans (Castello et al., 2012) and many of them are 
associated with major cellular processes. Cell-specific RBPs are required for regulation of 
cell growth, proliferation, differentiation, and development and are spatio-temporally 
regulated (Kishore et al., 2010). Two such important RBPs are the RNA-binding motif 
proteins RBM5 and RBM10. These two proteins are implicated in many processes 
including cell proliferation and apoptosis in tumor cells.  
1.2 RBM5 
The RBM5 gene, first cloned as Gene15 (Wei et al., 1996), is located on chromosome 
3p21.3 and encodes the RBM5 protein. RBM5 was originally identified as one of the 19 
genes belonging to the tumor suppressor locus that is deleted in lung carcinomas (Timmer 
et al., 1999). RBM5 is also known as LUCA-15 (Drabkin et al., 1999) and H37 (Oh et al., 
1999). 
1.2.1 Alternatively spliced variants 
A number of alternatively spliced variants have been identified for RBM5 (Figure 1.1). 
Full-length human RBM5 mRNA variant (NM_005778.3) is approximately 3kb containing 
25 exons. This variant encodes an 815 amino acid (aa) RBM5 isoform with a molecular 
weight of ~113 kDa. Deletion of exon 6 produces the RBM5r6 variant, which encodes a 
~17 kDa isoform due to a frame-shift mutation (Mourtada-Maarabouni et al., 2003). Two 
other variants retain introns: RBM5+5+6 retains introns 5 and 6; and, RBM5+6 retains 
intron 6. Both of these variants putatively encode ~17 kDa and 21.5 kDa proteins, 
respectively, however the transcripts could be destroyed by non-sense mediated decay 
(NMD) (Sutherland et al., 2005). A truncated transcript of RBM5+5+6, termed 
RBM5+5+6t or clone26, so named because of the presence of stop codon at intron 6, has 
also been identified (Sutherland et al., 2000, Sutherland et al., 2005). A non-coding RNA of 
antisense orientation termed RBM5-AS1 (previously termed LUST) is a 1.4kb fragment, 
antisense to introns 6 to 4 (Rintala-Maki and Sutherland, 2009). This fragment also 
includes Je2, a 326bp sequence initially identified in bone marrow by Sutherland et al. 
(2000). Therefore, generation of various transcripts by alternative splicing shows that 
RBM5 undergoes post-transcriptional modifications. 
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The mouse Rbm5 full-length variant (NM_148930.3) is 3104bp long. The cDNA is 90% 
and the protein is 97% identical to human RBM5. Using end-point PCR, Ozuemba (2011) 
identified that homologs to the human RBM5 variants RBM5, RBM5+6, RBM5+5+6 and 
RBM5-AS1 were present in mouse tissues such as brain, skin, skeletal muscle and heart. 
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Primers used in qPCR  
 
siRBM5 (siRNA), target site (end of exon 4 and beginning of exon 5) 
 
Antibody, LUCA-15UK 
Start and stop codons  
 
 
 
Gene-specific primer (mFactorXF) used in reverse transcription  
Figure 1.1 The various alternatively spliced human RBM5 mRNA variants. Diagram 
illustrating the alternatively spliced variants of RBM5 with the start and stop codon positions 
in the protein coding sequence. The antisense variant RBM5-AS1 is not included here. 
Location of primers used in reverse transcription and qPCR, antibody and siRNA used in this 
study are indicated schematically. Primers and siRNA were designed using mouse-specific 
Rbm5 mRNA sequence (NM_148930.3). Not drawn to scale. Adapted from Sutherland et al., 
2005. 
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1.2.2 RBM5 function 
RBM5 functions as a pro-apoptotic, anti-proliferative, putative tumor suppressor. It has 
been observed that changes in RBM5 expression affected approximately 35 genes 
associated with apoptosis and cell proliferation (Maarabouni and Williams, 2006). RBM5 is 
a putative tumor suppressor, particularly in lung carcinoma (Sutherland et al., 2010). RBM5 
is one of the 19 genes (370kb) undergoing allelic loss and homozygous deletion in lung 
cancer (Timmer et al., 1999). A recent study identified RBM5 as an important component 
in spermatid differentiation (O'Bryan et al., 2013). RBM5 was purified along with 
spliceosomal B complexes demonstrating that it is one of around 200 proteins involved in 
pre-mRNA splicing (Schmidt et al., 2014).  
1.2.2.1 Apoptosis 
Apoptosis, or programmed cell death, is a major player in tumorigenesis. Cancer cells 
evade apoptosis by up-regulating expression of anti-apoptotic proteins and down-regulating 
expression of many pro-apoptotic related proteins. When the full-length RBM5 was 
experimentally overexpressed in A549 cells (human alveolar basal epithelial 
adenocarcinoma) (Shao et al., 2012), Jurkat cells (human T-cell leukemia) (Sutherland et 
al., 2000), MCF-7 cells (human breast adenocarcinoma) (Rintala-Maki et al., 2004) or PC3 
cells (human prostate cancer) (Zhao et al., 2012), the cells died of apoptosis. In A549 cells, 
RBM5 regulated apoptosis by up-regulating the expression of the apoptotic protein Bax 
(Shao et al., 2012). When RBM5 was overexpressed in cisplatin-resistant A549/DPP cells, 
induction of apoptosis was through the mitochondrial intrinsic apoptotic pathway involving 
Cytochrome-c, Caspase-3 and Caspase-9 activation (Li et al., 2012). In Jurkat cells, RBM5 
overexpression led to apoptosis by activation of the extrinsic pathway via Fas, TNF-α and 
TRAIL (Sutherland et al., 2000). In MCF-7 cells, apoptosis was induced through the TNF-
α mediated pathway (Rintala-Maki et al., 2004). In PC3 cells, overexpression of RBM5 led 
to apoptosis by increasing the expression of p53, B3H-only proteins, cleaved Caspase-3 
and cleaved Caspase-9 (Zhao et al., 2012). RBM5 up-regulated the expression of BH3-only 
proteins, Bim, Bid and Bad, which affected the mitochondrial membrane potential and 
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triggered the mitotic apoptotic pathway. Thus, up-regulated RBM5 expression in tumor 
cells promotes apoptosis, thereby inhibiting tumor progression. Similarly, when RBM5 was 
overexpressed in vivo, there was increased apoptosis in lung adenocarcinoma xenografts 
(Shao et al., 2012). 
A recent study identified a mis-sense mutation in RBM5, which affected its ability to bind 
various mRNA targets, consequently resulting in male sterility in mice (O'Bryan et al., 
2013). This mutation of arginine to proline at the 263 amino acid position (R263P) caused 
testicular atrophy, spermatid differentiation arrest and sloughing of germ cells due to the 
loss-of-function allele. Besides affecting expression of many genes involved in these 
pathways, the RBM5 mutant activated the Caspase pathway; the levels of cleaved Caspase-
3 and Caspase-9 were high leading to apoptosis and sloughing of the male germ cells.  
Interestingly, the alternatively spliced variants of RBM5 were able to differentially regulate 
the expression of major apoptotic genes resulting in different effects (Maarabouni and 
Williams, 2006). The variants hold significant functions in tumorigenesis. As explained 
above, full-length RBM5 is pro-apoptotic, however, RBM5r6 (Mourtada-Maarabouni et 
al., 2003) and RBM5-AS1 (Je2 cDNA antisense fragment) (Mourtada-Maarabouni et al., 
2006) are anti-apoptotic. Overexpressed RBM5-AS1 decreased the expression of full-length 
RBM5 and changed the expression of six apoptotic genes in CEM-C7 cells (Mourtada-
Maarabouni et al., 2006). For example, RBM5-AS1 expression up-regulated the expression 
of Bax, down-regulated the expression of BCL-2 and BCL-XL, increased the release of 
Cytochrome-c and increased the activation of Caspase-9 and Caspase-3 (Mourtada-
Maarabouni et al., 2006). In CEM-C7 and Jurkat T- cells, RBM5-AS1 overexpression 
inhibited apoptosis via the Fas and TNF-α mediated extrinsic apoptotic pathway 
(Mourtada-Maarabouni et al., 2001, Sutherland et al., 2001). In contrast, overexpression of 
RBM5+5+6t is cytotoxic and in Jurkat cells leads to Fas-mediated apoptosis (Sutherland et 
al., 2000) indicating that this variant has similar functions to the full-length RBM5.  
1.2.2.2 Cell cycle arrest and cell proliferation 
Most tumor suppressors are negative regulators of cell growth. RBM5 has an anti-
proliferative function in tumor cells. When RBM5 was overexpressed in human breast 
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cancer cells, NCI-H740 (small cell lung cancer), H1299 (non-small cell lung carcinoma), 
A9 (mouse fibroblasts) and HT1080 (human fibrosarcoma) cells, there was growth 
suppression indicating anti-proliferative functions (Kobayashi et al., 2011). There was also 
a significantly lower proliferation index in RBM5 transfected PC-3 cells (Zhao et al., 
2012). Cell proliferation and cell cycle arrest are associated events. Cell proliferation is 
associated with initiating the cell cycle by activating the early events in G1 (Berridge, 
2007). RBM5 causes cell cycle arrest in G1 when overexpressed in CEM-C7 cells 
(Mourtada-Maarabouni et al., 2003). In A549 cells, the effect of RBM5 overexpression was 
through down-regulating expression of Cyclin A and retinoblastoma proteins leading to cell 
cycle arrest at G1 (Shao et al., 2012). When RBM5 was overexpressed in H1299 cells, 
suppression of cell growth was mediated via the p53 pathway (Kobayashi et al., 2011). 
Accordingly, RBM5 overexpression prevented formation of tumors in nude mice and 
inhibited the growth of human breast cancer cells and A9 mouse fibrosarcoma cells (Oh et 
al., 2002). Thus, both in vitro and in vivo, the effects of RBM5 indicate tumor specific anti-
proliferative functions.  
1.2.2.3 Splicing regulation 
One way of modulating protein expression is by alternative splicing of mRNA. As stated 
earlier, most RBPs are associated with post-transcriptional regulation by controlling 
alternative splicing because of their RNA-binding capacity. The function of RBM5 in 
regulating alternative splicing is confirmed by target identification and binding studies. 
RBM5 interacts with spliceosomal A complex (Bonnal et al., 2008, Fushimi et al., 2008). 
Specifically, RBM5 is associated with spliceosomal complexes such as U2AF65 and 
U2AF35. RBM5 controls splice-site pairing and directly binds to pre-mRNA (Bonnal et al., 
2008). RBM5 is a component of spliceosomal B complex (Schmidt et al., 2014). 
Besides affecting expression of apoptotic genes, RBM5 is shown to alternatively splice a 
few other apoptotic-related mRNAs. RBM5 is involved in the exclusion of exon 9 of 
CASP-2 by binding to a splice site in intron 9 (Fushimi et al., 2008). RBM5 has also been 
shown to regulate the exclusion of exon 6 in FAS and the exclusion of exon 7 in c-FLIP 
(Bonnal et al., 2008). When RBM5 was overexpressed in HeLa cells it induced alternative 
splicing changes in activation-induced cytidine deaminase (AID) such as skipping of exon 
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4 by inhibiting the splicing of intron 3, as RBM5 possibly competes with the U2AF65 and a 
weak U2AF35 binding site at the 3’ splice site of the mRNA (Jin et al., 2012). RBM5 is 
involved in regulating the alternative splicing of abscisic acid-insensitive3 (ABI3). 
Specifically, RBM5 decreases splicing of ABI3-β and increases splicing of ABI3-α, which 
is important for seed maturation in Arabidopsis thaliana (Sugliani et al., 2010). RBM5 is 
also involved in skipping exons 40 and 72 of the Dystrophin mRNA in humans (O'Leary et 
al., 2009). RBM5 is a splicing regulator in spermiogenesis (O'Bryan et al., 2013). RBM5 
bound to many splicing regulators such as the hnRNPs (heterogeneous nuclear 
ribonucleoproteins) hnRNP A2/B1, hnRNP K, hnRNP M and hnRNP UL1, the SR proteins 
(serine/arginine-rich splicing factor) SFRS1/ASF/SF2 and PSIP1, the splicing factor SFPQ, 
and the RNA helicase DDX5 and U1A, implicating a role in mRNA splicing during 
spermatid differentiation. In addition, other protein-binding partners included 
polyadenylate-binding protein 1 (PABP1), DEAD box helicase 4 (DDX4), paraspeckle 
component 1 (PSPC1) and embryonic lethal abnormal vision-like protein 1 (ELAV1), 
implying a role in RNA metabolism during sperm development. The pre-mRNAs that are 
spliced significantly by the R263P mutant were suppression of tumorigenicity 5 (St5) 
(increase in exon 3 skipping), ankyrin repeat and SOCS box containing 1 (Asb1) (exon 3 
and exon 4 skipping) and phospholipase A2, groupX (Pla2g10) (intron retention). 
Apparently, RBM5 was involved in promoting exon inclusion in a variety of mRNA. 
Besides these functions, RBM5 was down-regulated in metastasis, especially in stage I 
solid tumors (Ramaswamy et al., 2003). In lung and breast epithelial cells (BEAS-2B, 
MCF-10A), as well as in lung cancer cells (A549), knocking down RBM5 up-regulated 
proteins involved in cell adhesion, migration and motility such as Rac1, β-catenin, collagen 
and laminin, promoting metastasis (Oh et al., 2010). Thus, an additional function in 
metastatic processes has been suggested for RBM5. 
1.2.3 RBM5 expression profile 
RBM5 is ubiquitously expressed in human primary tissues, with the highest expression in 
heart, skeletal muscle and pancreas (Drabkin et al., 1999). Tissue-specific and spatio-
temporal expression was observed; for example, RBM5 expression was high in adult 
thymus and fetal kidney but was lowest in fetal thymus and adult kidney (Drabkin et al., 
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1999). Further, RBM5 levels were higher in adult thymus than in fetal thymus, higher in 
fetal kidney than in adult kidney and higher in older fibroblasts and cultured lymphocytes 
than in younger cells (Geigl et al., 2004). This shows that RBM5 expression is 
developmentally regulated. A recent study showed that the expression level of Rbm5 was 
highest in adult mouse testis, followed by ovary and brain, when compared with the levels 
in epididymis, uterus, kidney, lung, spleen, skeletal muscle, stomach and liver (O'Bryan et 
al., 2013). This group also reported that RBM5 is expressed in somatic, germ and 
differentiating cells, such as spermatogonia, spermatocytes and round spermatids. A recent 
report by Loiselle and Sutherland (2014) using H9c2 rat myoblasts revealed that RBM5 
was expressed in skeletal and cardiac lineage specific differentiation.  
As previously mentioned, alterations in gene expression characteristically reveals 
association with many diseased states. RBM5 is no exception. Aberrant expression and 
mutations in RBM5 have been associated with tumorigenesis and male sterility, 
respectively. Importantly, down-regulated expression of RBM5 was seen in pancreatic 
ductal adenocarcinoma (Peng et al., 2013), cancerous prostatic tissue (Zhao et al., 2012), 
lung adenocarcinoma (Shao et al., 2012), non-small cell lung carcinoma (NSCLC) (Liang 
et al., 2012), human vestibular schwannomas (Welling et al., 2002), stage III serous ovarian 
carcinoma (Kim et al., 2010) and biliary tract cancer (Miller et al., 2009). Reduced RBM5 
expression was also reported in A549 cells (Oh et al., 2006) and cisplatin-resistant A549 
cells (Li et al., 2012). In most cases, RBM5 was down-regulated, however, RBM5 was 
shown to be up-regulated in breast and ovarian cancer. Interestingly, this overexpression in 
breast cancer was associated with Her-2 overexpression (Rintala-Maki et al., 2007), which 
shows that there are other associated factors contributing to the expression and functional 
relevance of RBM5.  
The RBM5 mRNA variants have the ability to modulate expression of their own other 
variants, especially the antisense variants. Accordingly, when RBM5-AS1 was 
overexpressed, there was an increase in RBM5+5+6 levels but a decrease in RBM5+5+6t 
levels (Rintala-Maki and Sutherland, 2009). In addition, RBM5-AS1 (Je2) regulates the 
expression of full-length RBM5 (Mourtada-Maarabouni et al., 2002, Rintala-Maki and 
Sutherland, 2009). Internal control mechanisms are in place to regulate expression and thus 
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function. Therefore these variations in expression and their regulation suggest that RBM5 
gene expression and post-transcriptional modifications are likely in many systems of study.  
Thus far, only one mutation corroborates RBM5’s association with male sperm cell 
development. Mice with a mis-sense mutation (R263P) have abnormal spermatid 
differentiation and are sterile (O'Bryan et al., 2013). There was no reduction in RBM5 
mRNA or protein levels in the knockout mice having this mutation. Furthermore, besides 
human studies, animal gene expression studies reveal that Ras-transformed Rat-1 rat 
embryonic fibroblastic cells have reduced RBM5 levels (Edamatsu et al., 2000). This study 
also showed that the Rbm5+5+6t variant is expressed in rat fibroblasts. 
1.2.4 RBM5 structure  
A characteristic feature of RBPs is the presence of RNA-binding domains (RBDs). The 
RBDs bind to either double-stranded (ds) RNA or single-stranded (ss) RNA either in a 
sequence or structure dependent manner. Some well-characterized functional domains are 
RNA Recognition Motifs (RRMs), Zinc Finger (ZF) domains, Serine-Arginine (SR) 
domains, Glycine-rich patch (G-patch) domains, K-Homology (KH) domains, Octamer 
repeats (OCRE), DEAD/DEAH box and Piwi/Argonaute/Zwille (PAZ) domains (Lukong et 
al., 2008). The presence of these motifs is necessary to recognize different RNAs, 
particularly to form RNA-protein interactions which contribute to distinct functions; RNA 
helicase activity (DEAD/DEAH box), splicing (ZF and KH domains), translation, 
transcription, chromatin remodeling (KH domain), RNAi (PAZ domain) and promoters of 
protein-protein interactions (SR domain) (Wurth, 2012).  
Like all typical RBPs, RBM5 contains two RRM domains, two ZF domains (RanBP2 and 
C2H2), one SR domain, one glutamine-rich domain, one G-patch and one OCRE domain 
(Figure 1.2). Similarly, these various domains in RBM5 have been associated with various 
functions such as (a) RNA-protein interactions resulting in involvement in splicing, (b) 
protein-protein interactions involved in binding with other hnRNP/SR related proteins and 
(c) a localization sequence necessary for transport between the nucleus and cytoplasm. In 
silico analysis using the PROSITE database can be used to identify probable motif regions. 
Subsequently, the importance of these predicted sequence regions have been analyzed by 
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mutagenesis and deletion experiments. The RRMs are located in exon 6 (98-178 aa 
position) and exon 10 (231-315 aa position). The presence of two RRMs provides better 
recognition of target RNA sequences and enhanced binding kinetics by forming a RNA-
binding pouch. Furthermore,  Zhang et al. (2014) showed that deletion of both RRM 
domains inhibit cancer cell proliferation, are needed for apoptosis by activation of Caspase-
3 and contribute to alternative splicing of Caspase-2. The RanBP2-type ZF is located in the 
N-terminal region between the 181-209 aa residues, while the C2H2-type ZF motif region 
is located between 647-677 aa residues in the C-terminus (Mourtada-Maarabouni et al., 
2003). These two ZF motif regions are responsible for binding to specific RNA targets and 
thus are involved in splicing. The OCRE is located between 452-511 aa residues and is 
involved in regulating alternative splicing (Bonnal et al., 2008). The continuous Glycine-
rich region is located in the C-terminal position between 741-787 aa residues and functions 
in RNA splicing (Li and Bingham, 1991). Besides these RNA-binding associated motifs, 
RBM5 has two bipartite nuclear localization signals (NLS) and an arginine-rich N terminal 
region (RS-domain) suggesting localization to the nucleus. The Glutamine-rich domain 
located in the N-terminal region (362-385 aa) is a protein-protein interaction site 
(Mourtada-Maarabouni and Williams, 2002). Thus, detailed structural analyses of RBM5 
have revealed a number of sequence-specific regions, which help to predict RBM5 
function. 
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Figure 1.2 Protein domains of RBM5 and RBM10. Schematic description of the protein 
domain structures of the human A) RBM5 (UniProt ID P52756, NCBI accession number 
NP_005769.1) and B) RBM10 isoform1 (UniProt ID P98175, NCBI accession number 
NP_005667.2). RBM5 and RBM10 are RNA-binding proteins containing several motif 
regions associated with binding to RNA in a sequence or structure specific manner. The 
following are the description of each domain: RS= Arginine-Serine rich domain, RRM= RNA 
recognition motif, Z= Zinc finger motif (RanBP2 and C2H2), OCRE= Octamer repeat domain 
and G= Glycine-rich patch. The numbers indicate their corresponding amino acid positions.  
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1.2.5 RBM5 binding 
The first in vitro binding studies performed on RBM5 were by Drabkin et al. (1999). They 
showed that the RRM domains bind to poly (G) RNA thus demonstrating that RBM5 was 
indeed a RBP. A year later, Edamatsu et al. (2000) confirmed this poly (G) RNA-binding 
and further identified that the binding capacity was stronger to the RBM5 N-terminal 
fragment than to the RBM5 C-terminal fragment. Later, it was shown that the RRM domain 
binds to 5’ CUCUUC 3’ and 5’ GAGAAG 3’ sequences (Song et al., 2012). The OCRE 
domain of RBM5 interacts with the U5 snRNP and regulates FAS alternative splicing by 
associating with splice-site selection (Bonnal et al., 2008). The RanBP2 ZF motif binds to 
the GGU motif region of ssRNA (Nguyen et al., 2011). RBM5 also binds to UC rich 
sequences; for instance, it has been shown to bind to the 5’ 
CUCUUUUCCUAAGAACUUGGCUCUUCUCU 3’ region of intron 9 of Caspase-2 
mRNA. Furthermore, Niu et al. (2012) have shown that two splicing factors, the DEAH-
box polypeptide 15 (DHX15) and PRP19 are the nuclear binding partners of RBM5. 
Specifically, the G-patch domain of RBM5 interacts with DHX15 and is responsible for the 
helicase activity of DHX15. These binding studies have provided us with a clear picture of 
the role, the mode of action and the mechanistic regulation of RBM5. 
1.2.6 RBM5 subcellular localization 
Nuclear localization signals (NLS) are necessary for importing proteins into the nucleus. 
NLS are specific sequences, which bind to receptors such as importin α. Importin α and 
importin β form complexes with the protein “cargo”, which is transported into the nucleus 
and released resulting in protein translocation into the nucleoplasm (Freitas and Cunha, 
2009). NLS are of two types, monopartite and bipartite. Monopartite NLS are shorter basic 
amino acid sequences that are present as a single stretch of amino acids. Bipartite NLS are 
longer sequences containing two stretches of basic amino acids with a linker sequence 
between (Lange et al., 2007). RBM5 has two bipartite NLS. RBM5 was found in the nuclei 
of human fibrosarcoma HT1080 cells (Drabkin et al., 1999). Additionally, this group also 
detected a stronger nuclear signal in the C-terminal fragment compared to the N-terminal 
fragment stating that NLS in the C-terminal region could be the major constituent for the 
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nuclear localization. Immunohistochemistry (IHC) of RBM5 in prostate tissues revealed the 
presence of RBM5 in both the nucleus and cytoplasm. However, higher levels of RBM5 
were detected in the cytoplasm of cancer tissues than in normal prostatic tissues (Zhao et 
al., 2012). Localization studies for RBM5 have been done in adult male mouse testis 
(O'Bryan et al., 2013). RBM5 was localized to spermatogonia, spermatocytes and round 
spermatids (O'Bryan et al., 2013). Furthermore, RBM5 is seen to co-localize to the nucleus 
with hnRNPA2/B1 and SFPQ (splicing factors) in male germ cells such as spermatocytes 
and spermatids. Functional association of RBM5 with nuclear binding partners DHX15 and 
PRP19 further strengthens the nuclear localization claim for RBM5 (Niu et al., 2012). 
Gupta (2006) showed that RBM5 had a sub-nuclear distribution specifically in nuclear 
speckles in human umbilical vein endothelial cells (HUVEC), SV-40 large T-antigen 
transformed and immortalized cells (HT-6), NIH3T3 and HepG2 cells. It is evident from 
these localization studies that the location of RBM5 within the cell is an important criteria 
for a specific mechanistic role.  
1.3 RBM10 
Another RBP, a paralogue of RBM5, is RBM10. The RBM10 gene, located on the X 
chromosome at Xp11.23, encodes for the RBM10 protein. RBM10 was first cloned from 
bone marrow (Nagase et al., 1995). The rat homologue, S1-1 has been studied extensively 
(Inoue et al., 1996, Inoue et al., 2008). 
1.3.1 Alternatively spliced variants 
In humans, RBM10 is alternatively spliced to form RBM10 mRNA variant1 (RBM10v1, 
NM_005676.4), which is 3412 bp long and RBM10 variant2 (RBM10v2, NM_152856.2), 
which is 3178 bp long, which encode for ~100 kDa and ~95 kDa proteins, respectively 
(Wang et al., 2012) (Figure 1.3). The two human RBM10 isoforms contain 852 aa 
(NP_690595.1) and 930 aa (NP_005667.2). There are 24 exons in RBM10v1 and exon 4 
(77 aa residues) is alternatively spliced in RBM10v2. The protein sequences of RBM10v1 
and RBM10v2 have 49% and 53% homology to RBM5 (Sutherland et al., 2005). These two 
variants are extensively studied, however, a third variant (AK024839) exists, which was 
detected in primary smooth muscle cells of the coronary artery (Wang et al., 2012). Thus, 
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similar to RBM5, RBM10 is alternatively spliced and hence post-transcriptionally modified 
which is probably associated with functional relevance. 
The mouse RBM10 isoform 1 (NP_663602.1) is 96% identical to human RBM10 (Johnston 
et al., 2010). In mouse, three RBM10 isoforms containing 930 aa, 929 aa and 853 aa have 
been identified (Figure 1.4). The murine RBM10v2 (NP_001161247.1) is not the same as 
the human RBM10v2. The mouse RBM10v2 isoform has one aa (valine) deletion and in 
the other isoform RBM10v3 (NP_001161248.1), exon 4 coding for 77 aa is alternatively 
spliced. [The current study focuses on Rbm10v1 and Rbm10v3 for the purpose of more 
accurate comparisons to the human variants]. 
1.3.2 RBM10 function 
Initially, there were limited studies describing RBM10 function. However, recently, 
numerous studies have identified multiple functions for RBM10. RBM10 is implicated in 
apoptosis, alternative splicing and development and has been associated with cancer 
(Imielinski et al., 2012) and neurological diseases (Zhang et al., 2007). The rat RBM10 
orthologue, S1-1 functions in the regulation of transcription and alternative splicing (Xiao 
et al., 2013), which shows that it is an important RBP implicated in RNA-associated 
functions.  
1.3.2.1 Apoptosis and cell proliferation 
RBM10 is pro-apoptotic. RBM10 can modulate apoptosis in tumor cells (Wang et al., 
2012). Specifically, in Jurkat and MCF-7 cells, RBM10 induced apoptosis via the TNF-α 
mediated extrinsic pathway. When RBM10v1 was overexpressed, it significantly altered 
TNF-α, TNFRSF9 and TNFSF7 levels. When RBM10v2 was overexpressed, Caspase-4 
and TRAIL expression were affected (Wang et al., 2012). In breast cancer cells, expression 
of RBM10 is correlated with the expression of apoptotic Caspase-3 (Martin-Garabato et al., 
2008), and with Bax, p53 and VEGF (Martinez-Arribas et al., 2006). In addition to 
RBM10, two other RBM genes located on X-chromosome (RBM3 and RBMX) are 
associated with the expression of the apoptotic protein Bax and the angiogenic factors 
VEGF and CD105 (Martinez-Arribas et al., 2006). The human RBM10v1 is closely 
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associated with RBM3 and p53, whereas RBM10v2 is associated with higher proliferation. 
When the rat homologue, S1-1 was overexpressed it resulted in reduced proliferation and 
increased the rate of apoptosis in vascular smooth muscle cells (VSMC) (Mueller et al., 
2009). Their involvement in VSMC indicates potential roles in oxidative stress 
management and atherogenesis.  
1.3.2.2 Splicing regulation 
Similar to RBM5, RBM10 is a splicing regulator and interacts with spliceosomal 
complexes. In Hela cells, RBM10 was recovered from PRPF40A-U2 complexes and was 
identified as a component of the U2 snRNPs (Makarov et al., 2012). RBM10 was further 
shown to interact with spliceosomal A and B complexes (Agafonov et al., 2011). RBM10 
has overlapping functions with RBM5 in alternative splicing. For instance, knockdown 
(KD) of RBM5, RBM6 and RBM10 together resulted in inclusion of exon 6 during 
alternative splicing of Fas (Bonnal et al., 2008). RBM10 was shown to act as a splicing 
repressor, specifically causing exon 18 skipping in Discs large homolog 4/ post-synaptic 
density protein 95 (Dlg4/Psd-95) mRNA in primary neurons (Zheng et al., 2013). 
Additionally, RBM10-induced alternative splicing changes can be inferred from 
experiments where RBM10 was overexpressed or silenced in HEK293 cells leading to 
expression changes in a number of genes. When RBM10 was overexpressed, 19 genes were 
up-regulated and 49 genes were down-regulated and when RBM10 was silenced, 171 genes 
were up-regulated and 105 genes were down-regulated (Wang et al., 2013). Broadly, 
RBM10 is involved in splicing by (a) recognizing splice sites and/or pairing, and (b) 
interacting with snRNPs, and pre-mRNAs and removing introns. For instance, using 
photoactivable-ribonucleoside-enhanced cross-linking and immunoprecipitation (PAR-
CLIP), Wang et al. (2013) found that RBM10 bound close to the 5’ and/or 3’ splicing sites 
upstream or downstream of introns. Using RNA-sequencing, they identified 304 and 244 
exon splicing changes that were significantly enhanced after RBM10 was deleted or 
overexpressed, respectively. Notably, RBM10 expression was involved in promoting exon 
skipping. Thus, from studies that analyzed the interactions and splicing changes, we can 
conclude that RBM10 is an important splicing regulator.  
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Primers used in end-point PCR  
 siRBM10 (siRNA), target site (exon 17)   
Antibody, Bethyl 
Start and stop codons   
 
 
Figure 1.3 Alternatively spliced human RBM10 mRNA variants. Diagram illustrating the 
two alternatively spliced variants of RBM10, with start and stop codons positions in the 
protein coding sequence. Location of end-point PCR primers, antibody and siRNA used in 
this study are schematically represented. Primers and siRNA were designed using mouse-
specific Rbm10 mRNA sequences (NM_145627.2, NM_001167775.1). Not drawn to scale. 
Adapted from Sutherland et al., 2005. 
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Figure 1.4 Sequence alignment of the three murine RBM10 isoforms. Amino acid 
alignment using Multalign illustrates the three RBM10 isoforms. The murine RBM10v2 is not 
the human equivalent RBM10v2 but is RBM10v3, which is the exon 4 (77 aa) alternative 
spliced isoform. Sequences with high (red) and low (blue) consensus. 
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1.3.2.3 Development 
The association of RBM10 with mammalian development is evident from studies 
correlating RBM10 mutations with an X-linked developmental anomaly called TARP 
syndrome (Talipes equinovarus, atrial septal defect, Robin sequence and persistent left 
superior vena cava) in males (Gripp et al., 2011, Johnston et al., 2010). Limb deformities, 
neurological defects, cardiovascular defects and mandibular malformations are 
characteristics of this lethal defect. Therefore, the RBM10 loss-of-function due to 
mutational abnormality in TARP, clearly demonstrates its critical role in development. 
1.3.3 RBM10 expression profile 
Tissue-specific expression, invariably similar to RBM5 was detected, namely higher levels 
of expression in heart, skeletal muscle and pancreas 
(http://www.kazusa.or.jp/huge/gfimage/northern/html/KIAA0122.html). RBM10 
expression is up-regulated in primary chondrocytes that were induced to hypertrophy 
(James et al., 2007). RBM10 is expressed in quiescent, non-dividing cells such as Purkinje 
cells (cerebellum), cells of villi and Paneth cells of the small intestine and in non-
proliferating cells of the heart, skeletal muscle, intestine, kidney, spleen and adrenal glands; 
as well as in dividing cells such as spermatogonia (testis) (Inoue et al., 2008). Interestingly, 
higher expression was observed in cells undergoing transcription such as the spermatogonia 
and Purkinje cells than in the primary and secondary spermatocytes or the granulocytes, 
respectively (Inoue et al., 2008). The murine Rbm10 gene is expressed during embryonic 
development, specifically in mid-gestation embryos (Johnston et al., 2010). The highest 
expression was seen in the brachial arches, limb and tail bud regions between E9.5 to E11.5 
in these embryos. Similar to RBM5, RBM10 showed differential down-regulation in a 
lineage-specific manner in differentiating skeletal and cardiac H9c2 myoblasts (Loiselle 
and Sutherland, 2014). Indeed, during skeletal myoblast differentiation, the Rbm10v2 
mRNA levels decreased when compared to day zero (D0). However, the mRNA levels did 
not change during cardiac myoblast differentiation. The protein levels of both the 
RBM10v1 and RBM10v2 isoforms decreased significantly during skeletal differentiation 
and only the RBM10v2 isoform decreased significantly during cardiac myoblast 
differentiation. In addition, variant-dependent expression has been reported. For instance, 
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in human breast tumor specimens, the expression of one variant was dependent on the other 
variant (Martinez-Arribas et al., 2006).  In contrast, changes in the expression or detection 
of only one variant have also been reported. In human lung cancer cell lines, the RBM10v2 
isoform is not detected (Loiselle and Sutherland, 2014). In rat H9c2 differentiating 
myoblasts, the levels of only the RBM10v2 were high on day two (D2) compared to the 
levels in the differentiated myotubes (day seven) (Loiselle and Sutherland, 2014).  
More studies have identified RBM10 mutational defects associating with major 
developmental anomalies and cancer. As mentioned previously, a non-sense and frame-
shift mutation in RBM10 causes the TARP syndrome (Gripp et al., 2011, Johnston et al., 
2010). This non-sense mutation in the RRM2 domain and the frame-shift mutation in the C-
terminal region alters the conformation of the protein. Furthermore, an in-frame deletion of 
239 aa, including a region comprising the C2H2 domain, a portion of G-patch and one 
NLS, leads to a potential loss-of-splicing functions in the nucleus that was associated with a 
familial X-linked intellectual disability, which has overlapping phenotypes observed in 
TARP syndrome (Wang et al., 2013). Finally, truncating and mis-sense mutations are found 
in lung adenocarcinomas (Imielinski et al., 2012) and pancreatic intra-ductal papillary 
mucinous neoplasms (Furukawa et al., 2011). 
1.3.4 RBM10 structure 
RBM10 is structurally related to RBM5, which is evident from the presence of two RRM 
domains, two ZF domains (RanBP2 and C2H2), one G-patch, one SR domain and one 
OCRE domain (Sutherland et al., 2005) (Figure 1.2). Most of the structural studies for 
RBM10 were performed on the rat S1-1 protein. The RRM domains of S1-1 are each 
approximately 80-90 aa and contains two critical ribonucleoprotein (RNP) motif regions 
(RNP1 and RNP2), one each in the C-terminal and N-terminal regions (Xiao et al., 2013). 
The RBM10v2 isoform, which has exon 4 alternatively spliced out, lacks the RNP2 motif 
of RRM1 (Xiao et al., 2013).  
The probable motif regions of the murine RBM10v1 and RBM10v3 isoforms were mapped 
to amino acid locations using PROSITE (Figure 1.5). RRM1 domains were predicted at 
residues 129-209 (RBM10v1) and 37-132 (RBM10v3), and RRM2 was predicted at 
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residues 300-384 and 223-307 for RBM10v1 and RBM10v3, respectively. In RBM10v1, 
the RanBP2 ZF motif was located at residues 212-242, the C2H2 ZF motif at 759-789 aa 
and the G-patch at 858-904 aa positions. In RBM10v3, the RanBP2 ZF motif was located at 
residues 135-165, the C2H2 ZF motif at 682-712 aa and the G-patch at 781-827 aa 
positions. These sequence specific regions enable prediction of functions. 
1.3.5 RBM10 binding 
The first in vitro binding studies for RBM10 were done for S1-1. The rat homologue S1-1 
has been shown to bind poly (G) and (U) ribonucleotides (Inoue et al., 1996). S1-1 bound 
to 130 mRNA clones encoding for cytokines and proto-oncogenes (Bhattacharya et al., 
1999). S1-1 binds to the 3’ UTR of the AT1 receptor (renin-angiotensin system) mRNA 
and is responsible for its stability and mRNA transcription (Mueller et al., 2009). RanBP2 
possibly interacts with the AGGUAA sequence in the 5’ splice sites (Wang et al., 2012), 
which is different from the interaction reported for RBM5.  
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Figure 1.5 Domain structures of the mouse RBM10 isoforms. Schematic representation of 
the motifs and their corresponding locations predicted for the two isoforms, using PROSITE 
database. RBM10v1 is a 930 aa protein consisting of the following motifs; RRM1 at 129-209, 
RRM2 at 300-384, RanBP2 ZF at 212-242 and C2H2 ZF at 759-789 and G-patch at 858-904. 
RBM10v3 is an 853 aa protein with the following motifs; RRM1 at 37-132, RRM2 at 223-307, 
RanBP2 ZF at 135-165 and C2H2 ZF at 682-712 and G-patch at 781-827. 
RBM10v1 930a
a 
853aa RBM10v3 
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1.3.6 RBM10 subcellular localization 
RBM10 localizes in the nucleus in certain cells. Using immunoelectron microscopy, Inoue 
et al. (2008) determined that S1-1 (RBM10) was located in nuclear domains as punctate 
nuclear bodies and as diffused granules. RBM10 was present in the interchromatin space 
and perichromatin fibrils. In the nucleoplasm, RBM10 was absent in the nucleoli. They 
detected RBM10 in the nucleus of spermatogonia, Purkinje cells, cells of villi and Paneth 
cells (small intestine). In tissues such as heart, skeletal muscle, intestine, kidney, spleen and 
adrenal gland, RBM10 was present predominantly as punctate structures in the nucleus 
(Inoue et al., 2008). Xiao et al. (2013) studied the pattern of RBM10 localization in many 
different tissue types and cell lines. RBM10 localized to the nucleus in rat ARL cells (liver 
epithelial cells) and NIH3T3 cells (Xiao et al., 2013). Initially, it was believed that the 
RBM10 sequence contained two NLS signals necessary for nuclear localization (Inoue et 
al., 2008), however, it was recently shown that an additional NLS is present in the OCRE 
region (NLS3) and all three NLS function in a dependent manner (Xiao et al., 2013). The 
other two NLS are located between amino acids 743-759 (NLS1) and in the RRM1 domain 
regions (NLS1). Interestingly, RBM10 was found in both nuclear and cytoplasmic fractions 
in neutrophils, HeLa cells, HL-60 cells (premyelocytic leukaemia cell line), cirrhotic liver 
cells and hepatocellular carcinoma cells. Further, a K756A mutation in NLS1 leads to 
localization to the cytoplasm (Xiao et al., 2013). Recently, Inoue (2013) have observed 
nuclear and cytoplasmic localization in normal chorion and complete hydatidiform moles 
(disease of the chorionic villi). These observations, therefore, indicate that RBM10 
subcellular localization potentially relates to its specific regulatory functions.  
Most of the studies on RBM5 and RBM10 were focused on tumor cell lines with little 
information on their role in normal cells, specifically muscle, even though these RBPs were 
highly expressed in both skeletal and cardiac muscles. In order to functionally characterize 
these two proteins in different biological systems, it is necessary to define their potential 
specificity in both normal as well as transformed systems. In addition to the relatedness of 
the functional events associated with muscle development, such as cell cycle arrest, 
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apoptosis and alternative splicing, the involvement of RBM10 in development therefore 
suggests a prospective role for these two RBPs in myogenesis. 
1.4 Skeletal myogenesis 
There are three types of muscles in vertebrates; cardiac, skeletal and smooth muscles 
(Buckingham, 2001). Skeletal muscles are voluntarily controlled by the somatic nervous 
system via neuro-muscular junctions, which are necessary for neuronal firing and 
contractile response, whereas the contractile response of both smooth and cardiac muscle 
types are controlled involuntarily by the autonomic nervous system (Exeter and Connell, 
2010). The process of skeletal muscle development is termed “Skeletal Myogenesis” 
(Bentzinger et al., 2012). Myogenesis constitutes four specific phases; specification, 
determination, migration/commitment and differentiation (Perry and Rudnick, 2000). All 
four phases involve establishing the muscle-specific lineage from progenitor cells to 
developing a fully formed functional muscle fiber (Bentzinger et al., 2012). The somites, 
which produce the progenitors cells, are established from the mesodermal layer. Each 
mesodermal layer contributes to a specific location and type of muscle to be formed 
(Buckingham, 2002, Buckingham, 2006). Each phase in the myogenic program is 
monitored and accurately co-ordinated to generate the skeletal muscle (Buckingham and 
Rigby, 2014). 
1.4.1 Myogenic differentiation 
The final of the four phases in myogenesis is differentiation. Various changes occur during 
differentiation; the mono-nucleated myoblasts stop proliferating, withdraw from the cell 
cycle, elongate, migrate, align and fuse to form the multinucleated myotubes (Sabourin and 
Rudnicki, 2000). Myotubes mature to form myofibers. Mature myofibers are comprised of 
contractile units of the muscle, the sarcomeres, which contain actin and myosin 
myofilaments (Burattini et al., 2004). Myoblast proliferation and differentiation are distinct, 
temporal processes (Moran et al., 2002). Therefore, differentiation is tightly regulated with 
the end-result being the formation of multi-nucleated myofibers, which can contract and are 
adapted for specific functions. 
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Satellite cells are quiescent cells, different from myofibers, that reside in the spaces 
between the sarcolemma and basal lamina (Montarras et al., 2013). These cells are involved 
during injury, regeneration and repair. When stimulated (injury/trauma) these quiescent 
cells become activated and proliferate and undergo the regular process of differentiation to 
become adult myofibers (Charge and Rudnicki, 2004, Chang and Rudnicki, 2014). Young 
neonatal mice have 30% satellite cells of the total cell number, which decrease with age to 
4% in adult and 2% in aged mice. This age-dependent decrease in the satellite cell 
population is associated with the increase in oxidative myofibers (Hawke and Garry, 2001). 
The adult muscle regeneration process, which involves the activation, proliferation and 
migration of the satellite cell to the site of injury to form the functional myofiber is 
governed by additional and varied gene expression changes (Yusuf and Brand-Saberi, 
2012). 
1.4.2 C2C12 model 
Many in vitro tools such as primary cells and secondary cell lines such as C2C12, H9c2, 
L6E9 and L8 cells are available to study the fundamental cellular processes that occur 
during myogenesis (Miller, 1990). The most frequently used, well-established cell line is 
the C2C12 myoblast cell line. This in vitro mouse model is extensively used to study the 
process of myogenic differentiation. Blau et al. (1985) established this cell line as a 
subclone from the thigh muscle of a C3H mouse after injury (Yaffe and Saxel, 1977). Since 
then, scientists have used C2C12 cells in numerous transcriptomic and proteomic studies to 
identify the molecular mechanisms of the myogenic program (Casadei et al., 2009, Tannu 
et al., 2004). C2C12 myoblasts stop proliferating when the growth factors are depleted and 
this induces differentiation. According to Dedieu et al. (2002) fusion starts two days after 
differentiation induction and the rate of fusion is high by the fourth day and reaches a 
maximum level of cells being fused (60%) on the eighth day following induction. The 
C2C12 differentiation system is a model that represents a part of the skeletal myogenesis, 
beginning from the myoblast stage and ending in myofibre formation. While there are some 
differences between in vivo mouse myogenesis and C2C12 differentiation, the C2C12 
model provides insight in to the dynamic steps involved in skeletal differentiation and has 
been widely used. In vivo, the differentiation process ends in fully formed mature 
myofibres, governed by additional gene expression changes (Abmayr and Pavlath, 2012). 
 26 
 
C2C12 cells are a heterogenous group of phenotypes including mono-nucleated myoblasts 
and quiescent cells, which are dormant resting cells and are termed as reserve cells (Deato 
and Tjian, 2007, Riquelme et al., 2015). When the C2C12 cell population is subjected to 
differentiation, these reserve cells are those cells that escape differentiation and remain as 
undifferentiated cells (Yoshida et al., 1998).  
1.4.3 Myogenic gene expression changes 
Muscle-specific gene expression changes occur during differentiation (Heywood et al., 
1983, Merlie et al., 1977). Comparative genomic and proteomic profiling studies 
comparing early and late stages of muscle differentiation have identified alterations in 
numerous molecular players involved in cell signalling, cell cycle, apoptosis, contraction, 
cell-architecture, mobility/motility, transcriptional related genes/proteins (Figure 1.6). The 
known protein list is exhaustive and has been extensively reviewed (Knight and Kothary, 
2011, Molkentin and Olson, 1996). For the scope of this dissertation, a brief introduction 
on three specific events and a few associated essential proteins is presented here. Because 
of the relatedness of these events to RBM5 and RBM10 functions, the events that are 
elaborated are related to cell cycle withdrawal, apoptosis and alternative splicing.  
1.4.3.1 Cell cycle  
The first step in differentiation induction is cell cycle arrest (Walsh and Perlman, 1997). 
Gene expression changes occurring in transcription factors and cell cycle proteins during 
myogenesis are highly coordinated. The myogenic regulatory factors (MRFs), which are 
transcription factors, are the main key players. The four major MRFs are myogenic factor 5 
(Myf5), MyoD, Myogenin (MyoG) and muscle regulatory factor 4 (MRF4) (Olson et al., 
1991, Rudnicki et al., 1993). These MRFs belong to the family of basic helix-loop-helix 
(bHLH) muscle-specific transcription factors. First, MRFs heterodimerize with E proteins 
(E12/E47, HEB, E2-2) and then, the DNA-binding domain present in the MRFs bind to the 
DNA motif regions called the E-box on the promoters of many genes and activate 
transcription (Londhe and Davie, 2011). Each MRF is functionally activated during each 
stage of differentiation and therefore has a specific role during myogenesis (Sabourin and 
Rudnicki, 2000): Myf5 and MyoD are involved in determination and in cell cycle 
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regulation during differentiation (Rudnicki et al., 1993), MyoG in myotube formation 
(Faralli and Dilworth, 2012) and MRF4 in the terminal stage (myofibrillogenesis) of 
differentiation (Kassar-Duchossoy et al., 2004). MRF4 is also involved in postnatal 
myofiber regulation (Walters et al., 2000). 
Furthermore, some MRFs have redundant (Myf5 and MyoD) as well as conserved 
functions such as regulating transcription of specific subsets of muscle-specific genes 
(Kablar et al., 1997). Inhibition of MyoD, Myf5 and MyoG prevent fusion and varying 
degrees of delay are observed based on the day of inhibition of MRF expression (Dedieu et 
al., 2002). MRFs co-ordinate with another set of myogenic protein, the myocyte enhancer 
factor 2 (MEF2) family of MADS box factors, and together regulate most muscle-specific 
genes (Dodou et al., 2003). Cell cycle proteins such as p21, p57 and p27 are regulated 
during differentiation (Chan et al., 2011). p21, a cyclin-dependent kinase inhibitor causes 
cell cycle arrest by inhibiting cdk-2 (cyclin dependent kinase-2). p21 is activated by MyoD, 
which leads to cell cycle withdrawal (Guo et al., 1995) in concurrence with p57 (Zhang et 
al., 1999). It is also known that MyoG is expressed after p21 is expressed (Halevy et al., 
1995). Therefore after induction of differentiation, the levels of p21 are regulated, which 
invariably causes cell cycle arrest at G1 and also enables myotube formation by inducing 
MyoG expression. Cyclin D1 is expressed in proliferating myoblasts and p21 is expressed 
before fusion (Tannu et al., 2004). In addition, hypophosphorylated retinoblastoma protein 
associates with MyoD transactivating E-box-possessing muscle-specific promoters to 
maintain the differentiated state (Sabourin et al., 1999).  
It is important to note that the expression of the MRFs in vivo is governed by their location 
and timing during development (Sabourin and Rudnicki, 2000). For instance, during the 
development of the mouse embryonic musculature, Myf5 is the first MRF expressed in the 
somites in the trunk. MyoG is expressed next, followed by MRF4. MyoD is expressed later 
in the lateral part of the somites (Smith et al., 1994). MyoD expression begins on 
embryonic D10 and is expressed until birth (Borycki and Emerson, 1997). In vivo, 
development-associated signalling mechanisms regulate the progenitor cells to proliferate 
and for a certain population to differentiate, which requires cell cycle arrest to occur at G1 
so that they can proceed through differentiation (Pownall et al., 2002). In addition, the 
 28 
 
signalling mechanisms involving muscle regeneration are different from embryonic 
myogenesis (Mercer et al., 2005). In the C2C12 model, similar events have been shown to 
take place and the percentage of differentiated C2C12 cells ranges between 40% and 60% 
(Yoshida et a., 1998) and the remaining are the satellite cell-like reserve cells (Miller, 
1990). In vivo, the quiescent cells (satellite cells) that are located in the basal lamina 
express a distinct set of genes that regulate the expression of myogenic factors during 
muscle tissue injury and repair (Chang and Rudnicki, 2014; Charge and Rudnicki, 2004). 
Proteins such as paired box protein 7 (Pax7) and Myostatin maintain the satellite cells in a 
quiescent state and this state can be reversed by interacting with MEFs and MRFs, 
specifically MyoD and Myf5. MyoD inhibition controls the entry into S-phase in cell cycle; 
association with Myf5 activates the myoblasts (Buckingham et al., 2003). Immediately 
after injury (6 h), the expression of MyoD occurs in the activated satellite cells in vivo 
(Hawke and Garry, 2001). However, in the C2C12 model, MyoD appears to be expressed 
even in proliferating, non-differentiating (reserve) cells (Ferri et al., 2009), while MEF and 
MyHC are not expressed in the reserve cells until they are induced to differentiate (Blais et 
al., 2005).  
Using microarray profiling of C2C12 cells induced to differentiate, Rajan et al. (2012) 
identified up to four-fold difference in expression of transcriptomes, with down-regulation 
being more common than up-regulation, and these changes were observed between 12 h 
and 24 h after induction. Exit from the cell cycle happened within two days after serum 
withdrawal (Shen et al., 2003).  
1.4.3.2 Apoptosis 
In addition to inducing irreversible cell cycle withdrawal, apoptosis is necessary for the 
progression of differentiation (Fernando et al., 2002). However, once differentiation occurs, 
the cells are resistant to apoptosis (Sandri and Carraro, 1999). During differentiation of 
C2C12 muscle cells, which contains a heterogenous pool of myoblasts and reserve cells, 
expression of the anti-apoptotic gene Bcl-2 and pro-apoptotic genes Bax, Bad and Bak are 
highly regulated (Schoneich et al., 2014). Activation of caspases such as Caspase-3, 
Caspase-9 and Caspase-12 are reported in a specific population of cells, during the early 
stage of differentiation (Schoneich et al., 2014). Other apoptotic regulators such as DAD1, 
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Caspase-11 and glycogen synthase kinase-3β are differentially expressed during 
differentiation (Shen et al., 2003). Apoptosis of the incompletely differentiated or 
undifferentiated cells occur at 48 hours after switching to DM and leads to a 20-30% loss of 
myoblasts (Mercer et al., 2005). 
1.4.3.3 Alternative splicing 
Alternative splicing is highly regulated during myogenesis, exhibiting a greater degree of 
control on proteins expressed during this important phase of development, and during 
repair and regeneration (Llorian and Smith, 2011). Bland et al. (2010) identified regulation 
of 95 alternative splicing events during C2C12 differentiation using splicing-sensitive 
microarray analysis. Of these 95 transitions, 69 (73%) had increased inclusion and 26 
(27%) had increased exon skipping/exclusion. Functionally, these transitions were related 
to components of cytoskeletal, actin binding, cell junction, nucleotide kinase and integrin 
signalling pathways. The splicing transitions were conserved, coordinated and occurred in 
the proliferating myoblasts before the start of differentiation as well during the entire 
differentiation process. In addition, they also determined that 30% of the splicing events 
involved RBPs. Many cis-acting splicing regulators (FOX , MBNL, CUGBP1, hnRNP, 
PTB) that possess RNA-binding motifs showed expression level changes in response to 
alternative splicing transitions during myogenic differentiation in C2C12 cells. 
Interestingly, alternative splicing during myogenesis is implicated in a majority of muscle-
related diseases such as dystrophies, spinal muscular atrophy and rhabdomyosarcoma 
(Garcia-Blanco et al., 2004, Spletter and Schnorrer, 2014). 
α-Dystrobrevin is encoded by the DTNA gene. α-Dystrobrevin along with β-Dystrobrevin, 
dystrophin, sarcoglycan, syntrophins and dystroglycans form the dystrophin glycoprotein 
complex (DGC) (Ehmsen et al., 2002). DGC is essential for forming and maintaining the 
stability of synaptic clusters of nicotinic acetylcholine receptors. DGC is a structural 
component on the sarcolemma and is associated with muscular dystrophies (Metzinger et 
al., 1997). Multiple transcripts are generated due to alternative splicing and the splicing of 
DTNA is highly regulated (Nakamori and Takahashi, 2011). Differing degrees of splicing 
regulation are observed between human and mice; there are variations in the spliced 
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transcripts, expression profiles, location and function (Nakamori and Takahashi, 2011, 
Nakamori et al., 2008). Bland et al. (2010)  reported that Dtna has a 78% increase in exon 
inclusion during C2C12 differentiation and this splicing transition is part of the myogenic 
differentiation program because this transition was not present in BDM (2,3, butanedione 
monoxime)-treated differentiating C2C12 cells, in which differentiation was blocked. Exon 
11 is the alternatively spliced exon and inclusion of exon 11 occurs during the mid- and 
late-stages of C2C12 differentiation. Alternative splicing of this skeletal muscle 
differentiation specific variant, which was significant after the C2C12 myoblasts were 
induced to differentiate, indicates potential functions during this time-point.  
MEF2 proteins are a family of transcription factors involved in differentiation, especially 
during the terminal-stages of differentiation such as fusion and maturation (Black and 
Olson, 1998). MEF2 isoforms A, B, C, D are encoded by different genes and have 
overlapping as well as specific functions during myogenesis (Edmondson et al., 1994). 
Knockdown and knockout studies in zebrafish and mouse, respectively, revealed that 
Mef2c is involved in maintaining the integrity of the sarcomere and for postnatal 
maturation of skeletal muscle (Potthoff et al., 2007). Multiple alternatively spliced isoforms 
of Mef2c are generated by alternative splicing of the α, β and γ exons (Sekiyama et al., 
2012). Mef2c(γ-) is more active in transcription than Mef2c(γ+) and the alternative splicing 
of this γ domain is not dependent on the splicing events containing α/β domains (Zhu and 
Gulick, 2004). 
Integrins are extracellular matrix receptors with functions in cell adhesion, migration and 
signal transduction. There are 2 subunits, α and β. There are two alternatively spliced 
isoforms of β1 integrin, β1A and β1D, which have distinct functions (Cachaco et al., 2003). 
When both isoforms were separately overexpressed in C2C12 cells, the myogenic 
differentiation program was differentially affected (Cachaco et al., 2005). The integrinβ1A 
isoform, which is associated with primary myogenesis (Cachaco et al., 2003), is expressed 
in proliferating myoblasts and decreases during differentiation while integrinβ1D 
expression increases (Belkin et al., 1996). 
1.4.3.4 Associated proteins 
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There are other signalling pathways that exert a critical role in myogenic differentiation, 
such as the Notch pathway (Kopan et al., 1994, Nye et al., 1994). When the Notch pathway 
is activated, it inhibits differentiation (Nofziger et al., 1999). This effect is caused by an 
overexpressed Notch intracellular domain (NICD), which regulates MyoG and Myosin 
light chain 2 expression (Nofziger et al., 1999). When Notch is activated, it inhibits the 
three major muscle specific proteins, MEF2C, MyoD and MyoG (Kopan et al., 1994). 
Furthermore, the Notch pathway is implicated in activation of satellite cells and post-natal 
myogenesis, for instance, differentiation and fusion occurs when Notch signals are 
inhibited (Conboy and Rando, 2002). This down-regulation of Notch is caused by an 
apparent increase in NUMB expression, leading to myotube formation during injury 
(Conboy and Rando, 2002). Another pathway that regulates MyoG and MEF2 expression is 
the Rho family of proteins (Charrasse et al., 2002). Rho levels are high in myoblasts and 
down-regulated during differentiation (Iwasaki et al., 2008). 
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Figure 1.6 Expression of various proteins during C2C12 myogenic differentiation. 
Schematic representation of the approximate time-points of key events occurring during 
C2C12 myogenic differentiation and few of the associated proteins expressed at these 
various stages. 
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Many RBPs regulate myogenic genes post-transcriptionally during myogenesis (Apponi et 
al., 2011). They are important in regulating gene expression by splicing, maintaining 
mRNA stability, transport and translation. RBPs shown to be associated with myogenesis 
are; Human R antigen (HuR), KH-type splicing regulatory protein (KSRP), CELF (CUG-
BP- and ETR-3- like factors) CUGBP1, nuclear poly (A)-binding protein1 (PABPN1), Lin-
28 and Tristetraprolin (TTP). By binding to the U and AU-rich elements (AREs) of mRNA 
targets, HuR is involved in almost every aspect of RNA metabolism, including splicing, 
polyadenylation, transport from the nucleus to cytoplasm, translation and degradation 
(Hinman and Lou, 2008). KSRP regulates myogenesis as an alternative splicing regulator, 
and in mRNA decay, KSRP binds to ARE sequences (Apponi et al., 2011). CUGP1 
functions in alternative splicing, translation and stability. PABPN1 functions as 
polyadenylation complex (Apponi et al., 2011). Lin-28 is involved in translation (Apponi et 
al., 2011). TTP plays a pivotal role in mRNA stabilization and degradation by binding to 
ARE regions (Apponi et al., 2011). Using C. elegans as the model system, many RNA 
targets binding to RBPs have been identified (Tamburino et al., 2013). 
There are other RBM proteins shown to be associated with myogenesis. RBM38 is 
involved in cell cycle arrest and differentiation by binding to p21 (Miyamoto et al., 2009). 
RBM24, a paralogue of RBM38, regulates myogenesis via cell cycle regulation, not 
dependent on p21 (Miyamoto et al., 2009). These two RBM proteins have a similar 
expression profile, in particular, they are highly expressed in skeletal and cardiac muscle 
and are up-regulated during differentiation (Miyamoto et al., 2009). It was shown later that 
RBM24 binds to the 3’UTR of MyoG mRNA altering its stability, thereby inhibiting 
myogenesis (Jin et al., 2010). RBM4 and RBM20 are other important RBM proteins 
implicated in myogenesis (Lin and Tarn, 2011, Lin and Tarn, 2012). RBM4 functions as a 
positive myogenic regulator associated with both post-transcriptional and translational 
control during muscle differentiation. RBM4 is involved in alternative splicing of PTB, 
MEF2c, myocargin, α-tropomyosin, α-actinin, troponin T, vinculin, insulin receptor and 
ryanodine receptor (Lin and Tarn, 2011, Lin and Tarn, 2012). RBM20 is a splicing 
repressor in cardiac differentiation, specifically promoting intron retention, exon exclusion 
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and shuffling in Titin mRNA and in 31 other spliced genes (Li et al., 2013). These 
observations therefore indicate that regulation could be carried out in many different ways, 
affecting several mRNAs. In short, we can infer that there are numerous molecular players 
involved in differentiation to properly execute the myogenic program.  
1.5 Subcellular localization of myogenic proteins 
The location of major muscle-specific proteins in the cell is an important regulatory 
mechanism to streamline their expression and function. For instance, MyoD  is localized in 
the nucleus, more specifically in the interchromatin domains during the early- and late-
differentiation phase in C2C12 cells, but is seen only in the cytoplasmic space in the 
mitotic myoblasts (Ferri et al., 2009). Nuclear localization is seen in the interchromatin 
domains and not in the nucleolus. Myf5 exhibited different localization pattern during 
differentiation (Ferri et al., 2009). Myf5 was detected both in the nucleus and cytoplasm 
during early-, mid- and late- differentiation stages; however, Myf5 staining was more 
intense in the nucleus compared to the cytoplasm, indicating a strong nuclear presence 
during the entire differentiation process. In the nucleus, Myf5 was detected in the 
interchromatin domains and not in the nucleolus. Interestingly, the localization pattern for 
Myogenin, showed a stronger cytoplasmic presence in the myoblasts and as differentiation 
progressed, there was more nuclear distribution (Ferri et al., 2009). Similar to MyoD and 
Myf5, the distribution of Myogenin in the nucleus was focused in the interchromatin 
domains and not in the nucleolus. A distinct/stronger cytoplasmic presence was detected for 
MRF4, being distributed in the perinuclear space (Ferri et al., 2009). In addition, MRF4 
was also present in the nucleus especially in the interchromatin domains. Therefore, nuclear 
localization is associated with the transcriptional role of these MRFs and nucleo-
cytoplasmic shuttling of major muscle-specific myogenic factors during the differentiation 
process is not uncommon. 
1.6 Rationale and hypothesis 
There are close to 860 known RBPs. RBPs are necessary to recognize different sequences, 
to perform tight regulation/control and to coordinate gene expression changes. Therefore, 
RBPs have diverse functions; however, the functions of numerous RBPs are still 
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uncharacterized. Each stage of the myogenic program is highly controlled and new proteins 
in the pathway with distinct functions are constantly being identified. It is highly likely that 
some RBPs regulate the expression of myogenic transcription factors or other components 
that form part of the complex cascade of signaling events during myogenesis. In particular, 
RBPs may play important functions in muscle cell proliferation and differentiation, as well 
as in muscle development. Given that (a) RBM5 and RBM10 expression is high in skeletal 
muscle, (b) they have known functions related to cell cycle arrest, (c) they intervene in 
alternative splicing events, and (d) RBM10 is implicated in development, we hypothesize 
that RBM5 and RBM10 play an important role in skeletal myogenesis and that they exert 
their role by regulating alternative splicing of muscle differentiation specific mRNAs. 
1.7 Objectives 
The objectives of the study are firstly, to characterize the expression profiles of Rbm5, 
Rbm10  and their variants and isoforms in the C2C12 skeletal muscle differentiation model. 
Secondly, the study will involve experimentally repressing the expression of RBM5 and 
RBM10 and then allowing the cells to differentiate. The cell (myoblast to myotube) 
morphology will be studied in order to identify the phenotypic changes that result in 
response to knockdown in the differentiating cells. Thirdly, the study will assess molecular 
myogenic changes in the knockdowns by analyzing the expression of myogenic markers 
and a few alternative splicing events that occur during myogenesis.  
 36 
 
Chapter 2  
2 Materials and Methods 
2.1 Cell culture 
C2C12 myoblasts (ATCC® CRL-1772™, Manassas, VA, USA) were grown in growth 
medium (GM), which is Dulbecco’s modified Eagle’s medium (DMEM) (Life 
Technologies, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (FBS) 
(Life Technologies) and 1% antibiotic-antimycotic (Life Technologies). The DMEM 
consisted of the necessary nutrient supplements with 4.5% glucose and 4 mM L-glutamine. 
The cells were incubated in a humidified incubator at 37°C, in a 5% CO2 environment. The 
cells were maintained at 80-90% confluence during growth and the passage number did not 
exceed 20 for all the experiments (Table A1 in Appendix A). GM was changed every two 
days. When the cells reached 80% confluence, differentiation was induced using 
differentiation medium (DM), which is DMEM supplemented with 2% horse serum (HS) 
(Life Technologies) and 1% antibiotic-antimycotic (Sun et al., 2005). DM was changed 
every two days. For expression analysis, the cells were differentiated until day seven (D7); 
day zero (D0) representing the day on which the GM was replaced with DM (Figure 2.1). 
Cells were collected each day. For cell collection, the adherent cells were trypsinized using 
2.5% Trypsin (Life Technologies) for 5 minutes, after which, the trypsin was inactivated 
using serum-containing GM and pelleted at 16 200 x g for 8 minutes. The supernatant was 
discarded and the cell pellets were stored in -80°C until further processing for RNA and 
protein extraction. Simultaneously, duplicate cultures of C2C12 cells were grown on 
coverslips, induced to differentiate and fixed for immunofluorescence staining. 
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Figure 2.1 Time-line of expression analysis. Diagram showing the differentiation time-
frame, and the growth and differentiation conditions. C2C12 myoblasts were grown in GM 
containing 10% FBS and differentiated on D0 using DM which contained 2% HS. Cells were 
collected every day until D7 for total RNA and protein extraction. 
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2.2 Transfection 
2.2.1 siRNA 
RNA interference (RNAi) was used to silence mRNA expression. Small interfering RNAs 
(siRNAs) (Dharmacon, GE Healthcare, Lafayette, CO, USA), which are 21 nucleotide 
double stranded RNAs with sequences specific to Rbm5 and Rbm10 were used to generate 
RBM5 and RBM10 knockdowns (KD) respectively. The siRNA for Rbm5 with sense: 5’-
GAGCGAUAUUCGAGAAAUGUU-3’ and antisense: 5’-
CAUUUCUCGAAUAUCGCUCUU-3’ sequences, targeting sequence at the end of exon 4 
and the beginning of exon 5, will transiently silence all Rbm5 variants (Figure 1.1). The 
siRNA for Rbm10 with sense: 5’-UAUUAGUGCUCUACGAGAUUU-3’ and antisense: 
5’-AUCUCGUAGAGCACUAAUAUU-3’ sequences, targeting sequence at exon 17, will 
transiently silence both Rbm10v1 and Rbm10v3 variants (Figure 1.3). A scrambled siRNA 
(ON-TARGETplus #1, Dharmacon) with non-targeting sequences having at least 4 
mismatches to any mouse gene was used as the negative control to eliminate off-target and 
non-specific effects. In silico analysis of these siRNAs was done through NCBI’s BLAST 
to verify the sequence specificity. In silico analysis of these siRNAs revealed that the 
siRNAs were specific for the target mRNAs and that the scrambled siRNA did not target 
any mouse-specific sequence. 
2.2.2 Transient transfection  
C2C12 myoblasts were grown in six well plates with 2 ml GM. Optimization of siRNA 
concentration and the optimal cell density was done in order to increase KD efficiency. 
Briefly, the cells were transfected using a Tye 563 labeled siRNA duplex control 
(SR30002, OriGene Technologies, Rockville, MD, USA) to determine the optimal cell 
density and siRNA concentration. 
For transfection, the cells were grown to 40-50% confluence and briefly washed twice with 
PBS pH 7.4 (Life Technologies) after which 1.5 ml of GM with no antibiotics was added to 
the cells. Transfection was carried out using a lipid-based delivery system. Five ml of 
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Lipofectamine 2000 (Life Technologies) was mixed with 245 ml of Opti-MEM (Life 
Technologies) and incubated at 22°C for 5 minutes. Subsequently, a final concentration of 
10-25 nM of each siRNA (20 µM stock) was mixed with 245 ml of Opti-MEM and 
combined and all the reagents were incubated at 22°C for 20 minutes. This mixture was 
then added to the cells and the cells were maintained at 37°C in 5% CO2. The medium was 
changed to GM with 1% antibiotic-antimycotic after 24 hours. Cells were collected to 
determine the KD levels at 24 and 48 hours post-transfection. In order to analyze the effect 
of KD during differentiation, cells were induced to differentiate 24 hours after transfection 
by changing GM to DM. The cells were differentiated until day four (D4) and cell pellets 
from two pooled wells were collected every day for RNA and protein extraction (Figure 
2.2). Simultaneously, duplicate cultures of cells were grown on cover slips, transfected, 
induced to differentiate and fixed for immunofluorescence staining. 
2.3 RNA extraction 
RNA was extracted from the cells using Tri-Reagent (Molecular Research center Inc, 
Cincinnati, OH, USA) according to the manufacturer’s instructions. Total RNA pellets 
were resuspended in 20 µl TE (10 mM Tris-HCl and 0.1 mM EDTA) and 1 µl of RNAse 
OUT (40 U/20 µl reaction mixture) (Life Technologies) was added to inhibit RNAse 
activity. The total RNA was quantified using a NanoDrop 2000 UV-Vis spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA) and purity was assessed using the A260/A280 
ratio; samples with ratios between 1.8 to 2 were used for downstream analyses. 
Furthermore, the integrity of the RNA samples was checked by electrophoresis of 1µg 
RNA on a 1% agarose gel stained with SYBR® Safe DNA gel stain (Life Technologies). 
Samples with a 2:1 ribosomal 28S/18S ratio were used in the qPCR and end-point PCR 
analysis. 20 µg of RNA was DNase treated (Turbo DNA-freeTM Ambion kit, Life 
Technologies) according to manufacturer’s instruction in a 50 µl total volume to remove 
DNA contamination.   
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Figure 2.2 Time-line of knockdown analysis. Diagram showing the time-frame for 
transfection and differentiation induction post-transfection. C2C12 myoblasts were transiently 
transfected with specific siRNAs and the cells were collected at 24h and 48h post-transfection 
for total RNA and protein extraction. One set of the transfected myoblasts were induced to 
differentiate 24h after transfection and cells were collected every day until D4 for total RNA 
and protein extraction. 
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2.4 Reverse transcription (RT) 
All the primers were obtained from Alpha DNA (Montreal, QC, Canada). Reverse-
transcription was performed using 2 µg of DNase-treated RNA, 25ng of Oligo(dT) 
(500ng/ml stock), 0.5 mM dNTPs (10 mM stock) (Life Technologies), 1 x first-strand 
buffer (5 x stock), 10 mM DTT (0.1 M stock) and 10 U of Moloney murine leukemia virus 
(MMLV) reverse transcriptase (200U/µl stock) (Life Technologies) in a 40 µl reaction 
volume. A two-step RT was done; first denaturing the RNA at 65°C for 5 minutes followed 
by RT. RT conditions included incubation at 37°C for 2 minutes and addition of enzymes 
and continuation at 37°C for 50 minutes and the reaction was terminated by incubation at 
70°C for 10 minutes. For gene-specific primers, SuperScript II (Life Technologies) was 
used for first-stand cDNA synthesis. For this reaction, 1 µg of DNase-treated RNA was 
reverse-transcribed using 0.5 µM of primers (10 µM stock), 0.5 mM dNTPs (10 mM stock), 
10 mM DTT (0.1 M stock), 1 x first-stand buffer (5 x stock) and 10 U of SuperScript II 
(200U/µl stock) in a 20 µl reaction volume. RT was performed with the above mentioned 
conditions with the exception of carrying out the RT at 42°C for 2 minutes followed by 
incubation at 50°C for 50 minutes. The gene-specific primer mFactorXF (5’ GTT CAA 
ATA CTC TAC TTG GTC C 3’), located in the intronic region (intron 6), reverse 
transcribes the two Rbm5 intron-retaining variants Rbm5+5+6 and Rbm5+6 (Figure1.1), 
and mFactorXR (5’ GAT AGC CTT TAA GAT AAA TGT A 3’) reverse transcribes the 
antisense Rbm5 variant Rbm5-AS1 (Rintala-Maki and Sutherland, 2009). 
2.5 End-Point PCR 
End-point PCR for glyceraldehyde 3- phosphate dehydrogenase (Gapdh), Rbm10v1, and 
Rbm10v3 was carried out using the primers listed in Table 1. Primers were designed using 
PrimerQuest from Integrated DNA Technologies Inc. cDNA synthesis and genomic DNA 
contamination was verified by doing a PCR for Gapdh using exon-exon spanning primers. 
End-point PCR for Rbm10 variants was carried out to detect and quantify their relative 
mRNA expression levels during differentiation. The PCR reaction consisted of 100 ng of 
the cDNA template, 0.2 mM dNTPs (10 mM stock), 200 nM of forward and reverse 
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primers (10 µM stock), 1.25 U of Taq DNA polymerase and 1 x reaction buffer (New 
England Biolabs) in a 50 µl reaction volume. The DNA template was initially denatured for 
5 minutes at 95°C and amplified for 26 cycles for Gapdh and 40 cycles for the Rbm10 
variants, with denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds and 
extension at 72°C for 1 minute, followed by a final extension at 72°C for 10 minutes. A 
452 bp Gapdh product was visualized on a 1% agarose gel.  The use of genomic DNA 
contamination as template would generate a 646 bp fragment. End-point PCR using 
previously published primers (Table 1) was performed to detect the splicing transitions for 
three mRNAs: Dtna (Bland et al., 2010), Integrin β (Cachaco et al., 2003) and Mef2cγ 
(Hakim et al., 2010). The following thermal cycling conditions were used: initial 
denaturation at 95°C for 5 minutes, followed by 36 cycles for Integrin β and Mef2cγ, and 
40 cycles for Dtna at 95°C for 30 seconds, respective primer-dependant temperature 
annealing for 30 seconds and 72°C for 45 seconds and a final extension at 72°C for 10 
minutes, generating fragment sizes listed in Table 1. As negative controls, “RT-” samples, 
containing all reagents without reverse transcriptase and no template control (NTC) 
samples without cDNA template were included to detect any genomic DNA contamination 
or contaminants in the PCR master mix, respectively. No amplification of genomic DNA 
was seen. All of the PCR were performed in duplicates and all of the samples were 
electrophoresed on a 2% agarose gel in duplicates. The AlphaEase FC™ software program 
(Alpha Innotech, Genetic Technologies Inc, Miami, USA) was used to quantify the band 
densities. 
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Table 1 
Primers used in end-point PCR 
 
Transcript Primer ID 5´-3´ Primer sequence Tm °C 
 
Amplicon 
size (bp) 
 
Gapdh 
 
Gapdh F 
Gapdh R 
 
AACACAGTCCATGCCATCAC 
TCCACCACCCTGTTGCTGTA 
 
60 
62 
452 
Rbm10v1 
 
mRBM10E4 F 
mRBM10E8 R 
 
AGCAAAGTGCAGAGGATTCCTACGAG 
TTGGGCACACCACATTTGAAGCAC 
 
78 
72 
322 
Rbm10v3 
 
mRBM10E3 F 
mRBM10E8 R 
 
AGGGCAAGCATGAGTATGACGACT 
TTGGGCACACCACATTTGAAGCAC 
 
72 
72 
334 
Dtna 
 
Dtna F 
Dtna R 
 
AAGTCCCTGAGCTGTGCTTC 
CGATCAGCCTGTGTTCTTCA 
 
62 
60 
391/220 
Integrinβ 
 
Integrinb F 
Integrinb R2 
 
GGCAACAATGAAGCTATCGT 
CCCTCATACTTCGGATTGAC 
 
58 
60 
363/282 
 
Mef2cγ  
 
Mef2c gamma F 
Mef2c gamma R 
 
TCCACCTCGGCTCTGTAACT  
ATCTCGAAGGGGTGGTGGTA 
 
62 
62 
198/102 
     
Tm calculated by 4(G + C) + 2(A + T) °C (Wallace et al., 1979) 
 44 
 
 
2.6 Real-time quantitative PCR (qPCR) 
qPCR was carried out to quantify the mRNA expression levels of Rbm5 variants during 
differentiation. Primers were designed using PrimerQuest from Integrated DNA 
technologies Inc. In silico analysis to check for specificity was performed using the BLAST 
tool from NCBI. Using cDNA synthesized with Oligo(dT) primer, qPCR was carried out 
for Rbm5 (full length and all variants) and the reference genes Gapdh, hypoxanthine-
guanine phosphoribosyltransferase (Hprt) and ribosomal protein S12 (Rps12). cDNA 
synthesized with mFactorXF as template was used for Rbm5+5+6 and Rbm5+6. cDNA 
synthesized with mFactorXR as template was used for Rbm5-AS1. A NTC was used as the 
negative control. Using 21 ng of cDNA template, qPCR was carried out with 12.5 µl of 
iTaq™ SYBR® green super mix with ROX (Bio-Rad, Mississauga, ON, Canada), 300-400 
nM of forward and reverse primers (stock 10 µM) in a 25 µl reaction volume using an ABI 
Prism 7900T (Applied Biosystems, Life Technologies). qPCR was performed for four 
biological replicates with a varying number of technical replicates (2 to 7) and the reaction 
conditions were: denaturation at 95°C for 30 seconds followed by 40 cycles of 95°C for 30 
seconds and primer-dependent annealing temperature (Tables 2 and 3) for 60 seconds. A 
melt-curve analysis with data acquisition at 95°C for 15 seconds, 60°C for 15 seconds and 
95°C for 15 seconds was carried out to determine primer specificity. The absence of a 
melting curve in the NTC sample indicated that there was no contamination of the reagents 
and as well, no stable primer-dimers were formed. A standard curve was generated using 
dilutions of the pooled cDNA samples throughout differentiation and expression levels 
were quantified using the ABI software (SDS 2.4), calculated based on the formula log 
10^((Cq (sample)-y intercept)/(-slope)), where Cq (or Ct) is the cycle threshold value, and 
the y intercept and slope values are derived from the standard curve (Larionov et al., 2005).  
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Table 2 
Primers used in qPCR for quantifying Rbm5 mRNA variants 
Rbm5+5+6 
 
mrintron5  F 
mrintron6 R 
 
GGAACTGACTAACACGAGTATCC 
CTAGACTTGGTGAGTGAAGCAAC 
 
68 
68 
146 
Rbm5+6 
 
mrRBM5E5/6 F 
mrintron6 R 
 
GAGGAAAACAGTGTAAGCCGTG 
CTAGACTTGGTGAGTGAAGCAAC 
 
66 
68 
107 
Rbm5-AS1 
 
mrintron5  F 
mrintron6 R 
 
GGAACTGACTAACACGAGTATCC 
CTAGACTTGGTGAGTGAAGCAAC 
 
68 
68 
146 
Rbm5 (all) 
 
mqRbm5E2/3 F 
mqRbm5E3 R 
 
GACAAAAGAGTGAGTAGAACAGAACG 
ATCACCTCTCCGATCATCGCTTGA 
 
74 
72 
131 
 
Rbm5  
(Full length) 
 
mrRbm5E5/6 F 
rRbm5E7 R 
 
GAGGAAAACAGTGTAAGCCGTG 
GCATTGCAATGTGCTTTCCTTGA 
 
66 
66 
122 
     
 
 
 
 
 
 
 
 
 
mRNA  
transcript  
 
Primer ID 
 
 
 
Primer Sequence [5´to 3´] 
 
Tm 
   °C       
 
Amplicon 
length(bp) 
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Table 3 
Primers used in qPCR for optimizing reference genes for normalization 
 
Gene 
 
PubMed ID 
 
Function 
 
Primer Sequence [5´to 3´] 
 
Tm 
   °C     
 
Amplicon 
length(bp) 
 
 
Actb 
 
 
NM_007393.3 
 
Cytoskeletal 
protein 
 
F: TCCTGACCCTGAAGTACCCCAT  
R: CTCGGTGAGCAGCACAGGGT  
 
68 
66 
 
131 
Gapdh NM_008084.2 Metabolic 
enzyme 
F: ATGTTTGTGATGGGTGTGAA   
R: ATGCCAAAGTTGTCATGGAT  
56 
56 
131 
Hprt NM_013556 Enzyme F: ATGGACTGATTATGGACAGGACTG  
R: TCCAGCAGGTCAGCAAAGAAC  
70 
64 
124  
Rps12 
 
NM_011295.6 Ribosomal 
protein 
F: AAGGCATAGCTGCTGGAGGTGTAA  
R: AGTTGGATGCGAGCACACAGAGAT  
72 
72 
156  
Tbp 
 
 
 
NM_013684.3 
 
Transcription 
factor 
 
F: TGCACAGGAGCCAAGAGTGAA  
R: CACATCACAGCTCCCCACCA  
 
 
64 
64 
 
134 
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2.7 Protein extraction 
Protein extraction was carried out using radio immunoprecipitation assay (RIPA) cell lysis 
buffer [50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% NP-40, 100 mM NaF, 1 mM EDTA 
pH 8.0, 1 mM EGTA pH 7.5, 10 µl/ml of Protease inhibitor cocktail (Sigma-Aldrich)]. 
Briefly, cells were re-suspended in the cell lysis buffer, incubated on ice for 15 minutes and 
centrifuged at 16 200 x g for 15 minutes. The total protein in the supernatant was quantified 
using the Bio-Rad DC protein Assay kit (Bio-Rad). Absorbance was measured at 650 nm 
using a SpectraMax 340PC 384 absorbance microplate reader (Molecular Devices, 
Downingtown, PA, USA). Different dilutions of BSA were used for standard curve 
generation and r2 values of  > 0.9 were considered reliable. 
2.8 Immunoblotting 
Immunoblotting was carried out using rabbit anti-RBM5 at a 1:2 500 dilution (Sutherland 
et al., 2000), rabbit anti-RBM10 at a 1:500 dilution (A301-006A, Bethyl laboratories Inc, 
Montgomery, Texas, USA), mouse anti-α-tubulin at a 1:10 000 dilution (Sc-8035, Santa 
Cruz Biotechnology Inc.), mouse anti-MyoG at a 1:200 dilution (Sc-52903, Santa Cruz 
Biotechnology Inc.), rabbit anti-Myf5 at a 1:200 dilution (Sc-302, Santa Cruz 
Biotechnology Inc.) and rabbit anti-MyoD at a 1:200 dilution (Sc-304, Santa Cruz 
Biotechnology Inc.). Secondary antibodies conjugated to horseradish peroxidase (HRP) 
were goat anti-mouse IgG at a 1:10 000 dilution (Sc-2005, Santa Cruz Biotechnology Inc.) 
and goat anti-rabbit IgG at a 1:10 000 dilution (Sc-2004, Santa Cruz Biotechnology Inc.). 
50 µg of cell lysate in RIPA was re-suspended in 2 x SDS gel loading buffer (100 mM Tris-
HCl pH 6.8, 20% Glycerol, 4% SDS, 0.2% Bromophenol blue and 200 mM 2-
Mercaptoethanol) and after denaturing for 5 minutes at 100ºC was subjected to 
electrophoresis through a discontinuous SDS-PAGE gel prepared as per standard protocol 
(Simpson, 2006). Proteins were transferred onto methanol pre-wetted 0.45 µm PVDF 
membranes (Amersham Hybond-P, GE Healthcare, Mississauga, ON) using a wet transfer 
system. Transfer and loading accuracy was verified by staining with Ponceau S for 5 min, 
after which the membranes were washed with water. The membranes were blocked in 5% 
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non-fat dried milk in TBS-T (0.01 M Tris HCl, 0.15 M NaCl and 0.05% Tween 20) for one 
hour to prevent binding of non-specific proteins and were subsequently incubated over-
night at 4ºC with the respective primary antibodies re-suspended in 3% non-fat dried milk 
in TBS-T. After three washes in 1 x TBS-T, the membranes were then incubated with 
secondary antibodies re-suspended in 3% non-fat dried milk in TBS-T for one hour at 22ºC 
and the bands were visualised by exposure to X-ray film (Amersham hyper ECL film, GE 
Healthcare) using chemi-luminescent detection reagents (Amersham Western blotting 
detection reagents, GE Healthcare). A mild stripping procedure was used for stripping 
bound antibodies from the blot using buffer containing 0.02M glycine, 0.1% SDS and 0.1% 
Tween 20, at pH 2.2. The stripping efficiency was verified by re-probing secondary 
antibody-HRP again, after which the membranes were blocked and probed again with the 
appropriate antibodies. Each blot was stripped not more than three times. The AlphaEase 
FC™ software program was used to obtain the band intensities from the immunoblots. For 
this, the intensity of each protein band was quantified after subtracting the background. One 
limitation with this method is that if the bands are over exposed as observed in some of the 
blots, the intensity becomes saturated, which can affect quantification. 
2.9 Immunofluorescence  
For immunofluorescence (IF), cells were grown on glass coverslips in GM or DM as 
described previously. Cells were washed gently in PBS (pH7.4) to remove the medium and 
fixed for 10 minutes in 4% paraformaldehyde in PBS. Cells were permeabilized for 5 
minutes by incubation in 0.5% Triton X-100 in PBS and then blocked for 15 minutes in 5% 
goat serum in PBS. For localization studies, sequential double immunofluorescence was 
performed by using the primary mouse anti-Mf-20 (Developmental Studies Hybridoma 
Bank, Iowa City, IA) for myosin heavy chain (MyHC) at 1:100 dilution and incubated for 
one hour at 22ºC, followed by either rabbit anti-RBM5 (Sutherland et al., 2000) or rabbit 
anti-RBM10 (A301-006A, Bethyl laboratories Inc) at a 1:10 dilution, and incubated 
overnight at 4°C. The secondary antibodies, Alexa fluor 594 anti-rabbit IgG and Alexa 
fluor 488 anti-mouse IgG (Molecular Probes, Life Technologies) were used at a 1:200 
dilution for one hour. All antibodies were suspended in 5% BSA in PBS. For verification of 
the muscle skeletal prototype, the differentiating cells were labeled with Mf-20 as described 
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previously (Masilamani et al., 2014), followed by rhodamine phalloidin (Molecular Probes, 
Life Technologies) in PBS, which stains filamentous actin, at a 1:500 dilution. For KD 
studies, cells were stained with the primary mouse anti-Mf-20 (Developmental Studies 
Hybridoma Bank) at a 1:100 dilution and incubated for one hour at 22ºC followed by Alexa 
Fluor 488 anti-mouse IgG (Molecular Probes, Life Technologies) secondary antibody at a 
1:200 dilution for one hour. The nucleus was stained using 5 mM DRAQ5TM (Biostatus 
Ltd, Leicestershire, UK) at a 1:1 000 dilution in PBS for 30 minutes. The coverslips were 
then washed thrice in PBS and mounted on glass slides using 90% glycerol and sealed with 
nail polish. Control staining was performed to measure the level of detection of non-
specific signals (Table 4).  
2.10 Confocal LASER scanning microscopy (LSM) 
Images of the fluorescent slides were taken using a Zeiss LSM 510 Meta confocal 
microscope (Carl Zeiss, Oberkochen, Germany). The LASER excitation wavelengths were 
set at 633 nm (DRAQ5), 488 nm (MyHC) and 543 nm (RBM5 or RBM10/rhodamine 
phalloidin). The same settings were kept for cells at different differentiation time-points. 
For expression and knockdown studies, the images were taken using the 25X objective and 
to assess localization, the objective was set at 63X and then electronically magnified. 
Images were acquired sequentially to avoid bleed-through from spectral overlapping. For 
the localization studies, the laser settings were set to optimize signal detection rather than to 
control for protein expression levels. 
2.11 Measurement of cell parameters 
The cells were analyzed using the Cell Counter plug-in from ImageJ (Schneider et al., 
2012). For characterization of the differentiation morphology, 3 randomly chosen separate 
fields from one representative plate were counted for each day during differentiation. For 
the knockdown experiments, to determine the effect of KD on C2C12 cell count, 
differentiation, fusion and maturation, at least 8-12 randomly chosen separate fields were 
counted for each day and for each transfection condition. The numbers of nuclei was 
determined by DRAQ5 positive staining and counted for each separate field and indicated 
as the average nuclei number. The percentage of cells entering the differentiation phase is 
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represented as differentiation potential. The differentiation potential was calculated based 
on the ratio of nuclei in MyHC-positive cells/total number of nuclei in the field X 100 % 
(Shafey et al., 2005). The number of cells expressing the muscle-specific marker Mf-20 
from all the fields was counted to assess the expression of MyHC and denoted as average 
number of MyHC-positive cells. The extent of fusion was determined as the fusion index. 
The fusion index, expressed as a percentage, is the ratio of the number of nuclei in 
myotubes (MyHC-positive cells with two or more nuclei)/(total number of nuclei in 
myoblasts and myotubes) X 100 % (Ferri et al., 2009). In addition, the average number of 
myotubes (MyHC-positive cells with two or more nuclei) per field were counted and 
plotted as a graph. The maturation efficiency was obtained by calculating the average 
number of myofibers (≥5 nuclei) per field. 
2.12 Statistical analyses 
All statistical analyses were performed using either Microsoft excel or Graph Pad prism® 
(GraphPad software Inc, La Jolla, CA, USA). For all qPCR analysis, the mRNA expression 
values were normalized to the geometric mean of three reference genes (Gapdh, Hprt, 
Rps12). The relative fold-change in mRNA expression during differentiation was calculated 
from the quantitiy normalized to the level on day 0 from 4 biological replicates with 2-7 
technical replicates. Outliers were eliminated by inter-quartile range (IQR) analysis, based 
on the 25th and 75th percentile values. One-way ANOVA was used to calculate the 
statistical significance of the mRNA expression levels during differentiation. Pearson 
correlation (r) analysis was used to determine the relationship of expression of each Rbm5 
variant during differentiation. For all end-point PCR analysis, the average fold-change was 
calculated after normalization to Gapdh.  Fold-changes in expression for each day during 
differentiation compared to D0 were calculated from the normalized values from 4 
biological replicates with 2-4 technical replicates to assess the mRNA expression levels. 
Statistical significance was calculated using one-way ANOVA. The protein expression 
levels were normalized to α-tubulin. The relative fold change in expression for each day 
during differentiation was calculated from the normalized value on D0 from 4 biological 
replicates with 2 technical replicates. One-way ANOVA followed by Bonferroni post-hoc 
test was used to calculate statistical significance of the expression levels during 
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differentiation (amongst multiple data sets). A P value of  < 0.05 was considered 
statistically significant. 
Cell morphology parameters in the KDs were measured using the cell counter plugin from 
ImageJ. Cell count, differentiation, fusion and maturation were determined by counting 8-
12 randomly chosen sepatate fields from each plate for each day and each condition for the 
two trials. Statistical significance was calculated using unpaired Students’ t-test. A P value 
of < 0.05 was considered statistically significant.  
For quantification of exon inclusion, firstly, using densitometry, the band intensities of the 
control and KDs were quantified from 2-4 technical replicates. The values were normalized 
to the band intensity of Gapdh. Secondly, using the values, the percentage of inclusion was 
obtained by relative ratios of normalized inclusion/ normalized inclusion+exclusion X 100 
% (Chen and Zheng, 2009). 
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Table 4 
Controls for double immunofluorescence staining 
 
Control Conditions First primary antibody Second primary antibody 
Normal 
 
1⁰ Antibody 
2⁰ Antibody 
Labeling 
 
 
Rabbit anti-Rbm5 (or Rbm10) 
Goat anti-rabbit Alexa fluor 594 
Red 
 
 
Mouse anti-Mf-20 (MyHC) 
Goat anti-mouse Alexa flour 488 
Green 
 
No first 1⁰Ab  1⁰ Antibody 2⁰ Antibody 
Labeling 
 
 
None 
Goat anti-rabbit Alexa fluor 594 
No labeling 
 
 
Mouse anti-Mf-20 (MyHC) 
Goat anti-mouse Alexa flour 488 
Green 
 
No second 1⁰Ab  1⁰ Antibody 2⁰ Antibody 
Labeling 
 
 
Rabbit anti-Rbm5 (or Rbm10) 
Goat anti-rabbit Alexa fluor 594 
Red 
 
 
None 
Goat anti-mouse Alexa flour 488 
No labeling 
 
Adapted from (Burry, 2011) 
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Chapter 3  
3 Results 
Results obtained are divided into three sub-sections. The first sub-section details the 
establishment of the C2C12 differentiation model to study the expression and function of 
RBM5 and RBM10. The second sub-section describes the expression and cellular 
distribution of these two proteins in this model system. The third sub-section contains the 
results obtained when the cells were deprived of RBM5 and RBM10 and induced to 
differentiate. 
3.1 Assessment of the differentiation landmarks 
C2C12 myoblasts, a secondary cell line derived from mouse thigh muscle (Yaffe and Saxel, 
1977), were employed for elucidating the role of RBM5 and RBM10 in skeletal 
myogenesis. C2C12 myoblasts are well-characterized and reproducible model systems 
normally used in the study of the myogenic differentiation program (Casadei et al., 2009, 
Tannu et al., 2004) and are thus ideal for studying the effect of RBM5 and RBM10 in a 
normal non-transformed system, especially differentiating cells in culture.  
3.1.1 Cell morphology 
To determine the growth and differentiation profile, the C2C12 cells were examined 
visually using immunofluorescent staining. Using DRAQ5 nuclear stain, mouse anti-MyHC 
specific antibody Mf-20 and rhodamine phalloidin for actin staining, the distinctive 
morphology of the mono-nucleated myoblasts, elongated myocytes and fused multi-
nucleated myotubes were visualized (Figure 3.1). The cell nuclei were counter-stained with 
DRAQ5, which was visualized as a blue colour in our experiments. The red colour showed 
the characteristic pattern of filamentous actin (f-actin) and was clearly evident in all the 
cells stained with rhodamine phalloidin. The f-actin staining showed the muscle cell 
morphology and cytoskeleton and helped in distinguishing stained areas of cells from 
unstained areas. The Mf-20 antibody binds to the light meromyosin of the myosin heavy 
chain, which is present in the sarcomere (Bader et al., 1982). The green colour showed the 
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characteristics of the MyHC protein and was detected in the differentiating myocytes and 
myotubes.  
As differentiation was induced, we expected to see a change in morphology, from single 
mono-nucleated myoblats to multi-nucleated myofibers. Cell proliferation stops as 
myoblasts starts to differentiate. Cell proliferation should cease on starvation/serum 
deprivation and we would expect to see that the number of myotubes will increase soon 
after differentiation is initiated (by D2) and that the number of myofibers will increase later 
as differentiation proceeds (>D4).  
On D0, the cells showed the presence of DRAQ5-stained single nucleus. Between D0 and 
D1, the number of cells increased. The cells were becoming confluent as evident from the 
increase in the proportion of nuclei. As expected, by D2, the cell morphology changed; 
from being fusiform or star-shaped they became elongated and were compact. Initially, as 
the mono-nucleated myoblasts were proliferating there was no MyHC expression, however 
within two days after induction, the cells were positive for MyHC, one of the muscle 
differentiation-specific markers, which shows the induction of MyHC expression. On D3, 
fusion of cells was more evident because the MyHC-stained cells had two or more nuclei, 
which are called myotubes. As differentiation proceeded, the rate of cell fusion occurred 
faster, which was apparent from the increase in the number of nuclei arranged closely in a 
linear fashion in the myotubes and also an increase in the number of myotubes was 
detected. By D7, the number of myotubes was greater with an increase in the number of 
DRAQ5-stained nuclei inside the myotubes and the formation of myofibers (≥5 nuclei) was 
evident. Our IF staining results therefore show that co-ordinated events of differentiation 
are occurring phenotypically. 
Next, we proceeded to quantitatively assess the cell morphological parameters such as the 
total number of nuclei, the number of MyHC-positive cells, differentiation potential, fusion 
index, the number of myotubes (≥ 2 nuclei) and the number of myofibers (≥ 5 nuclei). As 
mentioned above, when differentiation is induced, cell proliferation should stop. When the 
number of cells are counted by counting the DRAQ5-stained nuclei, we should see a stop in 
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proliferation before D2, because cell cycle withdrawal occurs within two days (Shen et al., 
2003). Induction of MyHC expression should initiate differentiation.  
Our results (Figure 3.2) showed that the total cell number was less on D0 and increased on 
D1 and remained similar on D2 indicating that cell proliferation stopped on D1. 
Specifically, the total number of cells increased from 70±18/ high power field (hpf) on D0 
to 152±11/ hpf on D1 and was 153±10/ hpf on D2. The expression of MyHC, obtained 
from the count of MyHC-positive cells, occurred on D2, increased on D3, and reached a 
plateau thereafter. There were no MyHC expressing cells on D0 and D1, however on D2, 
there were 8±4 MyHC-positive cells/ hpf, which increased to 22±4 cells/ hpf on D3. 
Differentiation started on D2 and increased until D7. This was evident from the 5±2 % 
differentiating cells on D2 to the 19±6 % increase on D3. Fusion of the myocytes to form 
the multinucleated myotubes began on D3 and reached a maximum on D6. The number of 
fused cells increased from 9±2 % (D3) to 38±3 % (D6). Maturation potential, which 
followed fusion was indicated by the presence as well as an increase in the number of 
myotubes and myofibers. There were 8±1 myotubes/ hpf on D4, 9±0.3/ hpf on D5, 10±1.5/ 
hpf on D6 and 10±0 on D7. Myofiber formation started from D4. From these results it was 
clear that differentiation had occurred in the C2C12 murine myoblasts, which led to fusion 
and that the endpoint of differentiation has been reached in a timely manner.  
During the entire differentiation process, a small fraction of cells were present that were 
mono-nucleated and did not undergo differentiation, which were the reserve cells (Miller, 
1990). These cells did not express MyHC and were quiescent, which is what is observed 
normally (Yoshida et al., 1998). These MyHC-negative cells remained undifferentiated 
even after D4, however, during this time-point the MyHC-positive cells exhibited an 
increase in MyHC expression and were fusing.  
These results therefore, (a) correlated with the previously reported observations, (b) 
signified that the distinctive morphology is skeletal, and (c) asserted that differentiation 
progressed properly from myoblasts to form myotubes and myofibers.
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Figure 3.1 Visualization of the C2C12 differentiation morphology using IF. C2C12 myoblasts 
were grown to 80% confluency. On D0, the cells were induced to differentiate by removing growth 
factors (10% FBS to 2% HS) and were differentiated for 7 days (D0-D7). Cells were fixed, 
permeabilized and visualized by immunostaining. Phase contrast images and pictures of cells with 
DRAQ5, anti-mouse Mf-20 with fluorescein labeled secondary antibody and rhodamine phalloidin 
were taken using 25x objective, Scale Bar = 100µm. 
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Figure 3.2 Characterization of the C2C12 differentiation morphology. Differentiating C2C12 
cells were fixed, permeabilized and visualized by IF staining. Pictures of cells stained with 
DRAQ5, anti-mouse Mf-20 with fluorescein labeled secondary antibody were taken every day 
and cell count analysis was performed. A) The average number of cells obtained by counting the 
total number of DRAQ5-stained nuclei per field, B) The average number of MyHC-positive cells, 
C) Differentiation potential, ratio of number of nuclei in MyHC-positive cells to the total number 
of nuclei in the field X 100, C) Fusion index, ratio of the number of nuclei in MyHC-positive 
cells (≥2 nuclei) to the total number of nuclei in myoblasts and myotubes X 100, D) Maturation 
potential showing the average number of myotubes and the average number of myofibers (≥5 
nuclei) from all fields. Error bars represent SEM from 3 separate fields of view on each plate. 
B C 
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3.1.2 Expression of myogenic proteins 
Most of the phenotypic changes that occur during differentiation are caused by gene 
expression changes at the molecular level (Moran et al., 2002). Changes in the expression 
levels of differentiation markers such as MyoD and MyoG are clear indicators of the 
differentiating status of the cells (Sabourin and Rudnicki, 2000). MyoD is a marker that is 
expressed in the early stages (determination/initiation) (Louis et al., 2008, Tomczak et al., 
2004) and is necessary to maintain the cells in the differentiated state. MyoG is a 
characteristic differentiation protein marker that is not expressed during initiation but is 
present during the mid-stages of myogenic differentiation (Faralli and Dilworth, 2012). 
Expression of MyoG is the earliest indicator of differentiation. 
Therefore, the expression levels of MyoD and MyoG were analyzed during the time course 
for differentiation using immunoblot analysis. Alpha-tubulin was used as a loading control, 
as it is a commonly used loading control and the expression does not change during 
differentiation (Blais et al., 2005, Smith et al., 2009, Jin et al., 2010, Ferri et al., 2009). 
Previous investigators have shown that MyoD can be expressed in C2C12 cells 
independent of differentiation status (Ferri et al., 2009). We expected to detect MyoD in the 
myoblasts and myotubes (Blais et al., 2005), and the levels to remain the same throughout 
differentiation (Shen et al., 2003). MyoG levels were expected to be absent in the 
myoblasts but detected 24 hours after switching to DM and should be present during 
differentiation (Blais et al., 2005). 
As expected, MyoD (Dedkov et al., 2003) was expressed at D0 and the levels remained the 
same as differentiation proceeded (Figure 3.3). Next, as anticipated, MyoG (bottom band) 
(Favreau et al., 2004) was barely detected in undifferentiated myoblasts on D0 (Figure 3.4). 
Subsequently, MyoG levels increased after 24 hours of induction reaching the highest 
levels (four-fold) on D2 and then decreasing in the terminal-stages of differentiation. 
Transition from proliferation to differentiation after serum withdrawal indicates that the 
myoblasts are induced to differentiate. Accordingly, the absence of MyoG on D0 and high 
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levels on D2 indicated that induction of differentiation has occurred following the 
proliferation phase when the growth factors are removed.  
Therefore, from our experiments we can conclude that the change in MyoD and MyoG 
levels paralleled previous findings, which show that the MRF expression is regulated, and 
the time-line of expression followed the pattern previously observed (Dedieu et al., 2002). 
These results corroborated molecularly that (a) the C2C12 cells are differentiating, (b) 
serum withdrawal induced the cells to differentiate and (c) the formation of myotubes was 
skeletal muscle specific.  
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Figure 3.3 MyoD protein expression during C2C12 differentiation. MyoD is present on all 
days as differentiation proceeds. Using immunoblots, the MyoD (middle band) expression 
levels  were quantified. The expression levels during the time-course of differentiation were 
analyzed using densitometry and plotted on a graph. α-tubulin was used for normalization. 
Error bars represent SEM from four biological replicates with technical duplicates for each. 
Raw data in Appendix A-Figure A1.  
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Figure 3.4 MyoG protein expression during C2C12 differentiation. MyoG is barely 
detectable on D0, is highest on D2 and decreases in the terminal-stages of differentiation. 
Using immunoblots, the MyoG (bottom band) expression levels were quantified. The 
expression levels during the time-course of differentiation were analyzed using densitometry 
and plotted on a graph. α-tubulin was used for normalization. Error bars represent SEM from 
four biological replicates with technical duplicates for each. Raw data in appendix A-Figure 
A1. 
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3.2 RBM5 and RBM10 expression and localization during C2C12 
differentiation 
After confirming the differentiation pattern morphologically and assessing the myogenic 
gene expression changes at the molecular level in the chosen C2C12 mouse model, protein 
expression levels of RBM5 and RBM10 were analyzed. Next, to determine the level of 
regulation of RBM5 and RBM10 expression, the levels of mRNA variants were assessed. 
In addition, using antibodies specific to each RBP, the sub-cellular distribution and the 
localization pattern were explored. Thus, this expression profile analysis serves as the first 
step to assess if RBM5 and RBM10 are potentially involved in skeletal myogenesis. 
3.2.1 RBM5 and RBM10 are expressed in myoblasts, myocytes and myotubes 
The presence of endogenous RBM5 and RBM10 protein in C2C12 cells during 
differentiation was assessed using immunoblots. The measurement of RBM5 protein levels 
during differentiation has not been done previously. However, based on previous northern 
blots of human skeletal muscle (Drabkin et al., 1999), we expected to detect RBM5 in 
myotubes. As, expected we detected RBM5 in myotubes. The specific protein band for 
RBM5, which is the full length translated RBM5 protein, migrated at ~113 kDa (Figure 
3.5). Furthermore, the RBM5 band was detected during all seven days in the differentiating 
cells. Therefore, this experiment revealed that RBM5 was present in the murine myoblasts, 
myocytes and myotubes. 
Using the same total protein, the specific protein bands for RBM10 were visualized. The 
measurement of RBM10 protein levels during differentiation has not been done previously. 
However, based on previous northern blots of human skeletal muscle 
(http://www.kazusa.or.jp/huge/gfimage/northern/html/KIAA0122.html), we expected to 
detect RBM10 in myotubes. As, expected we detected RBM10 in myotubes. Interestingly, 
although only one RBM10 mRNA transcript was present in the northern blots; we detected 
two RBM10 bands, one of which corresponds to the full-length translated RBM10 protein 
isoform (RBM10v1) and the other, the exon 4 alternatively spliced shorter isoform 
(RBM10v3) (Figure 3.6). Thus, two RBM10 isoforms were present in C2C12 cells and 
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migrated at ~130 kDa and ~117 kDa. Furthermore, both of the RBM10 isoforms were 
expressed during all seven days in the differentiating cells. Therefore, similar to RBM5, 
both RBM10v1 and RBM10v3 were present in the murine myoblasts, myocytes and 
myotubes.  
In addition, it was evident that there was a difference in the expression of the RBM10 
isoforms. The expression levels of RBM10v3 were higher than RBM10v1. We observed 
this on all days during differentiation. This is different from the observations seen in 
transformed cell lines; the RBM10v2 isoform (which is the mouse RBM10v3) was not 
expressed (Loiselle and Sutherland, 2014). Our results were similar to that observed in 
H9c2 cardiac- and skeletal- specific differentiation (Loiselle and Sutherland, 2014).  
3.2.2 RBM5 and RBM10 expression decreases during differentiation 
The band intensity of RBM5 and the two RBM10 isoforms was measured using 
densitometry. The intensity levels were normalized to the band intensity of the loading 
control, α-tubulin, as described previously. Fold-changes in expression for each day, 
compared to D0 were calculated to assess the protein expression levels.  Based on the 
northern blots of human skeletal muscle, we expected to see high levels in the myotubes. 
However, our results indicate that the protein levels of both RBM5 and RBM10 decreased 
as differentiation progressed (Figures 3.5, 3.6). The amount of endogenous RBM5 and 
RBM10 was lower in differentiating myotubes than in proliferating myoblasts. There was a 
marked reduction in the protein levels during the later stages of differentiation but RBM5 
and RBM10 were still detectable.  
Certainly, the fold-change in RBM5 expression levels during differentiation was highly 
significant. Specifically, a decrease in RBM5 expression levels was noticed as the cells 
differentiated (P < 0.0001) (Figure 3.5). The reduction in the levels of RBM5 started on D2 
and decreased thereafter, except on D5, which showed a slight increase. Interestingly, when 
compared to D0, the expression levels dropped 50% by D3 and > 50% by D7. Importantly, 
this reduction in expression was significant, as confirmed by Bonferonni post-hoc multiple 
comparison test, when each day was analyzed; D0 vs D3, D4, D5 D6 and D7, D1 vs D4, 
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D6 and D7, and D2 vs D6 and D7, showed statistically significant (varying P values) 
differences in RBM5 levels. 
Based on the northern blots of human skeletal muscle, we expected to see high RBM10 
expression in the myotubes. On the contrary, our results showed that there was a highly 
significant down-regulation in the fold-change in expression levels of the RBM10 isoforms 
during differentiation. The protein expression levels for both of the RBM10 isoforms 
decreased during the terminal-stages of myogenesis, the reduction being more pronounced 
for RBM10v1 (P < 0.0001) than for RBM10v3 (P = 0.0374) (Figure 3.6). The levels of 
both RBM10 isoforms decreased starting from D2. The level of RBM10v1 was 
significantly reduced from D2 to D7 whereas the level of RBM10v3 was significantly 
lower only on D7, as confirmed by Bonferonni post-hoc multiple comparison test. Indeed, 
significant (varying P values) differences in RBM10v1 levels amongst D0 vs D2, D3, D4, 
D5 D6 and D7; D1 vs D4, D6 and D7; D2 vs D7 were observed. Furthermore, when the 
reduction in fold-change was assessed, the expression was decreased by >50% by D7 for 
RBM10v1 and exactly 50% for RBM10v3 compared to D0.  
To summarize, we detected RBM5, RBM10v1 and RBM10v3 in murine differentiating 
C2C12 myoblasts, and their presence was detected in all three myogenic cell types; 
myoblasts, myocytes and myotubes. The protein levels, however, were down-regulated 
during differentiation with a significant decrease by D7 when compared with D0. Finally, 
this similarity in the expression profile of both RBM5 and RBM10 proteins in 
differentiating C2C12 cells suggests a co-expression pattern for these two RBPs.  
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Figure 3.5 RBM5 protein expression during C2C12 differentiation. RBM5 is present in 
myoblasts, myocytes and myotubes. As differentiation proceeded RBM5 levels decreased and 
the decrease was significant from D3 onwards when compared with D0. Using immunoblots 
the RBM5 expression levels were quantified. The expression level during the time-course of 
differentiation was analyzed using densitometry and plotted on a graph. α-tubulin was used 
for normalization. Error bars represent SEM from four biological replicates with technical 
duplicates for each. Statistical significance was calculated using one-way ANOVA and 
Bonferonni post-hoc multiple comparison test,* P value < 0.05 were significant. Raw data in 
appendix A-Figure A2. 
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Figure 3.6 RBM10 protein isoforms expression during C2C12 differentiation. Both the 
RBM10 isoforms are present in myoblasts, myocytes and myotubes. As differentiation 
proceeded the levels decreased and the decrease was significant from D2 onwards when 
compared with D0 for RBM10v1. The decrease in expression in differentiating cells was 
significant on D7 compared with D0 for RBM10v3. Using immunoblots the expression levels 
of the RBM10 isoforms RBM10v1 and RBM10v3 were quantified. The expression level 
during the time-course of differentiation was analyzed using densitometry and plotted on a 
graph. α-tubulin was used for normalization. Error bars represent SEM from four biological 
replicates in technical duplicates. Statistical significance was calculated using one-way 
ANOVA and Bonferonni post-hoc multiple comparison test, * P value < 0.05 were 
significant. Raw data in appendix A-Figure A2. 
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3.2.3 Rbm5 and Rbm10 mRNA variants are expressed but their levels do not change in 
differentiating cells 
To explore if the changes in protein expression were contributed by post-transcriptional 
modifications, the mRNA expression levels of the alternatively spliced variants of RBM5 
and RBM10 were quantified. The Rbm5 mRNAs that were measured in this study are Rbm5 
(full-length), Rbm5+5+6, Rbm5+6 and Rbm5-AS1. These four RBM5 variants were 
analyzed because of their association with known functions such as cell cycle arrest, 
apoptosis and alternative splicing in other cell types (Mourtada-Maarabouni et al., 2006), 
which are the cellular events that underlie myogenesis.  
3.2.3.1 Rbm5 mRNA variants 
The expression level of the Rbm5 mRNA variants was quantitatively assessed using qPCR. 
Using the cDNA template reverse transcribed with Oligo(dT) and exon-specific primers 
located in exon 2/3 junction (forward primer) and exon 3 (reverse primer), the levels of all 
Rbm5 variants were quantified (Figure 1.1). Next, using the same cDNA template, but 
primers located in exon 5/6 junction (forward primer) and exon 7 (reverse primer), the full-
length Rbm5 levels were quantified (Figure 1.1). Finally, for quantifying the other three 
variants, qPCR primers were located in the intronic regions for the intron retaining variants 
Rbm5+6 and Rbm5+5+6, for which the cDNA template was synthesised using a gene-
specific primer (mFactorXF) and in the antisense strand for Rbm5-AS1, for which the 
cDNA template was synthesized using a gene-specific primer (mFactorXR).  
The coefficient of determination (R2) of the standard curves showed that the Cq of dilutions 
are a proper fit to the curve and were in the range of 0.98-0.99 and the qPCR efficiencies 
calculated based on the slope of the standard curve were 1.96 (Rbm5 full-length), 1.79 
(Rbm5 all variants), 1.73 (Rbm5+6), 2.04 (Rbm5+5+6) and 1.96 (Rbm5-AS1). The 
geometric mean of three reference genes (Gapdh, Hprt, and Rps12) was used for 
normalization because these three genes were found to be stably expressed during C2C12 
differentiation. These reference genes were chosen after proper validation using one-way 
ANOVA and NormFinder analysis (Masilamani et al., 2014) (See Appendix B). The R2 
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values for these three reference genes were a good fit to the standard curve and were in the 
range of 0.98-0.99; in addition, the qPCR efficiencies were 2.2 (Gapdh), 2 (Hprt) and 2.19 
(Rps12). RNA expression levels were calculated using the relative quantification method 
because of the variation in qPCR efficiencies.  
Our results revealed that full-length Rbm5, Rbm5+6, Rbm5+5+6 and Rbm5-AS1 were 
detected in the C2C12 murine cells throughout the myogenic differentiation process (Figure 
3.7). From this, we conclude that all the variants described in humans are present in mouse 
C2C12 cells. Based on our protein expression study results (Figure 3.5), we expected to see 
high Rbm5 mRNA levels in myoblasts than in myotubes. However, when the relative fold-
change in expression for the day of differentiation was calculated relative to the quantity on 
D0, the levels of all the Rbm5 variants (measured together) did not change during any day. 
Additionally, when each variant was measured individually, the levels did not change, 
which confirms the previous observation. Therefore, during differentiation, the mRNA 
levels remained relatively stable, except for small variations, which however, were not 
statistically significant. To conclude, during C2C12 differentiation, the Rbm5 mRNA levels 
remained unchanged. 
To determine if the variants regulated the expression of each other, using the fold-change in 
expression values we performed a pair-wise correlation using the Pearson correlation 
analysis (Mansson et al., 2004) (Table 5). A significant P value of 0.0003 with a R2 value 
of 0.9 (closer to +1, positive correlation) indicates that the expression of all variants 
collectively is correlated to the expression of each Rbm5 variant individually. This is 
indeed expected since it was found that there was a correlation in expression profile among 
all of the variants. However, no significant correlation was found when one variant was 
compared against the other. Therefore, in C2C12 myoblast differentiation, the Rbm5 
mRNA variants did not appear to have a regulatory relationship (linear positive correlation) 
on the co-expression of each other.  
To summarize, we detected four Rbm5 mRNA variants in the murine C2C12 differentiating 
cells and the variants were present at all differentiation time points (D0 to D7) in 
myoblasts, myocytes and myotubes. The levels were the same during the entire process, 
unlike the down- regulation observed in the RBM5 protein levels. Therefore, this implies 
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that the expression of RBM5 in differentiating C2C12 cells is not regulated at the 
transcriptional level but is subjected to post-transcriptional and/or post-translational 
regulation.  
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Figure 3.7 mRNA expression levels of Rbm5 variants during differentiation. All the 
variants seen in human are expressed in the mouse C2C12 differentiating cells. No significant 
change in expression was observed during differentiation. Using qPCR the mRNA expression 
levels of A) Rbm5 full length, B) Rbm5 (all variants), C) Rbm5+6, D) Rbm5+5+6 and E) 
Rbm5-AS1 were quantified. The graph represents the levels during the time-course of 
differentiation from D0 to D7. Specific primers as listed in Table 2 were used for qPCR. The 
expression levels were normalized to the geometric mean of Gapdh, Hprt and Rps12. Error 
bars indicate SEM from four biological replicates with n=2-7 technical replicates. Statistical 
significance was calculated using one-way ANOVA. 
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Table 5 
Pearson correlation for Rbm5 mRNA variants 
Significance: * p < 0.05, ** p < 0.01 and *** p < 0.001.  
Pearson’s correlation values closer to +1 or -1 indicate strong correlation. 
 
 
 
Parameter Rbm5 All Rbm5-AS1 Rbm5+5+6 Rbm5+6 Rbm5 FL 
Pearson r 0.9511 0.5541 0.5143 0.1238 0.04382 
95% confidence 
interval 
0.7472 to 
0.9914 
-0.2473 to 
0.9053 
-0.2988 to 
0.8947 
-0.6365 to 
0.7621 
-0.6820 to 
0.7262 
P value (two-tailed) 0.0003 0.1542 0.1923 0.7703 0.9180 
P value summary *** ns ns ns ns 
Is the correlation 
significant? 
(alpha=0.05) 
Yes No No No No 
R square 0.9046 0.3070 0.2645 0.01532 0.001920 
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3.2.3.2 Rbm10 mRNA variants 
The expression levels of the two Rbm10 mRNA variants were analyzed using semi-
quantitative RT-PCR (end-point PCR) with exon-specific primers (Figure 3.8). 
Specifically, the PCR was performed using a forward primer located on exon 4 along with 
the reverse primer located on exon 8, which would amplify only Rbm10v1 because of the 
absence of exon 4 in Rbm10v3 (Figure 1.3). PCR primers located on exon 3 (forward 
primer) and exon 8 (reverse primer) were used for Rbm10v3. Using densitometry, the band 
intensities were calculated and were normalized to the band intensity of Gapdh. Gapdh was 
used because the levels of Gapdh did not change during differentiation and hence was a 
suitable normalization control (Nishimura et al., 2008). Additionally, we have shown using 
qPCR that Gapdh is stably expressed during differentiation (Masilamani et al., 2014) (See 
Appendix B). Both the Rbm10v1 and Rbm10v3 variants were expressed in the myoblasts, 
myocytes and myotubes. Based on our protein expression results, we expected to see the 
myotubes with lower Rbm10 mRNA levels compared to the myoblasts. Interestingly, 
contrary to what was seen at the protein level, the mRNA expression levels for both of the 
variants remained the same. The expression did not change during the time-course of 
differentiation. Therefore, the expression of RBM10 in C2C12 cells does not appear to be 
regulated at the transcriptional level but is subjected to post-transcriptional and/or post-
translational regulation.  
One limitation of using end-point PCR is that it is a semi-quantitative approach and 
therefore in order to accurately assess the mRNA expression of both the RBM10 variants 
qPCR should be used. However, using qPCR for quantification of the two variants with 
231bp nucleotide difference requires proper design and validation of many different primer 
pairs. Though it is possible to design qPCR primers located at the alternative exon (Exon4) 
and the constitutive exon (Exon5) for amplifying Rbm10v1, designing primers located in 
the exon-exon junction (Exon3/5) and the constitutive exon (Exon5) for RBM10v3 can lead 
to generation of false-positives and decrease in fidelity because of sequence similarity at 
the exon-exon junction (Brosseau et al., 2010). 
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To conclude, the apparent discrepancy between changing protein levels and the steady state 
mRNA levels for both RBM5 and RBM10 in the differentiating cells (myoblasts to 
myotubes) suggests that post-transcriptional and/or post-translational modifications 
contribute to the regulation of RBM5 and RBM10 during differentiation. Interestingly, both 
Rbm5 and Rbm10 had a similar pattern of expression. This further confirms their co-
expression during differentiation, which possibly implies that they contribute to distinct 
functions in myogenesis. 
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Figure 3.8 mRNA expression levels of Rbm10 variants during differentiation. The two 
variants seen in human are expressed in mouse C2C12 differentiating cells. No significant 
change in expression was observed during differentiation. Using end-point PCR the mRNA 
expression levels of Rbm10 variants Rbm10v1 and Rbm10v3 were analyzed. The graph 
represents the levels during the time-course of differentiation from D0 to D7. Specific primers 
as listed in Table 1 were used for end-point PCR. The expression levels were normalized to 
Gapdh. Error bars indicate SEM from four biological replicates. Statistical significance was 
calculated using one-way ANOVA. Raw data in appendix A-Figure A3. 
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3.2.4 RBM5 and RBM10 are differentially localized in differentiating C2C12 cells 
To determine the subcellular location of RBM5 in the differentiating C2C12 cells, we 
carried out indirect double immunofluorescence (IF) microscopy using antibodies specific 
for MyHC and RBM5. The cell nuclei were counter stained with DRAQ5. The pattern of 
expression and cellular distribution was visualized under fluorescence using a confocal 
microscope. The same settings for image acquisition such as the intensity and exposure 
time were maintained through each day, for each experiment. Localization experiments do 
not control properly to allow quantification of signal intensity because of the structural 
difference of the cells. The confocal microscope settings were optimized to detect the 
localization of low levels of protein using immunofluorescence, which does not use the full 
range of intensity, which is therefore not quantitative. 
In order to ensure proper detection and specificity, IF staining was verified by having 
controls (Figure 3.9). RBM5 immunoblots served as primary antibody controls, in which 
only bands specific for RBM5 were seen when using LUCA-15 UK antibody targeted 
against RBM5 (Appendix A, Fig A2). Next, controls with and without antibodies (primary 
and secondary) served as controls for staining specifically. All the signals detected were 
checked for specificity and cross-reactivity. Indeed, without RBM5 primary and secondary 
controls, there was no red color detected, which suggests that the MyHC antibody detected 
in the cytoplasm was specific. Similarly, when the cells were not stained with Mf-20 
primary (MyHC) and secondary antibodies, only RBM5 (red color) was detected in the 
controls. No non-specific fluorescent signals were obtained.  
To our knowledge, this is the first study to demonstrate localization pattern of RBM5 in 
mouse muscle cells. Based on previous reports in human fibrosarcoma HT 1080 cells 
(Drabkin et al., 1999), we mainly expected to see RBM5 in the nucleus. As expected, our 
results revealed that RBM5 accumulated in the nucleus on D0 as evident from the localized 
pattern of the red color (Figures 3.10, 3.11A). However, as the cells were differentiating, 
RBM5 was expressed both in the nucleus and cytoplasm (Figures 3.10, 3.11B, 3.12). Some 
of the MyHC-positive cells had RBM5 and MyHC in their cytoplasm as seen with yellow 
color in the merged fields, which is caused by overlapping red and green colors. 
Specifically, starting from D2 the transition from nucleus to cytoplasm was clearly evident 
 76 
 
in the differentiating cells. Detection of RBM5 in the cytoplasm has been previously 
reported in prostatic tissues (Zhao et al., 2012), however, this is the first time, cytoplasmic 
(sarcomeric) presence was observed in muscle cells. Interestingly, we also observed that 
from D5 to D7, RBM5 was present in the nucleus in reserve cells (Figure 3.16). These are 
the single, mono-nucleated cells, which were not positive for MyHC even at the terminal-
stages of differentiation (Blais et al., 2005). 
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Figure 3.9 Controls for RBM5 and MyHC double IF staining. C2C12 myoblasts were 
induced to differentiate by changing GM to DM. The cells were grown on coverslips, fixed, 
permeabilized and stained. The staining procedure was verified using controls including A) 
no first rabbit anti-RBM5 primary antibody for D0 and D7 and B) no second mouse anti-Mf-
20 primary antibody for MyHC for D0 and D7. Scale bar = 100µm. 
DO 
D7 
Phase DRAQ5 MyHC RBM5 Merg
e 
B 
DO 
D7 
Phase DRAQ5 MyHC RBM5 Merg
e 
A 
 78 
 
              
DO 
D1 
D2 
D3 
D4 
D5 
D6 
D7 
Phase DRAQ5 MyHC RBM5 Merg
e 
Figure 3.10 Intracellular distribution of RBM5 in differentiating C2C12 cells. RBM5 is 
differentially localized during C2C12 differentiation. C2C12 myoblasts were induced to differentiate 
for seven days, cells were fixed, permeabilized and stained. Phase contrast, DRAQ5, MyHC, RBM5 
and merge panels showing the subcellular presence using IF staining. Scale Bar = 100µm  
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Figure 3.11 RBM5 cellular localization. RBM5 is detected in the nucleus in myoblasts, and 
in the nucleus and cytoplasm in myotubes. A) D0 showing nuclear localization, Scale Bar = 
2µm and B) D7 showing both cytosolic and nuclear localization, Scale Bar =10µm. Arrow 
heads (white) indicate cytosolic presence and arrows (yellow) indicate presence in nucleus in 
differentiating myotubes. Images were obtained using 63x objective and then electronically 
magnified. 
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Figure 3.12 RBM5 cellular localization in differentiated myotubes. Detection of RBM5 in 
the nucleus and cytoplasm in D7 differentiated C2C12 cells. Arrowheads (white) indicate 
cytosolic presence and arrows (yellow) indicate presence in nucleus in differentiated 
myotubes. Scale Bar=10µm. Images were acquired using 63x objective and electronically 
magnified. 
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Figure 3.13 RBM5 cellular localization in D5, D6 and D7 differentiating C2C12 cells. 
Detection of RBM5 in the nucleus and cytoplasm during differentiation. Arrowheads (white) 
indicate cytosolic presence and arrows (yellow) indicate presence in the nucleus in myotubes. 
Arrows (cyan) indicate presence in the nucleus in MyHC-negative (reserve) cells. Images 
were acquired using 25x objective. 
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As evident from the higher magnification images (Figure 3.13A), the nuclear localization 
pattern of RBM5 was intra-nuclear but probably not in the nucleoli because some areas in 
the nucleus were not stained with RBM5. This observation is in line with the result 
obtained by (Gupta, 2006). 
Next, in order to proceed with the immunofluorescence detection of RBM10, we had to 
ensure proper detection and specificity. Similar to RBM5, we performed control staining 
for RBM10 and MyHC (Figure 3.14). RBM10 immunoblots served as controls for the 
primary antibody, in which bands specific for RBM10v1 and RBM10v3 isoforms were 
seen when using Bethyl RBM10 antibody targeted against RBM10 (Appendix A, Fig A2). 
Controls with and without antibodies (primary and secondary) served as controls for 
staining specifically. All the signals detected were checked for specificity and cross-
reactivity. Indeed, without RBM10 primary and secondary controls, there was no red color, 
which suggests that the MyHC antibody detected in the cytoplasm was specific. Similarly, 
when the cells were not stained with Mf-20 primary (MyHC) and secondary antibodies, 
only RBM10 (red color) was detected in the controls. No non-specific fluorescent signals 
were obtained.  
This study is the first to determine the localization pattern of RBM10 in C2C12 cells, 
during proliferation as well as during the differentiation stages (Figures 3.15, 3.16, 3.17, 
3.18). Previous reports have shown that the rat S1-1 was observed as a punctate structure in 
the nuclear bodies in the rat heart and skeletal muscle, besides being present in kidney, 
intestine, spleen and adrenal gland (Inoeu et al., 2008). We expected to see RBM10 to be 
distributed in the nucleus and as expected, at D0, RBM10 localization was nuclear, as 
indicated by the red color in the myoblasts (Figures 3.15, 3.16A). This nuclear localization 
is clearly evident in Figure 3.16A, RBM10 stained in the nucleus in the myoblasts. Our 
observation is in line with the result reported by Xiao et al., (2013), wherein S1-1 (the rat 
homologue) was localized in the nuclei in rat liver epithelial cells. They observed that 
RBM10 was absent in the nucleolus. We observed some areas in the nucleus that were not 
stained with anti-RBM10 anti-serum, which could be the nucleoli. Interestingly, as the 
myoblasts proceeded to differentiate, we observed that starting from D1, the RBM10 
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staining was distributed in the cytoplasm as well (Figure 3.15, 3.16B, 3.17, 3.18). Nuclear 
and cytoplasmic localization has been reported for RBM10 in a variety of normal 
(neutrophils and villi) and as well as cancerous cells (Hela, HL-60 and hepato cellular 
carcinoma) (Xiao et al., 2013; Inoue. 2013). In the present study, RBM10, like that of 
RBM5, localized in the nuclei of some of the reserve cells from D5 to D7 (Figure 3.18).  
Interestingly, both RBM5 and RBM10 had a similar pattern of intracellular localization. 
Nuclear localization during the initial stages (in the myoblasts at D0 and in reserve cells in 
the myotube population on the proceeding days D5 to D7) and cellular localization in both 
cytoplasm and nucleus only during the later stages of differentiation indicates a level of 
functional regulation in these cells. The shift in intracellular distribution suggests that there 
is a potential need for these RBPs to be strategically positioned within the cell to perform 
site-specific functions. Furthermore, this mimics the localization profile of many myogenic 
factors such as MyoG, MyoD and Myf5 (Ferri et al., 2009) and indicates that nucleo-
cytoplasmic shuttling of important proteins is a common occurrence in muscle. 
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Figure 3.14 Controls for RBM10 and MyHC double IF staining. C2C12 myoblasts were 
induced to differentiate by changing GM to DM. The cells were grown on coverslips, fixed, 
permeabilized and stained. The staining procedure was verified using controls including A) 
No first rabbit anti-RBM10 primary antibody on D0 and D7 and B) no second mouse anti-Mf-
20 primary antibody for MyHC on D0 and D7. Scale bar = 100µm 
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Figure 3.15 Intracellular distribution of RBM10 in differentiating C2C12 cells. RBM10 is 
differentially localized during C2C12 differentiation. C2C12 myoblasts were induced to differentiate 
for seven days, cells were fixed, permeabilized and stained. Phase contrast, DRAQ5, MyHC, RBM10 
and merge panels showing the subcellular presence using IF staining. Scale Bar = 100µm  
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Figure 3.16 RBM10 cellular localization. Detection of RBM10 in the nucleus and 
cytoplasm. Nuclear localization on A) D0, Scale Bar=5µm and B) both nuclear and 
cytoplasmic localization on D7, Scale Bar=10µm. Arrowheads (white) indicate 
cytosolic presence and arrows (yellow) indicate presence in nucleus in differentiating 
myotubes. Images were acquired using 63x objective and electronically magnified. 
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Figure 3.17 RBM10 cellular localization in differentiated myotubes. Detection of 
RBM10 in the nucleus and cytoplasm in D7 differentiated C2C12 cells. Arrowheads 
(white) indicate cytosolic presence and arrows (yellow) indicate presence in nucleus in 
differentiated myotubes. Scale Bar=10µm (A) and 5µm (B). Images were acquired 
using 63x objective and electronically magnified. 
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Figure 3.18 RBM10 cellular localization in D5, D6 and D7 differentiating C2C12 cells. 
Detection of RBM10 in the nucleus and cytoplasm during differentiation. Nuclear and 
cytosolic localization on Arrowheads (white) indicate cytosolic presence and arrows (yellow) 
indicate presence in nucleus in differentiating myotubes. Arrows (cyan) indicate presence in 
the nucleus in MyHC-negative (reserve) cells. Images were acquired using 25x objective. 
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3.3 Knockdown analysis 
To elucidate the effect of RBM5 and RBM10 on skeletal muscle differentiation, we used a 
loss-of-function approach. More specifically, we performed three different knockdown 
(KD) experiments using RNA interference (RNAi): siRNA-mediated silencing of Rbm5 or 
Rbm10 or both Rbm5 and Rbm10 (double KD). When the C2C12 cells were 40-50% 
confluent, transient transfection using siRNA duplexes specific for Rbm5 or Rbm10 or 
Rbm5 and 10 (Rbm5+10) were performed. A non-specific small interfering RNA (siRNA) 
duplex (scrambled control) was used as a control to eliminate off-target effects and to 
verify experimental specificity. Three trials of KD experiments were performed for each 
condition (i.e. RBM5, RBM10, RBM5+10). Rajan et al., (2012) have carried out shRNA 
knockdown screens of close to 400 genes and considered a KD cut off between 40-60% and 
omitted those which had 20% KD from their analysis. Knockdowns of >50 % at the protein 
level were considered to be acceptable for our experiments.  
3.3.1 Knockdown efficiency 
Proteins extracted from the cells collected at 24 and 48 hours post-transfections were 
subjected to immunoblot analysis using antibodies specific for RBM5, RBM10 and α-
tubulin to assess the KD efficiency. Using densitometry the percentage of KD compared to 
control was calculated after normalizing the band intensity with α-tubulin (Blais et al., 
2005). The results are presented for each trial individually as summarized in Table 6. This 
has been done for the following reasons, a) because N is only 2 or 3, it is more transparent 
to interpret from individual trials rather than using means and 2) each trial had different 
degrees of knockdown, for instance the coefficient of variation for RBM10 KD from 3 
replicates was ~50% with a 4-fold difference in RBM10 expression, which would require 5 
to 6 replicates to detect changes. Therefore the effect of the knockdown was also assessed 
separately rather than combining the trials together. The controls did not show depletion of 
the specific mRNA, thus allowing us to proceed further with our analysis of the effects of 
RBM KD during differentiation. Any effects observed due to reduction in RBM5 and 
RBM10 is directly or indirectly attributable to depletion of the corresponding RBP. 
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24 hours after transfection with siRBM5, RBM5 expression was decreased by 64%, 74% 
and 80% compared with scrambled siRNA control in the three transfections (Figure 3.19). 
48 hours after transfection, the KD levels were 72%, 60% and 82% compared with 
scrambled siRNA control. The RBM5 KD levels were above 60% at both 24 and 48 hours 
post-transfection, thus meeting our expected degree of knockdown. 
In RBM10 KD, 24 hours post-transfection, RBM10 expression was decreased by 62% for 
RBM10v1 and 67% for RBM10v3 in trial 1, 27% for RBM10v1 and 24% for RBM10v3 in 
trial 2 and 85% for RBM10v1 and 72% for RBM10v3 in trial 3, compared with scrambled 
siRNA controls, respectively (Figure 3.20). 48 hours after transfection, the KD levels were 
77% for RBM10v1 and 67% for RBM10v3 in trial 1, 86% for RBM10v1 and 89% for 
RBM10v3 in trial 2 compared with scrambled siRNA control. The KD levels at 48 hours 
were comparatively higher than at 24 hours for both trial 1 and trial 2. The protein samples 
(siRBM10 and scrambled siRNA control) at 48 hours from trial 3 were not used in further 
analysis because they did not show a detectable band for RBM5 or RBM10 when probed 
with the specific antibody. The range of KD varied from 27% to 86% for RBM10v1 and 
24% to 89% for RBM10v3 at 24 and 48 hours post-transfection, however, met our 
acceptable degree of KD. The two exceptions, RBM10v1- 27% and RBM10v3-24% at 24 
hours (trial 2), met the acceptable degree of KD at 48 hours (RBM10v1- 86% and 
RBM10v3-89%).  
In the RBM5+10 KD, the levels of both RBM5 and RBM10 were experimentally down-
regulated as follows: trial 1, RBM5 was KD 67% (24h) and 52% (48h), RBM10v1 was KD 
41% (24h) and 49% (48h), and RBM10v3 was KD 42% (24h) and 76% (48h); trial 2, 
RBM5 was KD 50% (24h) and 81% (48h), RBM10v1 was KD 47% (24h) and 85% (48h), 
and RBM10v3 was KD 49% (24h) and 83% (48h); and trial 3, RBM5 was KD 48% (24h), 
RBM10v1 was KD 83% (24h), and RBM10v3 was KD 59% (24h) (Figure 3.21). The 
protein samples (siRBM5+10 and scrambled siRNA control) at 48 hours for trial 3 were not 
used in further analysis because they did not show a detectable band for RBM5 or RBM10 
when probed with the specific antibody. Except for trial 2, which had >80% KD of both 
RBM5 and RBM10 at 48 hours post-transfection, all the KD in trial 1 and trial 3 were 
variable and close to 50% and above. We also noticed that when both siRNAs were 
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introduced into the cells at the same time, the depletion of endogenous RBM5 and RBM10 
proteins, is less comparable to the levels when each were individually knocked down. 
To summarize, we were able to endogenously deplete RBM5 and RBM10 together in all 
the three trials for all three siRNA transfections and therefore proceeded to determine the 
effects of this depletion in C2C12 cells during differentiation.  
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Table 6 
Knockdown levels of RBM5, RBM10 and RBM5+10 at 24h and 48h post-transfection 
 
A) RBM5  
siRBM5 Time Point RBM5
% KD 
Trial 1 
24h 64 
48h 72 
Trial 2 
24h 74 
48h 60 
Trial 3 
24h 80 
48h 82 
B) RBM10 
 
siRBM10 Time Point RBM10v1
% KD 
RBM10v3 
% KD 
Trial 1 
24h 62 67 
48h 77 67 
Trial 2 
24h 27 24 
48h 86 89 
Trial 3 24h 85 72 
C) RBM5+10 
 
siRBM5+10 Time Point RBM5 
% KD 
RBM10v1 
% KD 
RBM10v3
% KD 
Trial 1 
24h 67 41 42 
48h 52 49 76 
Trail 2 
24h 50 47 49 
48h 81 85 83 
Trial 3 24h 48 83 59 
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Figure 3.19 RBM5 KD levels in C2C12 cells 24h and 48h post-transfection. C2C12 cells 
were transfected with siRBM5 and the levels of KD were analyzed by immunoblots for A) 
Trial 1, B) Trial 2 and C) Trial 3. The KD percentage compared to scrambled siRNA control 
(C) was quantified using densitometry and plotted as a graph. α-tubulin was used for 
normalization.  
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Figure 3.20 RBM10 KD levels in C2C12 cells 24h and 48h post-transfection. C2C12 cells 
were transfected with siRBM10 and the KD levels were analyzed by immunoblots for A) 
Trial 1, B) Trial 2 (whole blot in appendix A, Figures A6, A7 and A11) and C) Trial 3. The 
KD percentage compared to scrambled siRNA control (C) was quantified using densitometry 
and plotted as a graph. α-tubulin was used for normalization.  
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Figure 3.21 RBM5 and RBM10 KD levels in C2C12 cells 24h and 48h post-transfection. 
C2C12 cells were transfected with siRbm5 along with siRbm10 (siRBM5+10) and the KD 
levels were analyzed by immunoblots for A) Trial 1, B) Trial 2 and C) Trial 3. Whole blots in 
appendix A, Figures A9, A10 and A11. The KD percentage compared to scrambled siRNA 
control (C) was quantified using densitometry and plotted as a graph. α-tubulin was used for 
normalization.  
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3.3.2 Depleted RBM5 and RBM10 protein levels are replenished by D4 
In order to assess the stage of functional involvement of these two RBPs in myogenic 
differentiation, it was necessary to determine the time-point of restoration. Therefore, the 
levels of RBM5 and RBM10 were estimated during differentiation (D0 to D4). 
Differentiation was induced by changing GM to DM 24 hours post-transfection. 
Immunoblotting was performed using protein extracted from transfected cells that were 
subjected to differentiation. Using densitometry, the band intensity measurements were 
obtained and the protein levels were calculated after normalizing with α-tubulin. The levels 
were compared to the control (scrambled siRNA) during each day and plotted as a graph. 
This measure of endogenous restitution is a physiological indicator of the effectiveness of 
transfection and the cell’s ability to transcriptionally replenish the depleted mRNAs. We 
expected that over time, normal expression levels should occur, more specifically 3 to 7 
days after transfection (Leung and Whittaker, 2005). 
In RBM5 transfection experiments, RBM5 protein levels were measured from D0 until D4 
(Figure 3.22). RBM5 protein levels in trial 1 remained depleted until D3 and restoration 
trend was not seen until D3 (did not have D4 samples and therefore was not able to 
measure the level of restoration on D4 for this trial) (Figure 3.22A); in trial 2, were 
beginning to reach normal levels by D3 and reached control levels on D4 (Figure 3.22B); 
and in trial 3 reached normal levels by D3 (Figure 3.22C). This indicates that restoration of 
RBM5 protein occurs in two trials and KD is effective for at least for three days for trials 1 
and 2, and at least for two days for trial 3. Furthermore, the effect of depletion during 
differentiation until D3 in two trials and D2 in one trial is probably accounted for by 
reduction in RBM5. In addition, the KD levels were 72% (trial 1), 60% (trial 2) and 82% 
(trial 3) and the restoration was not dependent on the KD levels. 
In RBM10 transfection experiments, when RBM10 protein levels were measured from D0 
until D4, restoration to scrambled control levels occurred at different days for each trial 
(Figure 3.23). The RBM10v1 and RBM10v3 isoform levels were back to normal by D3 for 
trial 1 (Figure 3.23A); reached levels similar to control by D2 for trial 2 (Figure 3.23B) and 
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was not restored to normal levels even by D3 for trial 3 (Figure 3.23C). This indicates that 
the RBM10 isoform levels were restored at least on D2 and D3 in two trials, the KD was 
effective for these days and the effect observed in the KD during differentiation is 
accounted for by reduction in RBM10. In addition, the KD levels were 77% (RBM10v1) 
and 67% (RBM10v3) (trial 1), 86% (RBM10v1) and 89% (RBM10v3) (trial 2) at 48h and 
85% (RBM10v1) and 72% (RBM10v3) (trial 3) at 24h and the restoration was not 
dependent on the KD levels. 
In RBM5+10 KDs, restoration of RBM5 and RBM10 occurred to varying degrees in all of 
the three trials. RBM5 reached normal levels by D3 for trial 2 (Figure 3.24B) but was not 
restored in trial 1 and trial 3 (Figure 3.24 A and C). RBM10 reached normal levels by D3 
for trial 1 (Figure 3.24A) but was not restored in trial 1 and trial 3 (Figure 3.24 B and C). 
Therefore, the KD was effective for those days and the effect observed in the KD during 
differentiation is accounted for by reduction in RBM5 and RBM10.  
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Figure 3.22 RBM5 restoration post-transfection in C2C12 cells. C2C12 cells were 
transfected with siRbm5 or scrambled siRNA and the levels of restoration were analyzed by 
immunoblots for A) Trial 1(did not have D4 samples), B) Trial 2 and C) Trial 3. The protein 
expression levels compared to scrambled siRNA control (C) were quantified using 
densitometry and plotted as a graph. α-tubulin was used for normalization.  
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Figure 3.23 RBM10 restoration post-transfection in C2C12 cells. C2C12 cells were 
transfected with siRbm10 or scrambled siRNA and the levels of restoration were analyzed by 
immunoblots for A) Trial 1, B) Trial 2 (whole blots in appendix A, Figure A7) (did not have D4 
samples) and C) Trial 3 (whole blots in appendix A, Figure A11) D4 -RBM10 immunoblotting 
did not work. The protein expression levels compared to scrambled siRNA control (C) were 
quantified using densitometry and plotted as a graph. α-tubulin was used for normalization.  
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Figure 3.24 RBM5 and RBM10 restoration post-transfection in C2C12 cells. C2C12 cells 
were transfected with Rbm5 and Rbm10 siRNAs and the level of restoration was analyzed by 
immunoblotting for A) Trial 1, B) Trial 2 and C) Trial 3 (Whole blots in appendix A, Figures A9, 
A10 and A11). D3 (trial 2) and D4 (trial 3) RBM10 immunoblotting did not work. The protein 
expression levels compared to scrambled siRNA control (C) were quantified using densitometry 
and plotted as a graph. α-tubulin was used for normalization.  
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3.3.3 Depletion of one RBP does not effect the protein expression of the other 
Because the RBM5 and RBM10 proteins are 50% identical and have overlapping functions 
(apoptosis/cell proliferation) in cancer cells, there is a possibility that disrupting the 
expression of one may impact the expression of the other. There are a few studies that 
suggest such regulation (Wang et al., 2013). Therefore, in our mouse model system, we 
wanted to analyze the expression of each RBP when another one of the RBP was inhibited. 
Using immunoblots, we quantified the expression levels of RBM5 in RBM10 KDs, and 
RBM10v1 and RBM10v3 isoform expression levels in RBM5-depleted cells at both 24h 
and 48h post-transfection and during differentiation for all three trials. The expression 
levels of the KDs were compared to the scrambled siRNA control protein levels for each 
time-point. We did not see a significant increase or decrease in RBM5 levels in the RBM10 
KDs (Figure 3.25). We did not see any significant changes in both the RBM10 isoform 
levels in RBM5 KD (Figure 3.26). The Western blotting for RBM10 was not successful for 
24h, 48h and D1 samples for trial 3 RBM5 KDs. These results confirm that: (a) the 
repression in protein expression levels of one RBP is not regulated by the other RBP; (b) 
the KD is siRNA specific and the siRNAs are specific to the mRNA that they are intended 
to target; and, (c) reduction in one RBP is not compensated by an increase in the expression 
of the other RBP studied in the present investigation.  
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B 
C 
A 
Figure 3.25 RBM5 protein levels in RBM10-depleted cells. Depletion of RBM10 does not 
significantly increase or decrease RBM5 protein levels, post-transfection and during 
differentiation. C2C12 cells were transfected with RBM10 or scrambled siRNAs (C). RBM5 
protein levels compared to the control were quantified by densitometry from the immunoblots 
for A) Trial 1, B) Trial 2 and C) Trial 3. Whole blots in appendix A, Figures A6, A7 and A11. 
α-tubulin was used for normalization.  
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Figure 3.26 RBM10 protein levels in RBM5-depleted cells. Depletion of RBM5 does 
not significantly increase or decrease RBM10 protein isoform levels, post-transfection 
and during differentiation. C2C12 cells were transfected with RBM5 or scrambled 
siRNAs (C). RBM10 protein levels compared to the control were quantified by 
densitometry from the immunoblots for A) Trial 1, B) Trial 2 and C) Trial 3. Whole 
blots in appendix A, Figures A7, A8 and A10. α-tubulin was used for normalization.  
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3.3.4 Phenotypic consequences of RBM5 and RBM10 depletion 
After verifying the KD levels in all the trials, we proceeded to analyze the phenotypic 
effects of RBM5 and RBM10 depletion in C2C12 myoblasts. This was attained by 
assessing the morphological changes in the depleted cells compared to scrambled control 
transfections during proliferation and differentiation. Using indirect immunofluorescence 
technique, the cells were immunostained for MyHC and counterstained with DRAQ5. 
Phenotypic assessment was performed for two trials and as indicated previously under 
section 3.3.1the results are presented for each trial individually. The two trials for RBM5 
KD effect assessment are represented as Trial A (trial 2 in Table 6A) and Trial B (trial 3 in 
Table 6A); for RBM10 KD are represented as Trial A (trial 1 in Table 6B) and Trial B (trial 
3 in Table 6B); for RBM5+10 KD are represented as Trial A (trial 2 in Table 6C) and Trial 
B (trial 3 in Table 6C). Statistically significant changes in both the trials are used for 
interpretation. 
In our experiments, we have used the scrambled siRNA as our negative control because this 
acts as a control for transfection. Untransfected control was carried out along with 
scrambled siRNA control for the siRBM10 KD experiments. Comparable RBM10 levels 
were found in both untransfected controls and scrambled siRNA controls (Appendix A, 
Figure A6). This confirms at least at the protein level (target gene level), that any 
downstream effect of RBM KD is attributed to the silencing of the target protein, however 
does not eliminate any effect associated with baseline phenotype modifications such as cell 
density. 
Results in untransfected cells (Figure 3.2) showed that proliferation stops at D1 and the 
differentiation changes start at D1, with an increase in the differentiation potential as the 
days progress until D5 ~30%, after which it reaches a plateau ~30-40%. At least 10% of 
cells were fused by D3 leading to an increase in the number of myotubes and myofibers 
starting from D4. The cells started expressing the differentiation-specific marker MyHC 
beginning from D1 and by D4, 25±2.9 cells/ hpf expressed MyHC. 
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During these experiments it was noticed that the specific timing at which some 
differentiation markers were expressed was different between our early non-transfected 
cells and the scrambled control siRNA transfected cells. This difference may be related to 
the effects of transfection on decreasing cell survival and on inhibiting cell cycle 
progression. It is well known that lipofectamine-based transfection is associated with cell 
death and would be expected to decrease the number of surviving cells. In addition, cell 
density-dependant effects affect the expression of several proteins such as myogenic 
markers like MyoG, MyoD, MyHC, and cell adhesion and cytoskeleton related proteins 
such as actin, talin and cadherin, and cell cycle related factors like decorin, cyclin D3 and 
p21 (Tanaka et al., 2011). Therefore for these experiments, all KD samples are compared 
only to the scrambled siRNA controls processed in parallel. 
3.3.4.1 RBM5 depletion 
When RBM5 is endogenously over-expressed in cancer cells, it is anti-proliferative and 
apoptotic, specifically, the inhibition of tumor growth by RBM5 is associated with the 
regulation of Cyclin A and retinoblastoma proteins leading to cell cycle arrest at G1 (Shao 
et al., 2012) and the p53 pathway (Kobayashi et al., 2011); and alternative splicing of 
targets involved in cell proliferation and apoptosis (Fushimi et al., 2008). Therefore, in our 
experiments, when we down-regulated Rbm5, we expected to see an effect on cell number, 
specifically an increase in proliferation in the KDs. Differentiation of C2C12 cells involves 
both cell cycle arrest and apoptosis; therefore, since RBM5 is pro-apoptotic, we expected 
that the scrambled controls would have a fewer number of cells than siRBM5 transfected 
cells.  
The level of KD can be inferred from RBM5 IF staining in scrambled controls in 
comparison to RBM5 KDs, at 24 and 48 hours in one of the two trials (Appendix A-Figure 
A4). Fewer cells in the KD had RBM5 staining compared to the scrambled siRNA control 
cells. The RBM5 protein levels for trial A was reduced by 74% (trial 2 in Table 6A) and for 
trial B was reduced by 80% (trial 3 in Table 6A), as shown previously (Figure 3.19) by 
Western blots.  
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When RBM5-depleted and control cells were counted (DRAQ5 stained nuclei) 24 and 48 
hours post-transfection, we found that the number of nuclei remained the same. There was 
no difference in the cell number between the control and RBM5 KD. The graph in Figure 
3.27 depicts the average number of nuclei present in two separate trials. In trial A (Fig 
3.27A), in each high power field (hpf), an average of 29±2 and 32±2 nuclei were present in 
the scrambled siRNA control and the RBM5 KD cultures, respectively, at 24 hours post-
transfection. This increased to 76±5 and 84±8 nuclei / hpf in the scrambled siRNA control 
and RBM5 KD, respectively, at 48 hours post-transfection. In trial B (Fig 3.27B), in each 
high power field (hpf), an average of 39±4 and 46±4 nuclei were present in the scrambled 
siRNA control and the RBM5 KD cultures, respectively, at 24 hours post-transfection. This 
increased to 124±11 and 116±4 nuclei / hpf in the scrambled siRNA control and RBM5 
KD, respectively, at 48 hours post-transfection. The difference between the control and 
RBM5 KD was not statistically significant at both 24 hours and 48 hours post-transfection. 
Therefore, RBM5 KD did not immediately effect C2C12 cell proliferation and/or apoptosis.  
When RBM5-depleted and control cells were induced to differentiate and the cells were 
counted on D0, D1, D2, D3 and D4, we found that there was a difference in the number of 
nuclei (Figures 3.28A, 3.29A). An average of 176±6 (trial A) and 138±8 (trial B) nuclei / 
hpf were present in the control, whereas in the KDs the nuclei number was significantly 
reduced (P=0.0001 in both the trials) to 106±6 (trial A) and 97±2 (trial B) / hpf on D2. This 
drop in nuclei number was significant on D3 and D4 as well (P=0.0001). On D3, the nuclei 
number dropped from 190±8 (trial A) and 244±10 (trial B) nuclei / hpf to 102±5 (trial A) 
and 137±7 (trial B) nuclei / hpf in the KDs. On D4 the reduction was from 191±6 (trial A) 
and 168±12 (trial B) nuclei / hpf for the control to 118±2 (trial A) and 104±6 (trial B) 
nuclei / hpf in the KDs. Therefore, once differentiation was induced, the number of nuclei 
varied significantly between the control and RBM5 KD. These results, that silencing 
RBM5 resulted in reduction in the number of cells during differentiation suggest that 
RBM5 may be required during differentiation to maintain the necessary cell population in 
order to proceed with the differentiation process. Indirectly, this indicates an increase in 
apoptosis leading to loss of cells without RBM5. This result in C2C12 cells during 
differentiation therefore could possibly be associated with apoptosis because apoptosis in 
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C2C12 cells occurs between 48 hours of differentiation (Mercer et al., 2005) and 
proliferation stops prior to the beginning of differentiation.  
Furthermore, we analyzed the phenotypic effects of RBM5 depletion on differentiation by 
counting the total number of nuclei, number of myotubes, number of myofibers, and 
number of nuclei within the myotubes and myofibers. Using these values other cell 
parameters such as differentiation potential, fusion index and maturation efficiency were 
calculated (Figures 3.28, 3.29). Interestingly, RBM5-depleted cells had a significant 
increase in differentiation potential on D2 with P values of 0.0001 (trial A) and 0.04 (trial 
B) compared to scrambled controls (Figures 3.28B, 3.29B). However by D4, there was a 
significant reduction in the percentage of differentiated myotubes [P=0.0001 (trial A) and 
0.04 (trial B)] in the RBM5 KDs compared to scrambled controls. The number of MyHC-
positive cells was greater on D2 but the number decreased on D3 and D4, thus the decrease 
in MyHC expression partly contributed to the decrease in differentiation potential (Table 
7). The number of cells expressing the myogenic terminal differentiation marker MyHC 
was reduced significantly when RBM5 was depleted. Indeed, for trial A, P values were 
0.018 and 0.0001 for D3 and D4, respectively.  For trial B, the P values for D3 and D4 
were 0.0005 and 0.008, respectively. These results suggest that RBM5 may modulate 
MyHC expression during differentiation. Additionally, RBM5-depleted cells were slow to 
differentiate because of the difference in cell numbers. RBM5 transfected cells consistently 
showed a lower number of cells at D2-D4 compared to scrambled controls in both trials, 
which is evident from the decreased cell density. Cell density is an important determinant 
for C2C12 myoblasts to differentiate. Fewer cells causes less cell-cell contact thereby 
disrupting cell signalling pathways leading to delayed differentiation (Tanaka et al., 2011). 
The downstream effects associated with RBM5 depletion such as the delay in 
differentiation, fusion and maturation could be due to the decrease in cell density. 
The reduction in the fusion index contributed to less myotubes on D4 (Figures 3.28C, 
3.29C). The index was 20±2% in the controls, which was reduced to 10±2% in the RBM5 
KDs in trial A, with a similar reduction from 21±5% in the controls to 11±1% in the RBM5 
KDs in trial B. KD also affected maturation, as there were significantly less myofibers (5 or 
more nuclei) in the RBM5 KD cells (Figures 3.28D&E, 3.29D&E). In these cells, there was 
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a decrease in the number of nuclei in myotubes, as well as a decrease in myotube numbers 
(P=0.0027 (trial A) and 0.0002 (trial B)). There was a 10-fold difference in maturation 
when comparing the controls to the RBM5 KDs with a significant P value (0.0045 for trial 
A and 0.003 for trial B) . 
Although the two trials of RBM5 KD are considered separately, and despite having 
different levels of KD and different RBM5 protein restoration time points, they both show 
similar changes in the timing of the expression of the differentiation markers. In both trials, 
cells transfected with the scrambled siRNA control showed higher differentiation potential, 
fusion index and myotubes/field at D4 while the RBM5 KD cells showed that this effect 
was blunted (although to different extents) in both the experiments. These results suggest 
that RBM5 plays an important role in C2C12 differentiation by (a) having an effect on the 
number of cells, which probably results in the delay in differentiation; and (b) modulating 
the expression of MyHC during muscle cell differentiation. 
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Figure 3.27 Effect of RBM5 depletion on C2C12 cell count. C2C12 myoblasts were 
transiently transfected with a scrambled siRNA control or siRBM5. At 24h and 48h post-
transfection, the total cell count was estimated by counting the number of DRAQ5-stained nuclei 
in the field for A) Trial A and B) Trial B. The graph represents the average number of nuclei 
from 8-12 separate fields of view and the error bars represent SEM. The immunofluorescent 
images represent one representative field for the control and siRBM5 at 24h and 48h after 
transfection for the two trials. Scale bar = 100µm.  
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Figure 3.28 Quantitative analysis of RBM5 KD effect on C2C12 cell count, differentiation, fusion and 
maturation during differentiation (Trial A). A) The total number of cells was estimated by counting the 
number of DRAQ5-stained nuclei per field, B) Differentiation potential is the ratio of number of nuclei in 
MyHC-positive cells to the total number of nuclei in the field X 100, C) Fusion index is the ratio of the number 
of nuclei in myotubes (≥2 nuclei) to the total number of nuclei in MyHC-positive cells X 100, D) Average 
number of myotubes from all fields, E) Average number of myofibers (≥5 nuclei) from all fields and F) DRAQ5 
and anti-MyHC stained merged images from a single representative field of view, Scale bar = 100µm. Error 
bars represent SEM. Unpaired students t-test was used to calculate the statistical significance. * = P< 0.05, ** 
= P< 0.001, *** = P< 0.0001. KD levels at 24h were 74%. 
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Figure 3.29 Quantitative analysis of RBM5 KD effect on C2C12 cell count, differentiation, fusion and 
maturation during differentiation (Trial B). A) The total number of cells was estimated by counting the 
number of DRAQ5-stained nuclei per field, B) Differentiation potential is the ratio of number of nuclei in 
MyHC-positive cells to the total number of nuclei in the field X 100, C) Fusion index is the ratio of the number 
of nuclei in myotubes (≥2 nuclei) to the total number of nuclei in MyHC-positive cells X 100, D) Average 
number of myotubes from all fields, E) Average number of myofibers (≥5 nuclei) from all fields and F) DRAQ5 
and anti-MyHC stained merged images from a single representative field of view, Scale bar = 100µm. Error 
bars represent SEM. Unpaired students t-test was used to calculate the statistical significance. * = P< 0.05, ** 
= P< 0.001, *** = P< 0.0001. KD levels at 24h were 80%. 
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Table 7 
MyHC-positive cells in RBM5-depleted differentiating C2C12 cells 
 
 Trial A (74%)   Trial B (80%)  
 C  siRBM5 C  siRBM5  
 
Ave SEM Ave SEM Ave SEM Ave SEM 
D2 0.1 0.1 5 1.1 6.5 1.4 8.3 1.2 
D3 23 2.5 15* 2.1 33.6 2.4 19** 2.2 
D4 37 2.6 19*** 2.2 29.2 3.3 19* 1.6 
 
                 * = P< 0.05, ** = P< 0.001, *** = P< 0.0001.  
 
Percentage in brackets indicates the RBM5 KD % at 24 hours post-transfection.
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3.3.4.2 RBM10 depletion 
When RBM10 is depleted (mutated/KD/absent), it affects cancer cell proliferation. 
Specifically, RBM10 has been shown to be splicing NUMB to increase exon exclusion, 
which is anti-proliferative (Bechara et al., 2013). Therefore, when RBM10 is depleted we 
expected to see an increase in proliferating myoblasts.  
The level of KD was inferred from RBM10 IF staining in scrambled controls in comparison 
to RBM10 KDs, at 24 and 48 hours in one of the two trials (Appendix A Figure A5). Fewer 
cells in KD had RBM10 staining compared to the scrambled siRNA control cells. The KD 
levels for this trial A (trial 1 in Table 6B) at 24h were 62% (RBM10v1) and 67% 
(RBM10v3) and for trial B (trial 3 in Table 6B) at 24h were 85% (RBM10v1) and 72% 
(RBM10v3) as shown previously (Figure 3.20) by Western blots. 
Immediately following the transient transfection, the number of cell nuclei in RBM10 
depleted cells, were different from the number of nuclei in the control. As expected, during 
proliferation (i.e. 24 and 48 hours post-transfection) when the cells are actively dividing, 
there was a significant increase in the number of nuclei in the RBM10 KDs, although there 
were differences between the trials (Figure 3.30). Specifically, in trial A (Figure 3.30A), 
the number of nuclei in the control was 42±3.5 / hpf and 103±6.9 / hpf at 24 and 48 hours 
post-transfection, respectively. There were 57.8±5 nuclei / hpf at 24 hours and 158±8.9 
nuclei / hpf at 48 hours post-transfection in the RBM10-depleted cells. This difference was 
significant with P=0.02 at 24h and P=0.0001 at 48h. In trial B (Figure 3.30B), the total 
nuclei number was 54.6±6 / hpf at 24h and 135±23 / hpf at 48h in the control compared to 
95.5±10 / hpf at 24h and 153±16.6 / hpf at 48h in the RBM10 KDs. Though the same trend 
was observed in trial B, only the 24 hour post-transfection was significant (P=0.0019). The 
initial plate density in trial B was high as evident from the difference in cell nuclei with 
42±3.5 in trial A compared to 57.8±5 in trial B, and therefore we speculate that the effect 
on proliferation was more pronounced a day earlier in more confluent cultures. 
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When the RBM10-depleted and control cells were induced to differentiate (D1 to D4) there 
was no significant difference in the number of nuclei present (Figures 3.29A, 3.30A). The 
number of nuclei remained the same in the control and RBM10 KD cells during 
differentiation in both trials. Proliferation stops after D2 in both experiments. 
In addition, we assessed other cell parameters such as the differentiation potential (Figures 
3.29B, 3.30B), fusion index (Figures 3.29C, 3.30C) and maturation efficiency (Figures 
3.29D and E, 3.30D and E). Controls showed differences in the differentiation markers 
between trials: D3 vs D4, which may depend on plating density. Our results indicated that 
there was no significant change in either the fusion potential, the number of myotubes per 
field and the maturation capacity between the control and RBM10-depleted cells, in both of 
the trials. However, we did observe a difference in significantly lower number of MyHC-
positive cells on for trial A on D3 (P=0.0005) and on D4 (P=0.0004), and on D3 
(P=0.0012) for trial B in the RBM10 KDs when compared to control cells.  
Because there was no significant difference seen in the number of RBM10 KD cells and 
control cells during differentiation, the significant decrease in differentiation potential at 
D3/D4 indicated that the fewer number of differentiating cells in the KDs was not an effect 
associated with proliferation or cell density. As reported by Bechara et al. (2013), RBM10 
may be primarily involved in proliferation before induction of differentiation. The effect on 
the differentiation potential on D4 (trial A) and D3 (trial B), may be due to the decrease in 
the number of MyHC-positive cells (Table 8), thereby indicating that, like RBM5, RBM10 
possibly modulates MyHC expression during differentiation.  
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Figure 3.30 Effect of RBM10 depletion on C2C12 cell count. C2C12 myoblasts were transiently 
transfected with a scrambled siRNA control or siRBM10. At 24h and 48h post-transfection, the total 
cell count was estimated by counting the number of DRAQ5-stained nuclei in the field for A) Trial A 
and B) Trial B. The graph represents the average number of nuclei from 8-12 separate fields of view 
and the error bars represent SEM. The immunofluorescent images represent one representative field 
for the control and siRBM10 at 24h and 48h after transfection for the two trials. Scale bar = 100µm. 
Unpaired Students’ t-test was used to calculate the statistical significance. * = P< 0.05, ** = P< 0.001, 
*** = P< 0.0001  
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Figure 3.31 Quantitative analysis of RBM10 KD effect on C2C12 cell count, differentiation, fusion and 
maturation during differentiation (Trial A). A) The total number of cells was estimated by counting the 
number of DRAQ5-stained nuclei per field, B) Differentiation potential is the ratio of number of nuclei in 
MyHC-positive cells to the total number of nuclei in the field X 100, C) Fusion index is the ratio of the number 
of nuclei in myotubes (≥2 nuclei) to the total number of nuclei in MyHC-positive cells X 100, D) Average 
number of myotubes from all fields, E) Average number of myofibers (≥5 nuclei) from all fields and F) DRAQ5 
and anti-MyHC stained merged images from a single representative field of view, Scale bar = 100µm. Error 
bars represent SEM. Unpaired students t-test was used to calculate the statistical significance. * = P< 0.05. 
KD levels at 24h were 62% (RBM10v1) & 67% (RBM10v3). 
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Figure 3.32 Quantitative analysis of RBM10 KD effect on C2C12 cell count, differentiation, fusion and 
maturation during differentiation (Trial B). A) The total number of cells was estimated by counting the 
number of DRAQ5-stained nuclei per field, B) Differentiation potential is the ratio of number of nuclei in MyHC-
positive cells to the total number of nuclei in the field X 100, C) Fusion index is the ratio of the number of nuclei 
in myotubes (≥2 nuclei) to the total number of nuclei in MyHC-positive cells X 100, D) Average number of 
myotubes from all fields, E) Average number of myofibers (≥5 nuclei) from all fields and F) DRAQ5 and anti-
MyHC stained merged images from a single representative field of view, Scale bar = 100µm. Error bars 
represent SEM. Unpaired Students’ t-test was used to calculate the statistical significance. ** = P< 0.001. KD 
levels at 24h were 85% (RBM10v1) & 72% (RBM10v3). 
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Table 8 
MyHC-positive cells in RBM10-depleted differentiating C2C12 cells 
 
 Trial A (62% & 67%)  Trial B (85% & 72%) 
             C siRBM10 C siRBM10 
  Ave SEM Ave SEM Ave SEM Ave SEM 
D1 1.5 0.4 0.9 0.5 1.1 0.51 2.1 0.5 
D2 6.9 1.5 6.9 1.5 11 3.9 15.8 4.7 
D3 16 1.5 15 1.9 37 3.6 22.5** 1.6 
D4 29 2.2 17** 1.6 26 4.3 17.8** 1.2 
 
                 * = P< 0.05, ** = P< 0.001, *** = P< 0.0001.  
 
 Percentage in brackets indicates the RBM10v1 and RBM10v3 KD %, respectively at 24 
hours post-transfection.               
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3.3.4.3 RBM5 and RBM10 combined depletion 
Next, changes in morphology associated with depleting both RBM5 and RBM10 were 
examined. The KD levels for the two trials, trial A (trial 2 in Table 6C) at 24h were 50% 
(RBM5), 47% (RBM10v1) and 49% (RBM10v3) and for trial B (trial 3 in Table 6C) at 24h 
were 48% (RBM5), 35% (RBM10v1) and 59% (RBM10v3) as shown previously (Figure 
3.20) by Western blots. 
The number of nuclei in RBM5+10 KDs had a similar effect to that observed in RBM5-
depleted cells. At 24 and 48 hours post-transfection, the number of cells did not vary 
between the control and RBM5+10-depleted cells in both the trials (Figure 3.33A,B). The 
number of starting cells in the scrambled siRNA controls was larger compared to the KDs 
in trial B.  
When the cells were subjected to differentiation after transfection, the number of nuclei 
present were significantly lower in the RBM5+10 KDs (Figures 3.34, 3.35). Specifically, 
there were significant reductions on D1 (P=0.029), D3 (P=0.0001) and D4 (P=0.0037) for 
trial A (Figure 3.34A) and on D1 (P=0.0054), D2 (P=0.0002) and D4 (P=0.0036) for trial 
B. (Figure 3.35A).  This effect was similar to that seen in RBM5-depleted cells suggesting 
that RBM5 is likely exerting a predominant role during C2C12 differentiation. 
Next, we proceeded to assess the differentiation potential, fusion index and maturation 
index. The percentage of differentiating cells was lower in the RBM5+10 KDs. On D4, 
there was significant decrease in the differentiation potential (P=0.001) for trial A (Figure 
3.34B) and (P=0.0007) for trial B (Figure 3.35B). The percentage of differentiating cells 
was 33.7±4 % for trial A and 25±2.25 % for trial B in the control, which was reduced to 
23.5±3.6 % for trial A and 15±1.3 % for trial B in the RBM5+10 KDs. 
Interestingly, we did not see a statistically significant difference in the fusion index in the 
RBM5+10 KDs. Although a lower fusion index was noted for the KDs, it was not 
statistically significant. However, we observed that RBM5+10 siRNA silenced myoblasts 
fused into myotubes more slowly than the controls because there were less myotubes in the 
KDs. The number of myotubes in control cells were 4.5±1.2 cells / hpf, which was reduced 
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to 1.2±0.35 cells / hpf in the KDs on D3 for trial A, with a significant P value of 0.016. For 
trial B, the number of myotubes on D2 (P=0.0008) was 9.6±1.12 cells / hpf and 3.5±1 cells 
/ hpf in the control and KDs, respectively, and on D4 (P=0.0091) were 8.7±0.86 cells / hpf 
and 5.7±0.6 cells / hpf in the control and KDs, respectively. In both trials, there were 
significantly less MyHC-positive cells on D3 (P=0.0003) in trial A and on D2 (P=0.045) 
and D4 (P=0.0001) for trial B (Table 9) in the KDs compared to control. The difference in 
the starting cell number between the two trials could account for the differences seen 
amongst the two trials, especially in the MyHC-positive cells and myotubes /hpf.  
We also observed that there were significantly less myofibers (≥5 nuclei) / high power field 
in the double KDs compared to control. The maturation potential was at least eight-fold less 
in trial A (2.4± 0.7 in control and 0.3± 0.21 in KD) with a significant P value of 0.0093 
(Figure 3.34E)and four-fold less in trial B (1.8±0.5 control and 0.4±0.3 KD) with a 
significant P value of 0.025 (Figure 3.35E). 
To summarize, depletion of both RBM5 and 10 resulted in (a) a decrease in cell number 
during differentiation, (b) a decrease in the number of cells differentiating, (c) fewer 
myotubes and myofibers formation and (d) lower MyHC expression. 
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Figure 3.33 Effect of RBM5 and RBM10 depletion on C2C12 cell count. C2C12 myoblasts were 
transiently transfected with a scrambled siRNA control or siRBM5+10. At 24h and 48h post-
transfection, the total cell count was estimated by counting the number of DRAQ5-stained nuclei in 
the field for A) Trial A and B) Trial B. The graph represents the average number of nuclei from 8-12 
separate fields of view and the error bars represent SEM. The immunofluorescent images represent one 
representative field for the control and siRBM5+10 at 24h and 48h after transfection for the two trials. 
Scale bar = 100µm.  
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Figure 3.34 Quantitative analysis of RBM5+10 KD effect on C2C12 cell count, differentiation, fusion and 
maturation during differentiation (Trial A). A) The total number of cells was estimated by counting the 
number of DRAQ5-stained nuclei per field, B) Differentiation potential is the ratio of number of nuclei in 
MyHC-positive cells to the total number of nuclei in the field X 100, C) Fusion index is the ratio of the number 
of nuclei in myotubes (≥2 nuclei) to the total number of nuclei in MyHC-positive cells X 100, D) Average 
number of myotubes from all fields, E) Average number of myofibers (≥5 nuclei) from all fields and F) DRAQ5 
and anti-MyHC stained merged images from a single representative field of view, Scale bar = 100µm. Error 
bars represent SEM. Unpaired Students’ t-test was used to calculate the statistical significance. * = P< 0.05, 
** = P< 0.001, *** = P< 0.0001. KD levels at 24h were 82% (RBM5), 42% (RBM10V1) & 55% (RBM10V3). 
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Figure 3.35 Quantitative analysis of RBM5+10 KD effect on C2C12 cell count, differentiation, fusion and 
maturation during differentiation (Trial B). A) The total number of cells was estimated by counting the 
number of DRAQ5-stained nuclei per field, B) Differentiation potential is the ratio of number of nuclei in 
MyHC-positive cells to the total number of nuclei in the field X 100, C) Fusion index is the ratio of the number 
of nuclei in myotubes (≥2 nuclei) to the total number of nuclei in MyHC-positive cells X 100, D) Average 
number of myotubes from all fields, E) Average number of myofibers (≥5 nuclei) from all fields and F) DRAQ5 
and anti-MyHC stained merged images of a single representative field of view, Scale bar = 100µm. Error bars 
represent SEM. Unpaired Students’ t-test was used to calculate the statistical significance. * = P< 0.05, ** = 
P< 0.001, *** = P< 0.0001. KD levels at 24h were 48% (RBM5), 83% (RBM10V1) & 59% (RBM10V3). 
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Table 9 
MyHC-positive cells in RBM5+10-depleted differentiating C2C12 cells 
 
               Trial A (50%, 47% & 49%)           Trial B (48%, 83% & 59%) 
 C siRBM5+10 C siRBM5+10 
 
Ave SEM Ave SEM Ave SEM Ave SEM 
D2  6.5  1.3  6.1  0.8 37.8 5.8 21.9* 4.6 
D3 33.6 2.8 19.8** 1.4 52.2 3.6 45.5 5.8 
D4 29.2 3.3 22.9 3.7 37.6 2.7 18.9*** 1.7 
      
     * = P< 0.05, ** = P< 0.001, *** = P< 0.0001.  
 
Percentage in brackets indicates the RBM5, RBM10v1 and RBM10v3 KD %, respectively, 
at 24 hours post-transfection.
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3.3.5 Expression of myogenic proteins (MyoD, Myf5, MyoG and MyHC) during 
differentiation in RBM5- and RBM10-depleted cells. 
Inhibiting myogenesis (delay in differentiation, fusion and maturation) is a downstream 
phenotypic effect of gene expression changes in muscle specific factors. Previous results 
have shown that changes in the MRFs results in this delay (Sabourin and Rudnicki, 2000). 
Therefore, because of the inhibition in differentiation seen when RBM5 was KD, we 
expected to see changes in myogenic protein levels. When RBM5 was depleted in C2C12 
cells and they were induced to differentiate, there was a decrease in MyHC expression 
(Figures 3.28, 3.29 and Table 7). Proteins extracted from these cells were then processed 
for immunoblot analysis to determine the expression levels of MyoD, Myf5 and MyoG. 
Our results indicated that neither RBM5 nor RBM10 depletion affected the expression of 
MyoD and Myf5 (Appendix A-Figures A19 and A20). Interestingly, RBM5 suppression 
selectively reduced expression of MyoG (Figure 3.32). In the scrambled siRNA control 
cells, MyoG was barely detectable on D0, present on D1, increased on D2, reached the 
highest levels on D3 and then decreased on D4 (by which time fusion has already started). 
In RBM5-depleted cells, although, MyoG was absent on D0 and present on D1, it was 
reduced on D2, D3 and D4 compared to the scrambled siRNA control.  
As mentioned previously, when the RBM5 depleted cells were stained for MyHC, the 
number of MyHC-positive cells was significantly reduced (Table 7). This reduction was 
seen on D3 and D4 for trial 1 and trial 2. Therefore, these results suggest that RBM5 
participates in the differentiation process by regulating the expression of MyHC and MyoG 
but not MyoD and Myf5.  
In contrast, the RBM10-depleted cells did not show any change in MyoD, Myf5 and MyoG 
protein expression (Appendix A-Figures A18, A19 and A20). Interestingly, the same 
results were obtained in RBM5+10 combined KDs (Appendix A-Figures A18, A19 and 
A20). There was no change in MyoD, Myf5 and MyoG expression. With regard to MyHC 
expression, RBM10 and RBM5+10 KDs had down-regulated expression from that 
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observed in controls. As reported previously, the number of MyHC-positive cells was 
reduced during differentiation (Tables 8 and 9). 
Therefore, our results show that MyoD and Myf5 expression levels remains stable in the 
KDs and indicate that the effect of RBM5 and RBM10 in the differentiating cells probably 
occurs at the post-specification/determination stages. 
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Figure 3.36 MyoG expression in RBM5-depleted differentiating C2C12 cells. RBM5 
assists in myogenesis by modulating the expression of the MRF MyoG. Immunoblotting was 
performed using total protein extracted from scrambled siRNA control (C) and siRBM5 KD 
cells from three trials. Whole blots in Appendix A, Figure A18. α-tubulin was used as the 
normalization control. The graph depicts the fold-change in MyoG expression compared to 
the control levels, calculated using densitometry from technical duplicates.  
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3.3.6 Alternative splicing events that correlates with RBM5 and RBM10 depletion 
After morphologically characterizing the effect of the KD of RBM5 and RBM10 during 
differentiation, we proceeded to characterize few splicing changes induced by RBM5, 
RBM10 and RBM5+10 KD. In our experiments, we chose three splicing transitions that 
have been previously shown to occur during C2C12 differentiation and proceeded directly 
to check if there is alternative splicing of these specific mRNAs (alpha-dystrobrevin, 
myocyte enhancer factor 2c and beta-integrin) and whether these events are affected by 
RBM5 and RBM10 depletion. The three mRNAs are involved in the differentiation 
program and are shown to be associated with preferential inclusion or exclusion of exons.  
Alternative splicing constitutes an additional level of regulation in gene expression of many 
muscle-specific isoforms during the myogenic program (Bland et al., 2010). Because, 
RBM5 and RBM10 are splicing regulators and have been shown to be involved in mRNA 
splicing, we speculated that altering the levels of these two RBM proteins would affect the 
splicing of the three mRNAs, either by targeting exon inclusion in one variant and 
promoting the suppression of the other variant, which could delay differentiation or 
increase proliferation, as evident from the phenotypic effects associated during 
differentiation. We expected to see a change in timing and/or a change in the pattern of 
splicing (in early-expressed transcripts).  
3.3.6.1 Alpha-Dystrobrevin (DTNA) 
During C2C12 differentiation, the exon 11 of Alpha-Dystrobrevin gene is alternatively 
spliced. This splicing occurs after D2 and the detection of the exon 11 variant, reaches 78% 
in differentiated myotubes on D5 of differentiation. The increase in exon inclusion as 
differentiation progresses was shown to be associated with fusion during C2C12 
differentiation (Bland et al., 2010). We proceeded to test the alternative splicing of the Dtna 
mRNA variants in all three KD experiments (RBM5/RBM10 and RBM5+10) (Table 10, 
Figure 3.33). In our experiments, we expected to see a delay in the expression of the exon 
11 inclusion variant in the KDs.  
In siRBM10-transfected cells, on D2, there was about 15.5%, 21.1% and 17.6% inclusion 
of exon 11 when compared to 16.6%, 29.5% and 21.2% in the scrambled siRNA control 
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(C), respectively, from three trials. This trend was observed on D3, with 28.2%, 49.6% and 
32.2% inclusion in the KDs compared to 30.7%, 55.9% and 50.0% in the scrambled siRNA 
controls. Interestingly, we found that as differentiation progressed, KD of RBM10 led to a 
decrease in the inclusion of exon 11, which correlates with the inhibition seen in myogenic 
differentiation process. Therefore our data suggest that RBM10 promotes inclusion of exon 
11 in Dtna mRNA transcript during C2C12 skeletal muscle differentiation. We did not find 
any change in AS of Dtna that corresponded to all 3 trilas in the RBM5 and RBM5+10 
KDs. In our experiements, due to technical issues some data points are missing from the 
table, such as D4 differentiation for RBM5 KD (trial 1), RBM10 KDs (trial 2) and D2 
RBM5+10KD (trial 3).  
We observed a delay in splicing changes in the exon 11 variant in RBM10 KD trial 1 
wherein we see 32.9% inclusion, compared to trial 3, which has 43.6% inclusion. This 
delay was observed starting from D2. This could be due to a low initial plating density, as 
evident from the presence of 42±3.5 cells/hpf in trial 1 compared to 54.6±6 cells/ hpf in 
trial 3.   
These results indicate that RBM10 may regulate the alternative splicing of Dtna either 
directly or indirectly but additional experiments with stringent plating would be required to 
further elucidate the contributions of RBM10 in regulating the alternative splicing of this 
transcript. 
3.3.6.2 Myocyte enhancer factor 2c (MEF2C) 
Mef2c is responsible for maintaining the C2C12 cells in the differentiated state (Bachinski 
et al., 2010). Mef2cγ (-) activates transcription and Mef2cγ (+) represses transcription. 
Further, Mef2cγ (-) is associated with MyoD and cdk5 activity, which are involved in cell 
cycle arrest during the initial-stages of differentiation (Zhu and Gulick, 2004). The AS of 
Mef2cγ exon begins from D0 and continues to increase as differentiation progresses. Rajan 
et al. (2012) found that when the Mef2c mRNA was KD by shRNA, C2C12 cells had a 
lower fusion index of 8.25±3.42 with a mean cell count of 210.7±11.3 compared to 
scrambled control. Therefore, we expected to see an increase in Mef2cγ (+) variant in the 
RBM5 and RBM5+10 KDs. 
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When the alternative splicing of Mef2cγ was assessed in the RBM5, RBM10 and 
RBM5+10-depleted cells, as expected RBM5+10 KD showed an increase in γ exon 
inclusion when compared to the scrambled siRNA control (C) (Tables 11, 12, 13, Figure 
3.38). This increase was observed on D4 in the two trials. Specifically, trial 1 showed an 
increase from 73.7% in the scrambled siRNA controls to 76.7% in the KDs, trial 2 showed 
an increase from 65.3 % in the scrambled siRNA controls to 71.9% in the KDs and trial 3 
showed an increase from 76.3% in the scrambled siRNA controls to 80.3% in the KDs. In 
our experiements, due to technical issues some data points are missing from the table and 
therefore require additional biological replicates to confirm the AS changes observed in 
Mef2cγ , during the other time-points. 
Our results show that both RBM5 and RBM10 together could be potentially acting as 
splicing regulators during differentiation. We also observed that either RBM5 or RBM10 
did not have an effect on the alternative splicing of Mef2cγ exon. Therefore, these findings 
demonstrate that the alternative splicing of Mef2cγ is regulated by either synergistic or 
additive association of these two RBPs. 
3.3.6.3 Integrinβ1 
During C2C12 differentiation, expression of the β1A integrin isoform decreases while the 
β1D isoform levels increase and replaces β1A in mature myotubes (Belkin et al., 1996; 
(Quach et al., 2009). Functionally, isoform-specific functions have been identified for these 
two isoforms in myogenesis; specifically, when β1A was replaced with β1D by knock-in 
experiments in mice, primary myogenesis was affected (Belkin et al., 1996). When β1D 
was over expressed in C2C12 cells, there was a delay in myotubes formation and when 
β1A was over expressed it affected myotube maturation (Cachaco et al., 2003). 
Based on the importance of alternative splicing of Integrinβ1 during differentiation, we 
analyzed their alternative splicing pattern using exon-specific primers by end-point PCR. 
We compared the inclusion or exclusion of the β1A and β1D variants in the RBM5 and 
RBM10 KDs and controls (Figure 3.39). When the PCR products were analyzed, an 
integrin β1A variant at 282 bp was detected. This is the expected result since, during 
C2C12 differentiation, the β1D variant usually appears during the terminal-stages. In our 
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case, since our differentiation conditions did not proceed past D4, we can conclude that 
there was no integrin β1D (363 bp) detection until D4 in the KDs. This therefore indicates 
that neither RBM5 nor RBM10 is involved in the alternative splicing of integrin at least 
until D4 of differentiation. 
To conclude, the alternative splicing transitions that are affected by inhibiting these two 
RBPs either individually or dually are the exon 11 inclusion of Dtna (reduced) and the γ 
exon inclusion of Mef2c (enhanced). The depletion did not affect integrin β1A and β1D 
alternative splicing. Our results reveal a potentially new role for RBM10 and RBM5&10 as 
a splicing regulator during myogenesis.  
Overall, combining our expression and KD studies, we can infer that RBM5 is potentially 
crucial for differentiation, fusion and maturation. RBM10 likely has an alternative splicing 
role during differentiation and is required during proliferation before differentiation 
induction and for differentiation as well. 
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Table10. 
Dtna exon inclusion percentage during C2C12 differentiation 
 
RBM5KD Trial 1 (72% KD) 
 
Trial 2 (60% KD) Trial 3 (82% KD) 
C D2 29.5 35.0 41.8 
siRBM5 D2 26.6 35.6 40.9 
C D3 55.9 48.0 50.2 
siRBM5 D3 58.4 54.1 54.4 
C D4  59.2 61.0 
siRBM5 D4  54.3 62.8 
 
 
RBM10KD 
Trial 1 
(77% 10v1,  
67% 10v3 KD)  
Trial 2  
(86% 10v1,  
89% 10v3 KD) 
Trial 3  
(85% 10v1,  
72% 10v3 KD)# 
C D2 16.6 29.5 21.2 
siRBM10 D2 15.5 21.1 17.6 
C D3 30.7 55.9 50.0 
siRBM10 D3 28.2 49.6 32.2 
C D4 32.9  43.6 
siRBM10 D4 36.5  46.8 
 
siRBM5+10KD 
Trial 1 (52% 5, 49%  
10v1, 76% 10v3 KD) 
Trial 2 (81% 5, 85%  
10v1, 83% 10v3 KD) 
Trial 3 (48% 5, 83% 
10v1, 59% 10v3 KD)# 
C D2 30.6 41.8 21.2 
siRBM5+10 D2 21.2 30.0 
 
C D3 35.3 50.2 50.0 
siRBM5+10 D3 38.6 50.2 38.9 
C D4 46.9 61.0 43.6 
siRBM5+10 D4 37.3 61.9 41.0 
Percentage in brackets indicates the KD % at 48 hours post-transfection. # indicates the KD 
% at 24 hours. 5- RBM5, 10v1- RBM10V1 and 10v3- RBM10V3.  
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Figure 3.37 Alternative splicing of Dtna in RBM10 deficient differentiating C2C12 cells. RBM10 
promotes inclusion of exon 11 of Dtna during muscle differentiation. A) Diagram illustrating the 
formation of the two variants, the location of primers used in this study and the expected product sizes. 
Semi-quantitative end-point PCR was performed on total RNA extracted from control (C) and 
siRBM10 KD cells from 3 trials, B) Trial 1, C) Trial 2 and D) Trial 3. (Raw data in appendix A- 
Figures A12 – A17). Gapdh was used as normalization control. The graphs show the percentage of 
exon inclusion and exclusion calculated using densitometry from technical quadruplicates.  
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exon10 exon12 
exon10 exon11 exon12 391bp 
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 Table 11 
Mef2cγ exon inclusion percentage in Rbm5-depleted C2C12 cells  
 
 
 
 
Percentage in brackets indicates KD % at 48 hours post-transfection. %inc is the percent of 
exon inclusion. 
 
RBM5KD 
Trial 1  
(72% KD) 
Trial 2  
(60%KD) 
Trial 3  
(82% KD) 
  %inc %inc %inc 
C D0/24h 64.1  54.1 
siRBM5 D0/24h 61.4  51.6 
C 48h  65.5 53.5 
siRBM5 48h  65.1 49.4 
C D1 65.2 77.5 65.2 
siRBM5 D1 69.2 74.3 67.1 
C D2 76.1 82.5 67.2 
siRBM5 D2 75.1 82.5 69.1 
C D3 78.3 84.2 73.5 
siRBM5 D3 73.4 83.2 74.0 
C D4  74.1 65.3 
siRBM5 D4  76.4 71.9 
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Table 12 
Mef2cγ exon inclusion percentage in Rbm10-depleted C2C12 cells  
 
Percentage in brackets indicates the KD % at 48 hours, # indicates the KD % at 24 hours. 
%inc is the percent of exon inclusion. 
 
RBM10KD 
Trial 1 (77%  
10v1, 67% 10v3) 
Trial 2 (86% 
10v1, 89% 10v3) 
Trial 3 (85% 
10v1, 72%10v3)# 
  %inc %inc %inc 
C D0/24h 67.8 64.1 80.9 
siRBM10 D0/24h 71.8  70.2 
C 48h 75.0  71.9 
siRBM10 48h 69.7  76.9 
C D1 75.3 65.2 76.3 
siRBM10 D1 74.7 72.1 69.7 
C D2 74.5 76.1 80.3 
siRBM10 D2 73.3 75.0 78.7 
C D3 74.3 78.3 80.4 
siRBM10 D3 82.2 81.3 80.2 
C D4 84.1  76.3 
siRBM10 D4 80.2  79.5 
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Table 13 
Mef2cγ exon inclusion percentage in Rbm5- and Rbm10-depleted C2C12 cells  
 
 
RBM5+10KD 
Trial 1 (52% 5, 49% 
10v1, 76% 10v3) 
Trial 2 (81% 5, 85% 
10v1, 83% 10v3) 
Trial 3 (48% 5, 83% 
10v1, 59% 10v3)# 
 %inc %inc %inc 
C D0/24h 59.0 54.1 80.9 
siRBM5+10 D0/24h  54.2 75.1 
C 48h  53.5 71.9 
siRBM5+10 48h  49.4 70.4 
C D1 71.8 65.2 76.3 
siRBM5+10 D1 70.6 59.2 77.0 
C D2 71.6 67.2 80.3 
siRBM5+10 D2 71.1 66.0  
C D3 75.4 73.5 80.4 
siRBM5+10 D3 75.8 69.6 77.7 
C D4 73.7 65.3 76.3 
siRBM5+10 D4 76.7 71.9 80.3 
 
Percentage in brackets indicates KD %, # indicates the KD % at 24 hours, the rest are at 48 
hours. %inc is the percent of exon inclusion. 
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Figure 3.38 Alternative splicing of Mef2cγ in RBM5+10-depleted cells during C2C12 
differentiation. RBM5 and RBM10 collectively modulate alternative splicing of Mef2cγ during 
differentiation. A) Diagram illustrating the formation of Mef2c γ+ and γ- spliced variants, the location 
of primers used in this study and the expected product sizes. Semi-quantitative end-point PCR was 
performed on total RNA extracted from control (C) and siRBM5+10 KD cells on D4 differentiation 
from three trials, B) Trial 1, C) Trial 2 and D) Trial 3 (Raw data in appendix A-Figures A15, A16, 
A17). Gapdh was used as normalization control. The graphs show the percentage of exon inclusion 
and exclusion calculated using densitometry from technical quadruplicates.  
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Figure 3.39 Alternative splicing of Integrin β1A / β1D events in RBM5- or RBM10- depleted cells 
during C2C12 differentiation. RBM5 and RBM10 have no effect on the alternative splicing of 
Integrin β variants. A) Diagram illustrating the formation of Integrin β1A and Integrin β1D spliced 
variants, the location of primers used in this study and the expected product sizes. Semi-quantitative 
end-point PCR was performed on total RNA extracted from control (S) and siRBM5 (5) and siRBM10 
(10) KD cells from one trial (Trial 1) B) Agarose gel image showing Integrin β1A (282 bp) PCR 
product from D0-D3 in technical duplicates, but the other variant Integrin β1D (363 bp) was not 
detected.  
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Chapter 4  
 
4 Discussion 
4.1 C2C12 mouse myoblasts are appropriate model for 
determining the role of RBM5 and RBM10 during skeletal 
differentiation  
Different model systems have been used to understand the molecular intricacies of the 
myogenic program (Miller, 1990). The C2C12 model is a representative model as judged 
by the following factors: (a) it is a well-characterized model, and (b) the time-course of 
differentiation can be accurately studied. In addition, several alternative splicing patterns, 
which are dynamic and necessary for myogenesis, have been extensively studied in this 
model system. C2C12 myoblasts were grown in DMEM supplemented with growth serum, 
which provided the cells with essential growth factors. When the percentage of serum was 
reduced, it resulted in deprivation of growth factors, which triggered a cascade of numerous 
molecular signalling pathways. This led to induction and execution of the myogenic 
differentiation process, thereby causing the transition from myoblasts to myotubes.  
Many laboratories use different serum conditions for growth and differentiation such as 
varying the serum concentration and use of serum derived from different animals. For 
instance, some grow myoblasts in 10% fetal calf serum (FCS) and induce differentiation 
with 1% FCS (Ferri et al., 2009); others use 20% FBS in GM to 1% HS or 2% HS in DM 
(Ono et al., 2006, Mei et al., 2011), while some use 10% FBS for growth with differing 
concentrations (1%, 2% and 5%) of HS for differentiation (Louis et al., 2008, Sun et al., 
2005, Velica and Bunce, 2011). For our experiments, we used 10% FBS to grow the 
myoblasts and 2% HS to induce differentiation. When the proliferating C2C12 myoblasts in 
growth medium grown to 80% cell density were exposed to reduced serum they started 
differentiating. The effect of changing serum concentration in the C2C12 myoblasts was 
assessed. The differentiation landmarks were examined visually, and in addition, the 
expression of muscle differentiation-specific markers such as MyoD and MyoG 
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(Myogenin) were analyzed. Assessing the muscle differentiation-specific markers was 
necessary to determine the progress of differentiation and also to confirm antibody 
specificities. MyoD, a component of the bHLH myogenic transcription factor, is necessary 
for the regulated expression of early (adhesion and extracellular proteins), intermediate 
(transcription factors) and late-stage genes (myofibril and cytoskeletal proteins) (Ishibashi 
et al., 2005, Tapscott, 2005). On the other hand, a decrease in MyoD levels are observed in 
quiescent cells, in fact, down-regulated expression of MyoD and Myf5 can direct the 
C2C12 cells to become reserve cells (Yoshida et al., 1998). When serum depletion occurs, 
MyoD-positive cells should show an increase in MyoG expression (Yoshida et al., 1998). 
Different observations have been recorded concerning the expression levels of MyoD in 
C2C12 cells. For instance, Ferri et al. (2009), observed that the mRNA levels of MyoD did 
not change but there was a significant increase in protein levels on D1 when compared to 
D0, D3 and D7. According to Miller (1990), MyoD levels increased on D3 but this increase 
was seen in mRNA levels. In addition, the mRNA expression levels of MyoD were shown 
to be cell density-dependant; the mRNA levels during differentiation fluctuated depending 
on the confluence of the C2C12 cells at the time of seeding (Tanaka et al., 2001). Others 
have reported steady-state MyoD protein levels during differentiation (Mal and Harter, 
2003, Shen et al., 2003).  Our experiments, agrees with these two reports; we detected 
MyoD in both undifferentiated myoblasts and the myotubes and MyoD protein levels 
remained same throughout the differentiation process.  
Our assessments showed that differentiation was generated in the C2C12 cells treated with 
the lower concentration of HS and that the time-points of the differentiation morphology 
differed slightly from previously published reports. Tomczak et al. (2003), reported that by 
D2, the number of nuclei in multi-nucleated cells was 9±3% and by D4, the fusion index 
was 40±5% and by D6, the fusion index increased to 48±5%, with a marginal increase upto 
52±3% by D10. In their experiment, 20% FBS-containing media was used for growth and 
2% HS was used for differentiation. In our experiments, when using 10% FBS and 2% HS, 
we observed that the differentiation potential was at 9% between D2 and D3, and the fusion 
index was at 40% between D5 and D6 of differentiation. According to Ferri et al. (2009), 
wherein the experiments were performed using C2C12 cells, which were induced to 
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differentiate at 80% confluence, by changing 10% FCS to 1% FCS, the differentiation 
started 24 hours post-serum reduction. The fusion index was 8±3% on D2. On D3-D5, the 
fusion index increased to 35±5% and reached 60±6% at D7-D10. These suggest that based 
on the cell density and the percentage of serum used for growth and differentiation, there 
could be differences in the exact timing and the number of cells undergoing differentiation 
transformation. 
 Down-regulated expression of RBM5 and RBM10 during differentiation in this model 
tests the importance of time-dependant regulation and aligns with previous studies 
demonstrating that this intricate process is highly controlled. Thus, overall we can infer that 
the murine C2C12 myogenic differentiation cell line is a suitable model to study the role of 
RBM5 and RBM10 during the differentiation phase of skeletal myogenesis. 
There are limitations associated with using this C2C12 model system. This in vitro mouse 
muscle differentiation model has some differences compared to normal skeletal myogenesis 
that occurs in vivo; the differences being exhibited in the timing of MyoD expression, the 
role of “satellite-like” reserve cells, the myofibers formed are not mature myofibers and the 
differentiation phase is part of both embryonic and regenerative myogenesis. In addition, 
the C2C12 cells are capable of differentiating if they reach high confluence even when 
being maintained in GM. 
4.2 RBM5 and RBM10 are differentially expressed and tightly 
regulated during skeletal muscle differentiation  
RBM5 and RBM10 are important RNA-binding proteins implicated in functions such as 
cell proliferation, apoptosis and alternative splicing in transformed cells (Edamatsu et al., 
2000; Oh et al., 2002; Sutherland et al., 2000; Zhao et al., 2012; Shao et al., 2012; Fushimi 
et al., 2008; Bonnal et al., 2008; Wang et al., 2012). These two RBPs are associated with 
disease states such as tumors, including but not limited to lung, breast, ovarian, pancreas, 
etc. (Bechara et al., 2013). The precise mechanism of action of these RBPs in non-
transformed systems is beginning to be deciphered. RBM5 has recently been shown to be 
involved in spermatid differentiation (O'Bryan et al., 2013). Although RBM5 and RBM10 
are highly expressed in skeletal muscle, their exact role in muscle development has never 
 142 
 
been explored. Our research has focused on the expression and the regulatory role played 
by RBM5 and RBM10 during the normal skeletal muscle differentiation. We are the first to 
report an important role for these two RBPs in skeletal myogenesis.  
Firstly, we analyzed the expression levels for RBM5 and RBM10 in the mouse C2C12 
myogenic differentiation model. We found that both RBM5 and RBM10 are expressed in 
C2C12 cells and the expression decreased progressively during differentiation. From these 
results, we can infer that (a) the presence of these two RBPs throughout differentiation 
signifies their potential importance during the entire process of C2C12 differentiation, (b) 
their differential expression suggests effective regulation during myogenic differentiation 
and (c) there is a likely possibility that these RBPs might exert specific functions in 
myogenesis. These experiments also revealed that the protein abundance of RBM5 and 
RBM10 had similar trends, from which we can deduce that RBM5 is co-expressed with its 
paralogue RBM10 during myogenic differentiation, which suggests both proteins could 
possibly possess distinct functions. Lastly, the change in expression validates that the 
C2C12 differentiation model is a useful model to elucidate the role of RBM5 and RBM10 
in skeletal myogenesis.  
We were able to detect Rbm5 and Rbm10 mRNA variants during differentiation, however, 
we cannot determine if these levels were comparable to previous observations that showed 
high mRNA expression in mature human skeletal muscle. Different types of myofibers 
constitute the mature adult muscle and there are many gene expression changes associated 
with mature muscle fibre in vivo (Gunning and Hardeman, 1991). For instance, the G 
protein subunit, Gαz, which interacts with G protein-coupled receptors (GPCRs) and can 
modulate myogenin, was expressed during differentiation but was absent in adult muscle 
(Mei et al., 2011). SMAD3 and Notch3 are other muscle-related proteins that have shown 
transient expression (Kislinger et al., 2005). Some of the diversity is in part due to isoform-
specific expression and function. For instance, even though there are multiple MyHC 
isoforms, different isoforms are required for specific functions (Wells et al., 1996). Spatio-
temporal expression is not only associated with heterogeneity in fiber types but also with 
muscle-specific mechanical properties (Babu et al., 2000). In addition, inter-species 
variations, such as species-dependant fiber type specification are reported. For instance, in 
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rodents and birds, the myoblasts fuse in two stages generating the primary myotubes and 
the secondary myotubes, however, in humans, a third stage occurs leading to the formation 
of tertiary myotubes (Gunning and Hardeman, 1991). It is therefore possible that the down-
regulated expression in humans corresponds to additional regulation. 
We found an apparent discrepancy between the differential down-regulation of protein 
levels and the steady state mRNA levels for all of the variants suggesting that expression is 
regulated at a post-transcriptional and/or post-translational level. Differences in the mRNA 
stability and degradation of differentiation-specific transcripts when compared to 
proliferating and differentiating cells, indicates that when there is no functional 
requirement, these mRNA can be destroyed ('t Hoen et al., 2011). When they measured 
mRNA half-life, albeit for only 8 hours in proliferating and differentiating cells, factors 
such as decay rate and splice variants were shown to control the mRNA stability of many 
muscle-related mRNAs. Furthermore, our results are in line with the skeletal-specific 
differential expression (of both Rbm5 and Rbm10) observed in the rat H9c2 model 
(Loiselle and Sutherland, 2014). Thus, these findings indicate that the levels of RBM5 and 
RBM10 are tightly regulated during skeletal differentiation, suggesting an important role 
for these two RBM proteins in the myogenic process, and denoting functional specificity.  
During C2C12 differentiation, the two RBM10 isoforms were differentially expressed 
where RBM10v3 was more highly expressed than RBM10v1. Our results are similar to that 
observed in H9c2 cells, in which RBM10v2 (Human/Rat RBM10v2 is equivalent to the 
mouse RBM10v3) was two-fold higher than RBM10v1 (at both protein and mRNA levels) 
during skeletal-specific differentiation (Loiselle and Sutherland, 2014). This trend was 
observed in cardiac lineage-specific differentiation as well (Loiselle and Sutherland, 2014). 
This may specify functional differences between cancer and normal cells. In human 
transformed cell lines, which are associated with lung adenocarcinomas (A549, GLC20), 
only one RBM10 variant (RBM10v1) is abundant and the other variant is nearly 
undetectable (Loiselle and Sutherland, 2014). Thus, our results clearly indicate that the 
level of regulation and functional implications of RBM10 in normal cells is different than 
in transformed cells. Many RBPs are alternatively spliced leading to isoform-specific 
functions (Glisovic et al., 2008). For instance, a spliced isoform of the RBP, hnRNP A/B 
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protein is involved in the regulation of alternative splicing during erythropoiesis (Glisovic 
et al., 2008). The human RBM10v2 isoform lacks certain domains such as the RNP2 motif 
region (Xiao et al., 2013), which suggests that this isoform may not be important during 
tumorigeneis, however, it may be required during myogenic differentiation. As suggested 
by Xiao et al., (2013), the presence of both isoforms in certain cellular systems, denoting 
binding to different RNA targets or different RNA-binding ability, could hold true for 
differentiation as well. 
The expression of Rbm5 variants is regulated post-transcriptionally in myogenesis, which is 
a normal cell developmental condition, unlike in cancer cells where it is regulated in 
relation to tumorigenesis (Sutherland et al., 2005). Similarly, the expression of Rbm10 
variants and isoforms are regulated during normal cell development, which however 
correlates with a previous result that RBM10 is expressed during mid-gestation embryos 
(Johnston et al., 2010). RBPs are regulated depending on tissue-specific functions 
(Dreyfuss et al., 2002, Reed and Hurt, 2002). Post-transcriptional regulation of myogenic 
events is a necessary component for muscle differentiation. The presence of both RBPs 
during the initial stages of differentiation is therefore thought to provide better control.  
Protein and mRNA levels do not always correlate (Greenbaum et al., 2003). In addition, the 
discrepancy between the mRNA and protein levels have been previously reported for 
myogenic proteins such as Myf5, Myogenin, MyoD and MRF4 during C2C12 
differentiation and this has been accounted for by post-transcriptional mechanisms (Ferri et 
al., 2009). Furthermore, the relative difference between protein and mRNA expression 
during differentiation, suggests that micro RNAs (miRNAs) could regulate RBM5 and 
RBM10 accumulation. This argument stems from two observations. Firstly, miRNAs play a 
role in myogenesis by either repressing translation or promoting mRNA degradation 
(Soleimani and Rudnicki, 2011, Ge and Chen, 2011). Secondly, RBM5 is one of the lung-
carcinoma associated putative target genes of hsa-miR-151a-3p (Pang et al., 2014).  It is 
also shown that the expression of human RBM5 is repressed by miRNA (miR-660) and 
hence, is down-regulated (-1.96 fold) during myoblast differentiation (Dmitriev et al., 
2013). No reports have thus far identified miRNA repression of RBM10. 
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The steady-state Rbm5 mRNA levels measured in the differentiating C2C12 cells are 
different from the down-regulation observed during in vitro myogenic differentiation of 
human primary myoblasts (Dmitriev et al., 2013). However in those microarray 
experiments, the RNA was isolated from CD56+ myoblasts, which eliminates non-
myogenic cells, whereas C2C12 cells are heterogenous population. In addition, there are 
possible differences in expression that could exist between species.  
Post-translational modifications such as phosphorylation, sumoylation and ubiquitinylation 
of these muscle-specific regulators have also been shown to contribute to the discrepancy in 
the protein and mRNA levels (Naya and Olson, 1999). Based on the localization studies of 
MRFs such as Myf5, Myogenin, MyoD and MRF4, Ferri et al., (2009) have suggested the 
occurrence of stage-specific post-translational regulation of these myogenic proteins during 
differentiation. In addition, post-translational changes such as phosphorylation, arginine 
methylation and sumoylation are responsible for altering the localization, binding 
specificity/capacity and thus the function of many RBPs (Glisovic et al., 2008). Further 
research is warranted to elucidate the regulation of these two RBPs at the post-
transcriptional and post-translational levels during myogenesis. 
Accurate timing in the expression of MRFs is an important factor in myogenesis. As stated 
earlier, MRFs are expressed in a distinct manner, which denotes that the myogenic program 
is highly detailed and co-ordinated. We have therefore determined the approximate time-
period when these RBM5 and RBM10 variants/isoforms are expressed during C2C12 
differentiation to gain a better insight into their function, using our experimental conditions, 
specifically growing the C2C12 myoblasts in GM containing 10% FBS and inducing 
differentiation by changing to DM containing 2% HS. Based on the expression profile, 
RBM5 and RBM10 show potential involvement during the early- and mid- stages but not 
the terminal-stage. Therefore, our results on stage-specific expression of RBM5 and 
RBM10 led us to explore further their importance during myogenic differentiation. These 
expression studies therefore enabled us to proceed with our knockdown studies to validate 
our conclusion regarding the stage-specific expression and to determine a possible 
regulatory role for these two RBPs during myogenesis. 
 146 
 
4.3 RBM5 and RBM10 are differentially localized in 
differentiating C2C12 cells 
Intracellular localization of RBM5 and RBM10 in the differentiating cells revealed that 
both RBM5 and RBM10 were localized to the nucleus in the myoblasts and, as 
differentiation proceeds, they were present in both the cytosol and nucleus of the 
differentiating myotubes. This is the first report to show the subcellular distribution of 
RBM5 and RBM10 in a mouse myogenic differentiating cell line. Localization studies help 
in predicting functions, identifying interactions with the cellular machinery and to some 
extent, deducing the mechanism of action. The differential localization observed for RBM5 
and RBM10 suggests a potential regulatory role in biological processes. The nuclear 
localization during the initial-stages, and both nuclear and cytosolic detection during the 
mid- and late- stages of differentiation implies multiple functions potentially related to 
mRNA biogenesis. Specifically, nuclear and cytoplasmic localization during the later 
stages of differentiation, especially in the myotubes, suggests potential involvement in 
export of mRNA targets. Many hnRNP proteins travel between the nucleus and cytoplasm, 
necessitated by their involvement in multiple functions at different stages, either during 
transcriptional pre-mRNA packaging, and/or post-transcriptional transport (Pinol-Roma 
and Dreyfuss, 1993, Dreyfuss et al., 1993). Furthermore, binding of RBPs to their target 
mRNAs is stage-specific; binding can occur to mRNAs at different stages and in different 
locations (Glisovic et al., 2008). Therefore, the presence of these two RBPs in specific 
cellular compartments suggests RNA binding, leading to involvement in 
transcriptional/post-transcriptional regulation. Based on the RBM5 and RBM10 expression 
profiles, we speculated their functional involvement during the early- stages of 
differentiation. The cytosolic (sarcomeric) localization observed after differentiation 
induction, during the mid- and late- stages of differentiation denotes that it could be a 
possible mechanism to confer functional control, specifically to retain these two RBPs in 
the cytoplasm and to prevent their splicing activity in the nucleus.  
Previously, localization studies for RBM5 in non-transformed cells were carried out in 
adult testis through IHC, where both nuclear and cytosolic expression was observed 
(O'Bryan et al., 2013). The RBM5 plant homolog, SUA, was detected in the nucleus of 
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developing plant embryo tissue (Sugliani et al., 2010). Our results on the differential 
distribution of RBM5 during differentiation are in accord with previous studies (conducted 
in other cell types); while most have reported a nuclear presence, some have also found 
cytosolic localization.   
The subcellular localization of RBM10 is initially in the nucleus of the proliferating 
myoblasts and then becomes localized in both the nucleus and cytoplasm as the cells 
differentiate. This indicates that the localization is stage-specific. Only a few reports have 
investigated the localization pattern of RBM10 in the cell (Inoue et al., 2008, Xiao et al., 
2013). RBM10 was present in both dividing and non-dividing cells, as well as in terminally 
differentiated cells (Inoue et al., 2008). Transcriptional and post-transcriptional states of the 
cell induced reversible changes in the subcellular localization of RBM10 to the nucleus. In 
C2C12 differentiating cells, RBM10 was detected in the nucleus in reserve cells. Reserve 
cells exist in a dormant state (Montarras et al., 2013). Our result is in line with previous 
observation that RBM10 is expressed regardless of the state of the cell 
(proliferating/quiescent) (Inoue et al., 2008). 
The percentage of differentiated C2C12 cells ranges between 40% and 60% (Yoshida et a., 
1998) and the remaining are reserve cells (Miller, 1990). Interestingly, the myogenic 
proteins such as MyoD and Myf5 are localized specifically in the nuclei of undifferentiated 
C2C12 myoblasts, but in differentiated cells were mostly present in myocytes and 
myotubes and only in trace amounts in the reserve cells (Yoshida et al., 1998). The 
detection of RBM5 and RBM10 in these reserve cells, albeit not in all of them, does place 
them as important RNA-binding factors necessary for adult myogenesis.  
The functional relevance of these two RBPs during differentiation is further supported by 
this specific localization patterns in the myoblasts and in differentiating myotubes. 
Additionally, it does not rule out the possibility of an involvement during regenerative 
myogenesis when necessary because both RBM5 and RBM10 are expressed in reserve 
cells, thus warranting further studies of their role in tissue injury and repair. 
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4.4 Possible functions of RBM5 and RBM10 during myogenesis 
Several lines of evidence are presented in this dissertation to support the hypothesis that 
Rbm5 and Rbm10 are involved in regulating myogenesis. The expression profiles of Rbm5 
and Rbm10 are consistent with a potential regulatory role during the initial- and mid- stages 
of differentiation. The functional regulation was predominantly examined by analysing the 
changes in cell morphology, expression of myogenic proteins and changes in alternative 
splicing following down-regulation of these RBPs using siRNAs (loss-of-RBM5 and -
RBM10 functions). Depleted RBM5 and RBM10 levels altered expression and alternative 
splicing of several targets, which affected differentiation and led to the delay in fusion, 
respectively, thus indicating that both RBM5 and RBM10 might be essential during 
myogenesis. These effects during myogenesis may be due in part to their effects on MyoG 
and MyHC expression, and on alternative splicing of Dtna and Mef2c.  
The last few years have witnessed a plethora of studies exploring the regulation of 
expression and function of RBM5 and RBM10 in many different systems in order to 
deduce their role. RBPs functioning in cell growth, proliferation and differentiation can 
also be involved in tumorigenesis (Kim et al., 2009). Therefore, these two RBPs, which 
have a functional role in cancer cell proliferation and apoptosis, may also possess a possible 
role in normal muscle cell differentiation. We were able to identify a stage-specific 
involvement. Thus, RBM5 and RBM10 are now emerging as multi-functional proteins 
possessing a wide range of functions in transformed as well as non-transformed cells. 
4.4.1 RBM5 and RBM10 have functional role in the myogenic program 
In order to elucidate the role of RBM5 in muscle cell differentiation, we decreased the level 
of RBM5 in C2C12 cells using siRNA transfection. Subsequently, differentiation was 
induced and the changes in cell morphology were assessed. Staining with DRAQ5 (an 
anthroquinone), the nuclear marker that intercalates to A-T of DNA, allowed us to count all 
the cells present in the field of view. This method of assessing cell number correlates with 
other cell counting methods such as the 5-Bromo 2’-deoxyuridine (BrdU) assay with the 
exception that DRAQ5 intercalates to DNA at any stage of the cell cycle whereas BrdU 
incorporation occurs only in newly synthesized DNA.  
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The results indicated that in differentiated C2C12 cells (D2-D4), RBM5 KD cells had 
fewer nuclei than controls and were slow in differentiating. In the RBM5 KD cells, the 
reduction in nuclei number during differentiation could be due to death of unfused cells. 
Fewer cells (nuclei) led to availability of less nuclei for fusion and thus affected the 
myogenic fusion process. Based on previous studies, there is enough evidence to suggest a 
putative tumor suppressor role for RBM5 by modulating both apoptosis and cell cycle 
arrest (Sutherland et al., 2005). The function of RBM5 in myogenesis is different from its 
tumor-specific anti-proliferative function. In tumorigenesis, RBM5 inhibits cell growth, 
however in differentiating C2C12 cells, RBM5 depletion has an opposite effect, and cell 
number is drastically reduced rather than being increased.  
Similarly, the function of RBM5 in differentiation is different from its pro-apoptotic role in 
cancer cells (Sutherland et al., 2005). In our C2C12 cell system, higher RBM5 expression 
during the initial days of culture indicates a possible role in apoptosis, however, in the 
RBM5-depleted cells there were fewer nuclei rather than the expected increase in cell 
number. During C2C12 differentiation, apoptosis occurs during the initial stages of 
differentiation (approximately between D0 to D2) and apoptosis could either promote 
differentiation (positive role) or could also cause the cells to die leading to a delay 
(negative role) (Sandri and Carraro, 1999). We have not determined directly if RBM5 
depletion affects cell proliferation or apoptosis. However, our results reveal that RBM5 
likely functions in a different manner in non-tumor cells (C2C12) compared to tumor cells.  
In addition, C2C12 myoblasts with transiently depleted RBM5 exhibited impaired fusion 
into myotubes. The RBM5 KD cells had decreased MyoG as evidenced by immunoblot and 
reduced MyHC protein levels from confocal analysis, which shows that the decrease in the 
expression of these myogenic proteins may be linked to this delay in myotubes formation. 
Changes in expression of many cell cycle proteins such as Ccnd1, Ccna2, Ccne2 (down-
regulation) and Ccnd3 and Cdkn1a (up-regulation), occurs during the first two days of 
induction of differentiation (Shen et al., 2003). Between 12-24 hours after induction, 
C2C12 cells showed an increase (over four-fold) in expression, which demonstrates that 
this is the critical period for gene expression regulation during differentiation (Rajan et al., 
2012). The reduction in cell number detected two days after induction of differentiation is 
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the downstream effect of RBM5 inhibition, indicating either a direct or indirect effect on 
cell cycle or apoptotic genes to be the likely mechanism by which RBM5 affects cell 
density during C2C12 differentiation. In addition, the antagonistic function of two other 
Rbm5 mRNA variants RBM5r6 (Mourtada-Maarabouni et al., 2003) and RBM5-AS1 (Je2 
cDNA antisense fragment) (Mourtada-Maarabouni et al., 2006) in comparison to the full 
length Rbm5 mRNA transcript, especially in progression of tumor growth is another likely 
mechanism by which this RBP could regulate the cell number during differentiation. 
Hence, additional mechanistic studies are required to determine the level of regulation of 
RBM5 during C2C12 differentiation. ` 
Next, we down-regulated RBM10 in C2C12 cells using siRNA. The cells were analyzed 
morphologically. Interestingly, unlike RBM5 KD, we observed increased nuclei number in 
the post-transfection phase, during which time the cells were still proliferating. Without 
RBM10, the cells were increasing in number compared to the control, which indicates that 
the effect of RBM10 during differentiation is either to control cell proliferation rate or 
induce apoptosis. This is in accord with the observations seen in smooth muscle cells and 
cancer cells wherein overexpressed RBM10 induces apoptosis and reduces proliferation 
(Mueller et al., 2009). RBM10 is definitely not associated with late stages but is a 
contributor in early-stages of differentiation. These results suggest that RBM10 possibly 
plays an important role in C2C12 differentiation by aiding in maintaining the necessary cell 
population prior to induction and additional modulation of MyHC expression. 
To reiterate, the pattern of RBM5 expression is similar to that observed in cancer cells but 
was functionally different in normal cells. In the case of RBM10, there was a difference in 
expression between cancer and normal cells but functionally they were similar. Therefore, 
this discord in expression pattern and in function observed during differentiation highlights 
the importance of regulation of these two RBPs during myogenesis. 
Our results show that RBM5 functions in a different manner from RBM10. Our results are 
similar to the results of Bechara et al. (2013) where depletion of RBM5 was anti-
proliferative, and the depletion of RBM10 was proliferative. RBM5 and RBM10 possibly 
coordinate with regulators of cell cycle withdrawal, apoptosis and muscle-specific factors; 
perhaps one is needed for initiation and the other for maintenance of the myogenic 
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differentiation process. The presence of RRMs and other domains involved in mRNA 
splicing mechanisms are not only indicators of functional association, but could provide an 
insight into the mechanisms of action. RBM5 and RBM10 are almost 50% identical; the 
remaining unique regions likely cause structural differences that could contribute to unique 
functions and binding targets. The difference in function between RBM5 and RBM10 
observed during myogenesis would support this latter statement. From our findings, we can 
infer that although RBM5 and RBM10 have 50% homology, it is likely that they do not 
have redundant function in muscle cells.  
Bechara et al. (2013) have shown that RBM5/6 and 10 have specific fuctions and are 
antagonistic in regulating cell proliferation; this effect was mostly related to NUMB 
alternative splicing. The two variants generated from the inclusion/exclusion of exon 9 has 
distinct roles; one is involved in proliferation whereas the other enhances differentiation. 
This study suggests that the effect (observed phenotypically) is an indirect effect of 
RBM5/10 through the regulation of AS of gene targets associated with cell proliferation, 
apoptosis and muscle differentiation.  
In order to identify the transitions that are alternatively spliced by RBPs, usually, as a first 
step, high throughput techniques such as microarrays (splice-sentisitive/exon-exon 
junctions) and RNA sequencing could be employed, which would enable identification of a 
large cohort of potential splicing and expression changes (Blanchette et al., 2009, 
Kechavarzi and Janga, 2014, Katz et al., 2010). Once splicing events are identified, they are 
confirmed using end-point PCR (Venables et al., 2009). There are thousands of splicing 
changes that occur during differentiation. In this dissertation, we directly assessed three 
splicing events. These three targets were chosen because (a) studies have already showed 
that these are alternatively spliced during differentiation (in C2C12 cells) and (b) 
preference for one variant over another has been suggested to have a functional association 
with myogenesis. For example, the integrinβ1A isoform, which is expressed in proliferating 
myoblasts, decreases during differentiation while integrinβ1D expression takes precedence 
(Belkin et al., 1996), however integrinβ1A is associated with primary myogenesis (Cachaco 
et al., 2003).  
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4.4.2 RBM5 possibly affects the myogenic program by modulating the 
expression of muscle specific proteins (MyoG and MyHC) 
Our results allow the characterization of possible mechanisms by which RBM5 modulates 
differentiation. To determine whether the delay in differentiation in the RBP-depleted cells 
was mediated through MRFs, we analyzed MyoG, MyoD and Myf5 protein expression 
levels by immunoblot analysis. MyHC levels were assessed by counting the nuclei of 
MyHC-positive cells after immunostaining. Expression of MRFs is critical for skeletal 
myogenesis (Berkes and Tapscott, 2005). MyoD and Myf5 are required for specification 
and MyoG is required for directing the myoblasts towards muscle specific lineage and 
terminal differentiation (Francetic and Li, 2011). Mutations in MyoD and Myf5 does not 
affect normal muscle formation but leads to defective and delayed development (Rudnicki 
et al., 1993). Similarly, MyoG knockout mice show defective muscle formation; indeed the 
myocytes in MyoG null mice are not able to fuse into myotubes (Francetic and Li, 2011). 
MyHC is a sarcomeric terminal differentiation marker expressed along with muscle 
creatinine kinases, which leads to fusion of myocytes and the formation of a functional 
myotube (Clegg et al., 1987). In our RBM5 KD experiments, the expression of MyHC and 
the major muscle-specific transcription factor MyoG were down-regulated and there was no 
change in Myf5 and MyoD expression. The decrease in MyHC and MyoG levels in the 
RBM5 KDs possibly indicates a mechanistic interaction between RBM5 and these two 
muscle-specific proteins at the molecular level and thereby promote a delay in 
differentiation, fusion and maturation phenotypically. RBM5 is likely to exert its function 
prior to MyoG induction, which correlates with the high expression levels of RBM5 in the 
initial-stage of differentiation because MyoG expression occurs later, but before the 
terminal-stages of differentiation. 
The increase in MyHC expression on D2 contributed to the increase in differentiation 
potential. However, the levels of MyHC decreased significantly by D3 and D4 thereafter. 
This increase on D2 did not likely have any downstream association with fusion or 
maturation. 
These results provide evidence that RBM5 is one of the RBPs involved in regulating 
expression of muscle-specific proteins such as MyoG and MyHC during myogenesis. Our 
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findings also show that RBM5 is related to regulating the expression of a specific subset of 
MRFs in a distinctive manner. 
RBM5- and 10- depleted cells were slow in differentiating as evidenced by the decrease in 
MyHC protein levels and significantly reduced myotubes/myofibers. Our results also 
indicated that RBM5 and RBM10 are probably functionally different in the myogenic 
differentiation program except in modulating the expression of MyHC. Overall these 
results indicate that RBM5 and RBM10 slows the rate of differentiation, however it does 
not completely prevent the myoblasts from forming myotubes. Furthermore, when both 
RBM5 and 10 are KD together, only the effect of RBM5 were predominant. This was 
evident despite the different degrees of RBM5 KD levels, i.e. depletion of minimal levels 
of RBM5 in C2C12 cells was enough to produce the observed phenotypic modifications. 
These effects for RBM5 and/or 10 could be direct or indirect. RBM5/10 could act directly 
affecting cell proliferation or apoptosis to alter the timing of differentiation or act indirectly 
by having an effect on splicing of critical differentiation mediators that in turn affect the 
timing of differentiation.  
4.4.3 RBM10 affects the myogenic program by modulating the alternative 
splicing of Dtna 
In this study, we attempted to identify the changes in alternative splicing events promoted 
by these  two RBMs during C2C12 differentiation and therefore looked at the exon 
inclusion/exclusion of  Dtna, Mef2c and Integrin. Depletion of RBM10 in C2C12 
myoblasts resulted in three specific changes. Firstly, RBM10-depleted cells showed 
increased proliferation. Depletion of RBM10 maintained the myoblasts in a proliferative 
state. The idea is that, before differentiation is induced, RBM10 is required to maintain the 
necessary cell population. It still remains to be elucidated whether this results from changes 
in apoptosis or cell proliferation. The downstream consequences of RBM10 depletion 
during differentiation can affect the ability to differentiate (differentiation potential), but 
there was no delay in fusion or maturation.  
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Secondly, RBM10 modulates the expression of MyHC on D3/D4. Cells with a RBM10 KD 
did not have an impact on myogenesis-related gene expression, especially MyoG, MyoD 
and Myf5, however they did decrease MyHC expression.  
Thirdly, RBM10-depleted cells had decreased inclusion of exon 11 in Dtna, which implies 
that RBM10 is involved in the alternative splicing of Dtna by promoting inclusion of exon 
11. α-dystrobrevin is a predominant muscle-related component of DGC and has a crucial 
role in muscular dystrophies when it is aberrantly expressed (Metzinger et al., 1997). Dtna 
knockout mice show a mild form of myopathy (Grady et al., 1999). The change in the 
pattern of splicing in Dtna during C2C12 myogenic differentiation has been described 
previously (Bland et al., 2010). During differentiation, the exon 11(+) transcript increases 
as the exon 11(-) transcript decreases. Therefore, involvement of RBM10 to preferentially 
direct splicing to one variant that is important for promoting differentiation indicates that 
RBM10 does indeed act as a splicing regulator. It appears that the change in splicing 
pattern is temporal. The limitations of this study are that the effect seen is observed in only 
two out of three trials and therefore requires additional biological replicates.  
4.4.4 Rbm5 and10 together affect the myogenic program by modulating 
the alternative splicing of Mef2cγ 
When both RBM5 and RBM10 were depleted, we observed an increase in γ exon inclusion 
of a key transcription factor, Mef2c on D4. The Mef2 group of transcription factors are 
involved in skeletal muscle and neural differentiation, and heart and bone development 
(Hakim et al., 2010). Mef2c is specifically associated with muscle differentiation and the 
formation of synapses in the brain, and is mainly regulated by alternative splicing (Zhu and 
Gulick, 2004). Mef2c splicing is complex, selective and is dependent on the stage of 
development, tissue and other specific conditions such as calcium dependence or presence 
of co-regulators (Zhu and Gulick, 2004). In addition, Mef2c was responsible for 
maintaining the C2C12 cells in the differentiated state (Bachinski et al., 2010). The γ exon 
of Mef2c contains sequences involved in repression of transcription and is phospho-serine 
dependent (Zhu and Gulick, 2004). Therefore, Mef2cγ (-) is a transcription activator, while 
Mef2cγ (+) is a transcription repressor. Further, Mef2cγ (-) is associated with MyoD and 
cdk5 activity, which are involved during the initial-stages of differentiation (Zhu and 
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Gulick, 2004). Furthermore, both γ exon inclusion and exclusion were present and were 
expressed equally in undifferentiated and differentiated P19 cells, P19CL6 cells and in 
adult skeletal muscle (Hakim et al., 2010). However, in the control C2C12 myoblasts, at 24 
and 48 hours post-transfection and during differentiation, we observed the presence of more 
γ; there was more inclusion as differentiation proceeded (Appendix A-Figures A12-A17). 
The significant increase in exon inclusion in the RBM5+10 KDs on D4, thus, supports the 
idea that this alternative splicing is not necessarily involved in delaying differentiation and 
that the reduction in abundance of one variant possibly has downstream effects during the 
differentiation process. Our results indicate that both RBM5 and RBM10 together act in a 
synergistic/additive fashion to modulate the alternative splicing of these transcripts because 
neither RBM5 nor RBM10 alone favoured the generation of more Mef2cγ (+). Previous 
studies have shown that other RBPs are involved in regulating the alternative splicing of 
Mef2c. For instance, the PTB protein is responsible for β exon inclusion of Mef2c (Lin and 
Tarn, 2011). It is possible that different RBPs are needed that target different splice sites to 
generate many variants of Mef2c during differentiation. 
4.4.5 Proposed model for regulatory role 
Based on our results and previous binding/regulatory studies, a model is proposed to 
explain how RBM5 could regulate the delay in differentiation and how RBM10 could 
regulate cell proliferation before induction (Figure 4.1).  
The role of RBM5 during differentiation is possibly mediated through p21 and MyoG 
expression and stability. RBM5 could regulate the expression of p21 because in RBM5 
KDs, both cell number and fusion were affected. During C2C12 differentiation, when cell-
cell contact was inhibited because of the reduction in cell density, one of the proteins that 
was affected is p21 (Tanaka et al., 2011). Furthermore, p21 regulates the expression of 
MyoG (Halevy et al., 1995). Many RBPs are involved in stabilizing mRNA. mRNA 
stability depends on the stage of differentiation and on the status of the differentiating cell. 
Importantly, the half-life of certain proteins involved in myogenesis increased as 
differentiation proceeded. For instance, MyoG and p21 had increased half-lives, thus were 
stabilized during differentiation (Figueroa et al., 2003). Another aspect of mRNA stability 
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is binding to 3’ UTRs. Many MRFs have specific sequences (destabilizing elements) in 
their 3’ UTR, which are either AU rich elements (AREs) or GU rich elements (GREs) 
(Apponi et al., 2011). These MRFs are depleted by certain decay mechanisms set up to 
have a tight control over differentiation. These specific sequence elements are targets for 
many RBPs. For example, HuR protein, which is a RBP and a splicing regulator, binds with 
the 3’UTR of Myogenin mRNA (van der Giessen et al., 2003). The Hu family of proteins 
binds to AU rich regions in 3’ UTRs and are involved in degrading Myogenin. Hence, we 
speculate that RBM5 is another RBP involved in regulating p21 expression and/or stability 
and Myogenin mRNA stability. 
The effect of RBM10 during proliferation is possibly mediated through Notch signalling. 
The Notch pathway is important for tissue development, maintenance and repair with 
significant involvement in skeletal muscle (Nye et al., 1994). When Notch is activated, 
there is inhibition of differentiation especially through the NCID factor and via down-
regulation of MyoG and Myosin light chain expression (Luo et al., 2005). Another 
important component of this Notch-mediated signalling pathway during differentiation is 
Mef2c. Notch inhibits Mef2c and its activation. Mef2c interacts with MAML1 
(Mastermind-like protein 1) and is responsible for crosstalk between Notch and Mef2 
during differentiation (Shen et al., 2006). Mef2 acts as a positive regulator and is involved 
in regulating the expression of MyoG and other transcription factors such as MyoD. During 
muscle injury, Notch activates satellite cell proliferation, especially during the early phase 
to direct the quiescent satellite cells to generate progenitor cells (Luo et al., 2005). When a 
sufficient progenitor population is reached, the Notch inhibitor NUMB is activated to 
produce regenerated muscle tissue. During myogenesis, isoform specific regulation of 
NUMB occurs (Beres et al., 2011). A recent study identified that Rbm5, 6 and 10 were 
responsible for NUMB alternative splicing in cancer cells (Bechara et al., 2013). The 
RBM10-depleted cells showed increased proliferative capacity and regulated alternative 
splicing of exon 9 in NUMB (induced exon inclusion). We speculate that the effect of 
RBM10 in regulating the initial phase of cell proliferation before differentiation is mediated 
through the alternative splicing of NUMB and the related downstream effects such as 
MyHC expression associated with the involvement of the Notch signalling pathway.  
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The effect of RBM5 and RBM10 combined mechanism of action is possibly mediated 
through alternative splicing of Mef2c. Mef2cγ (+) transcript is a transrepressor. Regulated 
transcription is required during differentiation, and multiple transcription activators and 
repressors are involved during the entire myogenic differentiation process. Based on the 
increase in Mef2cγ (+) inclusion on D4 observed in our experiment, we speculate that there 
are downstream effects associated with the transcription repression of Mef2c target genes 
such as structural proteins, enzymes, transporters and stress signalling molecules (Zhu and 
Gulick., 2004).  
4.4.6 siRNA specificity 
Because RBM5 and RBM10 levels were already high during the initial stages of 
differentiation, in order to functionally characterize their involvement during myogenesis, 
we depleted the expression of endogenous RBM5 and RBM10 in myoblasts using siRNAs. 
We believe that this is an effective approach rather than exogenously overexpressing the 
proteins. KD reduces the endogenous levels of the RBPs while overexpression would create 
super-physiological levels. 
siRNA directed towards RBM5 and RBM10 was effective at lowering the levels of target 
mRNA because of the different effects such as the effect of RBM5 on fusion and 
maturation index and the effect of RBM10 on cell number before induction, were observed 
between the RBM5 and RBM10 KDs. This indicates that the siRNAs used were target-
specific.  
Although RBM5 depletion in some of the KD experiments was only close to 40 -50%, the 
observed inhibition of myogenic differentiation process indicates that the C2C12 
differentiating cells need only a minimal amount (a threshold) to proceed with 
differentiation. In addition, phenotypic changes did not correlate directly to the level of KD 
because either the relationship is not linear or because of off-target non-specific effects. 
The latter is not likely the case because the effects of RBM5 and RBM10 on cell 
proliferation are entirely different.  
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During C2C12 differentiation, the transition from cell proliferation (prior to induction) to 
the progression of differentiation is a highly governed process. Maintaining the adequate 
number of cells during proliferation is crucial because proper cell-to-cell contact is required 
for fusion and maturation. Factors such as passage number, initial plating density, 
confluence of the cells at induction (serum deprivation) and transfection could be 
deteriments to differention, hence could be limiting factors in the KD experiments. 
Although, passage number is not a limiting factor in the current study; we know that plating 
density-dependant variations were observed in two of the KD trials. Transient KD meant 
that RBM5/10 expression was restored during differentiation, which could have some 
effect on cell behaviour. Therefore, these limitations should be considered while 
performing the KD experiments.  
Transient transfection experiments are practically quick and easy way to characterize the 
function of RBM5/10 in the muscle system. However, our transient KD studies are limited 
in their ability to identify the potential effect of both these RBPs in differentiation because 
of the turn-over rate. The siRNA approach creates only a short-term reduction (restoration 
seen by D4 in our experiments). The entire C2C12 differentiation process can take up to 8 
to 10 days and therefore in order to fully characterize their role in differentiation future 
experiments might utilize stable transfectants. The potential off-target effects if any, should 
be verified, either by performing “rescue” approach of the target gene by over expressing to 
validate the target-specific effect or use more than one siRNA to target different areas of 
the gene. Inclusion of negative controls, not only scrambled siRNA control but a 
combination of mismatched and scrambled siRNA, untransfected control and mock 
transfection controls in future experiments will increase the confidence in the results 
obtained. 
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Figure 4.1 Proposed model of RBM5 and RBM10 mechanism of regulation during 
C2C12 differentiation. Model of regulation via p21 for RBM5 or NUMB for RBM10 or 
Mef2c for both RBM5 and 10 during differentiation. Expression of RBM5 and RBM10 is 
high during the initial-stages of differentiation indicating functional relevance at this stage. A) 
Depletion of RBM5 possibly affects p21, which has a direct effect on MyoG expression, thus 
causing the delay in fusion. B) Depletion of RBM10 possibly affects alternative splicing (AS) 
of NUMB during proliferation thereby targeting the NOTCH downstream pathways, along 
with AS of Dtna, both together causing the delay in differentiation. C) Depletion of RBM5 
and 10 affects Mef2c, thus possibly affecting transcription of Mef2c-associated target factors 
such as structural proteins, enzymes, stress-signaling molecules and transporters. 
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4.5 Conclusion 
The expression profile of Rbm5 and Rbm10 suggest a potential regulatory role during the 
initial phase of differentiation. This thesis demonstrates for the first time the role of the two 
RBPs, RBM5 and RBM10, in myogenic differentiation; in particular the association of 
RBM5, a putative tumor suppressor, as a mediator of delayed differentiation and inhibition 
of fusion through regulation of MyoG and MyHC expression, likely by stabilizing 
Myogenin or MyHC mRNA. In addition, we also show an association of RBM10 as a 
positive regulator of differentiation only, through modulating MyHC expression and as 
well regulating alternative splicing of Dtna mRNA. We further suggest that though both 
have specific and distinct functions, they possess some overlapping functions in 
differentiation and fusion by modulating the alternative splicing of Mef2cγ mRNA, 
amongst many others that still remain to be uncovered.  
Given the previously identified role in cancer, especially in lung adenocarcinomas 
(RBM10) and NSCLCs (RBM5), this report on the role of RBM5 and RBM10 in normal 
muscle cell development hence provides a starting point for future functional 
characterization of these RBPs in muscle. This study has enabled us to determine the stage 
at which RBM5/10 exert their functions, however it will be of interest to carry out a 
detailed analysis on how precisely the regulation occurs, to identify the signalling 
pathways, binding partners and additional mRNA targets associated with these RBPs in 
differentiation. For instance, using this model system, we can carry out binding studies 
using gel-shift experiments to determine if RBM5 bind to the 3’UTRs of Myogenin and 
MyHC mRNA, and whether these interactions are direct or indirect. It will be of interest to 
determine the RNA-binding capacity of RBM5 and RBM10 using techniques such as (a) 
RNA-binding protein immunoprecipitation-microarray profiling (RIP-Chip) to identify 
RNAs that interact with these two RBPs (b) PAR-CLIP to identify binding sites of these 
two proteins and (c) Glutathione-S transferase (GST)-pull down assays to identify the 
binding partners. It would not be surprising to find additional target mRNAs that are 
alternatively spliced by these two RBPs during myogenesis, and furthermore, one would 
not find the same targets that were identified in a different system because there could be 
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tissue-specific regulation (O'Bryan et al., 2013). Future work can focus on identifying if it 
is cell proliferation or cell cycle arrest by which RBM10 perturbs the cell population during 
the proliferative stage before the myoblasts start differentiating, especially by performing 
BrdU incorporation assays to assess DNA synthesis or mitosis. Additional experiments are 
needed to determine if NUMB mRNA is alternatively spliced and the associated 
downstream effects on the Notch pathway when RBM10 is depleted. Similarly, if p21 
levels are affected and to determine whether p21- dependent or independent mechanisms 
regulate MyoG expression when RBM5 is depleted. The physiological relevance of 
alternative splicing of Mef2c during differentiation in the RBM5+10 KDs needs further 
characterization.  
Many RBPs are implicated in human diseases; hence it would also be worthwhile to 
explore RBM5 and RBM10 involvement in muscular atrophies and rhabdomyosarcoma. In 
vivo experiments using conditional knockout mice to look at the importance of these two in 
myogenesis could then be carried out in the long run. 
RBM5 shares high sequence similarity with RBM6 and RBM10, with some overlapping 
functions (Sutherland et al., 2005). For example, when RBM5, RBM6 and RBM10 were 
depleted at the same time, they affected cell proliferation via alternatively splicing NUMB 
(Bechara et al., 2013). RBM6 is located adjacent to RBM5 on 3p21and also belongs to the 
homozygously deleted region in lung cancers. Expression patterns and in vitro RNA-
binding studies show that RBM5, RBM10 and RBM6 are evolutionarily conserved RBPs 
(Drabkin et al., 1999). Therefore, there is a possibility of overlapping functions of all three 
during differentiation, so future studies can incorporate KD of all three RBPs to determine 
the combined regulatory role. 
In summary, our findings provide a starting point to assess the role of these two RBPs in 
skeletal muscle differentiation. RBPs are key components in many cellular processes. With 
the recent increase in the identification of the multitude of RBPs, our findings are timely 
and provide a new insight into the functional involvement of these two RBPs in 
myogenesis.  
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     Appendix A
MyoD 
~45kDa 
MyoG 
~34kDa 
α-tubulin 
~55kDa 
Figure A1. MYOD, MYOG and α-tubulin during C2C12 differentiation. Raw 
Western blot images for MyoD, MyoG and α-tubulin from D0 to D7 differentiating 
C2C12 cells. Presented here are 4 biological replicates in technical duplicates (for 2 
trilas) that are representative of the replicates used in the analysis. BenchMark protein 
ladder (M) (Life Technologies) was used as the molecular weight (in kDa) standard. 
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Figure A2. RBM5, RBM10 and α-tubulin during C2C12 differentiation. Raw 
Western blot images from four biological replicates for RBM5, RBM10 and α-tubulin 
from D0-D7 differentiating C2C12 cells. Full-length blots are shown to indicate only 
bands specific for RBM5 were seen when using LUCA-15 UK antibody targeted 
against RBM5 and for RBM10 isoforms when using Bethyl antibody targeted against 
both the isoforms. BenchMark protein ladder (Life Technologies) was used as the 
molecular weight (in kDa) standard. 
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Figure A3. Rbm10v1, Rbm10v3 and Gapdh during C2C12 differentiation. Raw end-point PCR 
images for Rbm10v1, Rbm10v3 and Gapdh from D0-D7 differentiating C2C12 cells. Presented here 
are 3 biological replicates that are representative of the 4 biological replicates used in the analysis. –rt 
and NTC are negative controls; G (C2C12 cells in growth medium) and P (pooled cDNA) are positive 
controls. Amplified PCR products were visualized in a 1% agarose gel stained with SYBR® safe 
DNA gel stain. 100bp DNA ladder (Life Technologies). 
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Figure A4. RBM5 IF staining in the KDs. IF images of Draq5 (blue) and RBM5 (red) staining 
in scrambled siRNA control and RBM5 KD C2C12 cells at 24h and 48h post-transfection from 
one trial. The KD levels measured by Western were 74% at 24h and 60% at 48(Trial A).  
Scrambled siRNA control  siRBM5  
Phase  Phase  
Phase  Phase  
DRAQ5  DRAQ5  
DRAQ5  DRAQ5  
RBM5  RBM5  Merge  Merge  
24h  
48h  
RBM5 RBM5 Merge Merge 
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Figure A5. RBM10 IF staining in the KDs.  IF images of Draq5 (blue) and RBM10 
(red) staining in scrambled siRNA control and RBM10 KD C2C12 cells at 24h and 48h 
post-transfection from one trial (trial A). The KD levels measured by Western were 62% 
(RBM10v1) and 67% (RBM10v3) at 24h and 77% (RBM10v1) and 67% (RBM10v3) at 
48h. 
Scrambled siRNA control  
DRAQ5  RBM10  Merge  
 siRBM10 KD  
DRAQ5  RBM10  Merge  
DRAQ5  RBM10  Merge  DRAQ5  RBM10  Merge  
24h  
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24h/D0 48h D1 D2 D3 D4 
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α -Tubulin 
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RBM5 
Figure A6. RBM5, RBM10 and α-tubulin levels in RBM10 KDs: Raw Western blot 
images for RBM5, RBM10 and α-tubulin from siRBM10 (si10), untransfected control (U) 
and siRNA scrambled control (S) C2C12 cells at 24h, 48h post-transfection and at D0-D4 
differentiation, in technical replicates (Trial1). BenchMark protein ladder (M) (Life 
Technologies) was used as the molecular weight (in kDa) standard. 
			S		si10	S	si10 
D4 48h 
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RBM5 
RBM10 
α-Tubulin 
RBM5 
RBM10 
α-Tubulin 
RBM10 
RBM5 
α-Tubulin 
Figure A7. RBM5, RBM10 and α-tubulin levels in RBM5 and RBM10 KDs: Raw Western 
blot images for RBM5, RBM10 and α-tubulin from siRBM5 (5 or RBM5) (Trial 1), siRBM10 
(10 or RBM10) (Trial 2) and siRNA scrambled control (S) C2C12 cells at 24h, 48h post-
transfection and at D0-D3 differentiation, in technical replicates. 10x (or RBM10ex) is 
RBM10v1 specific KD and is not included in the scope of this thesis. BenchMark protein 
ladder (M) (Life Technologies) was used as the molecular weight (in kDa) standard. 
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RBM5 
α-Tubulin 
RBM5 
RBM10 
α-Tubulin 
Figure A8. RBM5, RBM10 and α-tubulin levels in RBM5 KDs. Raw Western blot 
images for RBM5, RBM10 and α-tubulin from siRBM5 (5) and siRNA scrambled 
control (S) C2C12 cells at 24h, 48h post-transfection and at D0-D4 differentiation, in 
technical replicates (Trial 2). 10x is Rbm10v1 specific KD and is not included in the 
scope of this thesis. BenchMark protein ladder (BM) (Life Technologies) was used as the 
molecular weight (in kDa) standard. 
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Figure A9. RBM5, RBM10 and α-Tubulin levels in RBM5+10 KDs. Raw Western blot 
images for RBM5, RBM10 and α-tubulin from siRBM5+10 and siRNA scrambled control (S) 
C2C12 cells at 24h, 48h post-transfection and at D0-D4 differentiation, in technical replicates 
(Trial 1). 5+10a (also labelled as 5+10 1) & 5+10b (also labeled as 5+10 2)- Two different 
concentrations of siRNA were used for RBM5+10 KD. For the purpose of this thesis only the 
results obtained from 5+10b are used for interpretation. BenchMark protein ladder (BM) (Life 
Technologies) was used as the molecular weight (in kDa) standard. 
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Figure A10. RBM5, RBM10 and α-Tubulin levels in RBM5 and RBM5+10 KDs. 
Raw Western blot images for RBM5, RBM10 and α-tubulin from siRBM5 (trial3), 
siRBM5+10 (5+10) (trial2), and siRNA scrambled control (S) C2C12 cells at 24h, 48h 
post-transfection and at D0-D4 differentiation, in technical replicates. BenchMark 
protein ladder (BM) (Life Technologies) was used as the molecular weight (in kDa) 
standard. 
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Figure A11. RBM5, RBM10 and α-Tubulin levels in RBM10 and RBM5+10 KDs. 
Raw Western blot images for RBM5, RBM10 and α-tubulin from siRBM10 (10), 
siRBM5+10 (5+10b) and siRNA scrambled control (S) C2C12 cells at 24h, 48h post-
transfection and at D0-D4 differentiation, in technical replicates (Trial 3). BenchMark 
protein ladder (Life Technologies) was used as the molecular weight (in kDa) standard. 
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Figure A12. Gapdh, Dtna and Mef2cγ levels in RBM10 KDs. Gapdh, DtnaA and Mef2cγ end-
point PCR products visualized in a 2% agarose gel stained with SYBR® safe DNA gel stain for 
determining the alternative splicing changes in RBM10-depleted (Trial1) C2C12 cells collected 
at 24h, 48h post-transfection and at D0-D4 differentiation. S- Scrambled control, 10- Rbm10 
KD, -rt and NTC – negative controls. Presented here are technical duplicates that are 
representative of the technical quadruplicates. 100bp DNA ladder (Life Technologies). 
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Figure A13. Gapdh, Dtna and Mef2cγ levels in RBM5 and RBM10 KDs. Gapdh, Dtna and 
Mef2cγ end-point PCR products visualized in a 2% agarose gel stained with SYBR® safe DNA 
gel stain for determining the alternative splicing changes in Rbm5-depleted (trial 1) and 
RBM10- depleted (trial2) C2C12 cells. S- Scrambled control, 5- Rbm5 KD, 10- Rbm10 KD 
and 10x- Rbm10 v1 KD. –rt and NTC-negative controls. Presented here are technical replicates 
that are representative of the technical quadruplicates used in the analysis. 100bp DNA ladder 
(Life Technologies). 
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Figure A14. Gapdh, Dtna and Mef2cγ in RBM5 KDs. Gapdh, Dtna and Mef2cγ end-point PCR 
products visualized in a 2% agarose gel stained with SYBR® safe DNA gel stain for determining 
the alternative splicing changes in Rbm5-depleted (trial 2) C2C12 cells. S- Scrambled control, 5- 
Rbm5 KD and 10x- Rbm10 v1 KD. –rt and NTC-negative controls. Presented here are technical 
replicates that are representative of the technical quadruplicates used in the analysis. 100bp DNA 
ladder (Life Technologies). 
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Figure A15. Gapdh, Dtna and Mef2cγ levels in RBM5+10 KDs. Gapdh, Dtna and Mef2cγ end-
point PCR products visualized in a 2% agarose gel stained with SYBR® safe DNA gel stain for 
determining the alternative splicing changes in Rbm5&10-depleted C2C12 cells (trial1). S- 
Scrambled control, A&B- Two different concentrations of siRNA were used for RBM5+10 KD. 
For the purpose of this thesis only the results obtained from ‘B’ are used for interpretation. –rt 
and NTC- negative controls. 100bp DNA ladder (Life Technologies). Presented here are 
technical replicates that are representative of the technical quadruplicates used in the analysis. 
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Figure A16. Gapdh, Dtna and Mef2cγ levels in RBM5 and RBM5+10 KDs. Gapdh, Dtna and 
Mef2cγ end-point PCR products visualized in a 2% agarose gel stained with SYBR® safe DNA 
gel stain for determining the alternative splicing changes in Rbm5-depleted (trial3)and 
RBM5&10- depleted (trial2) C2C12 cells. S- Scrambled control, 5- Rbm5 KD and B- Rbm5+10 
KD. –rt and NTC- negative controls. 100bp DNA ladder (Life Technologies). Presented here are 
technical replicates that are representative of the technical quadruplicates used in the analysis. 
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Figure A17. Gapdh, Dtna and Mef2cγ in RBM10 and RBM5+10 KDs. Gapdh, DtnaA and 
Mef2cγ end-point PCR products visualized in a 2% agarose gel stained with SYBR® safe DNA 
gel stain for determining the alternative splicing changes in Rbm10-depleted (trial 3) and 
RBM5&10- depleted (trial 3) C2C12 cells. S- Scrambled control, 10- Rbm10 KD and B- 
Rbm5+10 KD. –rt and NTC- negative controls. 100bp DNA ladder (Life Technologies). 
Presented here are technical replicates that are representative of the technical quadruplicates 
used in the analysis. 
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α-Tubulin  
~55kDa 
Figure A18. MyoG levels in the KDs. Raw Western blot images for MyoG levels in RBM5 KD, 
RBM10 KD and RBM5+10 KDs at 24h and 48h post-transfection and at D1-D4 differentiation from 
3 trials. BenchMark protein ladder (Life Technologies) was used as the molecular weight standard. α-
Tubulin levels are also shown in these images. Presented here are technical replicates that are 
representative of the technical quadruplicates used in the analysis. 
α-Tubulin  
α-Tubulin  
α-Tubulin  
MyoG  
MyoG  
MyoG  
MyoG  
α-Tubulin  
MyoG 
~34kDa 
 200 
 
 
 
 
 
 
MyoD 
~45kDa 
Figure A19. MyoD levels in the KDs. Raw Western blot images for MyoD levels in 
RBM5 KD, RBM10 KD and RBM5+10 KDs at 24h and 48h post-transfection and at 
D1-D4 differentiation. BenchMark protein ladder (Life Technologies) was used as the 
molecular weight standard. α-Tubulin levels are shown in Fig A18.  
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Figure A20. Myf5 levels in the KDs. Raw Western blot images for Myf5 levels in 
RBM5 KD, RBM10 KD and RBM5+10 KDs. BenchMark protein ladder (Life 
Technologies) was used as the molecular weight standard. α-Tubulin levels are shown 
in Fig A18. 
Myf5 
~32kDa 
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Table A1: Passage number of the C2C12 cells used in the experiments 
 
Passage number Experiment 
P13, P16, P13, P18 RBM5 and RBM10 expression during differentiation  
P10 RBM5 and RBM10 expression during differentiation (IF)  
P14 RBM10 (trial2) and RBM5 (trial1) KDs  
P20 RBM10 KD (trial1)  
P12 RBM5 KD (trial2)  
P13 RBM5+10 KD (trial1) 
P15 RBM5 (trial3) and RBM5+10 (trial2) KDs 
P16 RBM10 (trial3) and RBM5+10 (trial3) KDs 
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Abstract Skeletal muscle differentiation occurs during
muscle development and regeneration. To initiate and
maintain the differentiated state, a multitude of gene
expression changes occur. Accurate assessment of these
differentiation-related gene expression changes requires
good quality template, but more specifically, appropriate
internal controls for normalization. Two cell line-based
models used for in vitro analyses of muscle differentiation
incorporate mouse C2C12 and rat H9c2 cells. In this study,
we set out to identify the most appropriate controls for
mRNA expression normalization during C2C12 and H9c2
differentiation. We assessed the expression profiles of
Actb, Gapdh, Hprt, Rps12 and Tbp during C2C12 differ-
entiation and of Gapdh and Rps12 during H9c2 differen-
tiation. Using NormFinder, we validated the stability of the
genes individually and of the geometric mean generated
from different gene combinations. We verified our results
using Myogenin. Our study demonstrates that using the
geometric mean of a combination of specific reference
genes for normalization provides a platform for more
precise test gene expression assessment during myoblast
differentiation than using the absolute expression value of
an individual gene and reinforces the necessity of reference
gene validation.
Keywords Skeletal differentiation ! C2C12 ! H9c2 !
Myogenesis ! Real-time quantitative PCR ! Reference
genes ! Normalization ! Geometric mean
Introduction
Myogenesis, a multistep, highly orchestrated process that is
inherently necessary for muscle development and regener-
ation, involves a multitude of gene expression changes [1].
Exploring the molecular pathways of skeletal and cardiac
myogenesis involves quantifying the expression of tran-
scription factors [2], growth factors [3], calcium channels
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[4] and kinases [5] that play a major role during initiation
and maintenance of the differentiated state. Murine C2C12
and rat H9c2 cells are secondary cell line-based models that
are used for the study of gene expression during the dif-
ferentiation phase of myogenesis [6–10]. Real-time quan-
titative PCR (qPCR) is an effective and reliable method for
the accurate assessment of gene expression changes. Using
qPCR, the normal differentiation-associated changes in
gene expression, as well as disease-associated changes,
equivalent to those that occur in muscular dystrophy and
cancer, can be investigated [11–13].
In qPCR, good RNA integrity and the use of reference
genes whose expression levels (a) do not change, and
(b) are similar to those of the test gene, are vital for the
accurate assessment of gene expression. RNA integrity can
be determined using gel electrophoresis to visually assess
the amount of ribosomal RNA degradation, or using a
bioanalyzer that calculates the RNA Integrity Number
(RIN) [14]. Purity is generally assessed using a spectro-
photometer to determine the 260/280 absorbance ratio. Any
variability in sample preparation attributed to, e.g., sample
purity, handling and enzyme efficiencies, is minimized by
the use of a normalization control, typically either a ref-
erence gene or input foreign RNA. Reference genes for
expression normalization are usually ‘‘housekeeping’’
genes, genes that are ubiquitously and constitutively
expressed, and required for cell viability [15].
Amajor criterion for a reference gene is that its expression
levels remain constant without bias to treatment, age, tissue
type, nutrition, gender, etc. Unfortunately, the expression of
many genes is effected by the vagaries of experimental
conditions [16, 17]. The use of more than one reference gene
increases accuracy by reducing noise and error, and is
becoming an accepted standard in expression studies [18].
Ideally, multiple reference genes would be empirically val-
idated and the ones with minimal experimentally associated
expression level variability would be used to normalize,
either by averaging [19] or using the geometric mean [18] of
the expression levels. Software programs, such as Best-
Keeper [20], GeNorm [18] and NormFinder [21], are avail-
able to help with reference gene validation, each using a
different algorithm to calculate expression stability.
The two genes most commonly used for normalization
in mouse and rat expression studies are b-actin (Actb) and
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) [8,
22, 23]. Mouse reference genes have also included hypo-
xanthine phosphoribosyltransferase (Hprt) [24], ribosomal
protein S12 (Rps12) [25], TATA binding protein (Tbp)
[26], b-glucuronidase (GusB) [27], ribosomal RNA small
subunit (18S) [28], b-2 microglobulin (B2 M) [29] and
cyclophilin D (CycD) [30].
The objective of our study was to examine the expression
of various genes during C2C12 and H9c2 myoblast
differentiation. To accomplish this, we needed to establish
which genes would make optimal reference genes for
expression normalization. We set out to identify a normali-
zation control with (a) static RNA expression during dif-
ferentiation, and (b) suitability for both high and low
expressing test genes. ForC2C12 differentiation,we chose to
assess the suitability of Actb, Gapdh, Hprt, Rps12 and Tbp
transcripts (Table 1). The Actb transcript encodes a cyto-
skeletal protein that is ubiquitously and highly expressed. As
a component of cytoskeletal microfilaments, it functions in
cell motility and the transport of organelles and chromo-
somes [31]. The Gapdh transcript encodes amajor metabolic
enzyme that is ubiquitously and highly expressed, and
involved in many processes including apoptotic initiation,
transcription activation and endoplasmic reticulum to Golgi
shuttling [32]. Hprt encodes a transferase enzyme that is
ubiquitously but not highly expressed, and is involved in the
salvage pathway that generates purine nucleotides [33].
Rps12 produces the ribosomal subunit 40S, and was identi-
fied bymeta-analysis as one of the top fifteen novel candidate
reference genes in humans and mice [25]. Tbp encodes a
transcription factor that binds to the TATA box, and is a
component of the pre-initiation transcription complex for all
three RNA polymerases [34]. Gapdh and Hprt were previ-
ously used [35, 36] as individual reference genes and thus
were included as study controls. Actb was included out of
curiosity since, despite the fact that it was previously deter-
mined to be unsuitable for C2C12 differentiation studies [37,
38], many studies still incorporate it as a normalization
control. For H9c2 differentiation, we chose to assess the
suitability of Gapdh and Rps12 transcripts (Table 1). Gapdh
was chosen since it has been routinely used for rat expression
studies, but we found no prior publication validating its use
as a reference gene for H9c2 differentiation studies. Rps12
was chosen as a second candidate gene for validation
because in humans andmice itwas identified as one of the top
potential reference genes [25]. Following our examination of
reference gene expression, we used the geometric mean for
normalization of Myogenin levels.
Materials and Methods
Cell Culture and Differentiation
C2C12 murine myoblasts (a gift from Dr. Celine Boudreau-
Larivie`re) were grown in Growth Medium (GM) containing
Dulbecco’s Modified Eagle’s Medium (DMEM)-High Glu-
cose (Life Technologies, Burlington, ON, USA) supple-
mented with 10 % Fetal Bovine Serum (FBS) (Life
Technologies) and 1 % antibiotic–antimycotic (Life Tech-
nologies). Differentiation was induced, at 80 % confluence,
by replacing the GM with differentiation medium (DM)
330 Mol Biotechnol (2014) 56:329–339
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containing DMEM-High Glucose supplemented with 2 %
horse serum (Life Technologies) and 1 % antibiotic–anti-
mycotic. Day 0 (D0) indicates the day on which the cells
were switched fromGM toDM.H9c2 rat myoblasts (ATCC-
CRL1446) were grown in DMEM-High Glucose supple-
mented with 10 % FBS (GM) and skeletal differentiation
was induced at 80 % confluence by switching GM to
DMEM-High Glucose containing 1 % FBS (DM). C2C12
and H9c2 cells were incubated at 37 !C with 5 % CO2, and
the medium was replaced every two days. Adherent cells
were harvested using 2.5 % trypsin (Life Technologies).
Trypsin was inactivated using GM; the cells were centri-
fuged at 16 200 9 g, and then stored at -80 !C.
Immunofluorescence and Confocal Laser Scanning
Microscopy (LSM)
C2C12 and H9c2 cells were grown on coverslips (VWR
International LLC, Radnor, PA, USA). Differentiation was
induced with the respective conditions and coverslips were
collected on D0, D4 and D7. The cells were fixed with 4 %
paraformaldehyde and permeabilized using 0.5 % Triton
X-100. 5 % goat serum was used for blocking. Immuno-
fluorescence was performed with a 1:100 dilution of Myo-
sin Heavy Chain (MHC) mAb MF20-b (Developmental
Studies Hybridoma Bank, Iowa City, IA) and probed with
AlexaFluor 488 anti-mouse IgG secondary antibody (1: 200
dilution) (Molecular Probes, Life Technologies). The
nucleus was stained with DRAQ5 (1:1 000 dilution) (Bio-
status Ltd, Leicestershire, UK). Confocal pictures were
taken on a Zeiss LSM 510 Meta confocal microscope using
the same settings for D0, D4 and D7 (excitation at 633 nm
for DRAQ5, 488 nm for Mf-20 and 543 nm for Phalloidin).
RNA Extraction and Reverse-Transcription (RT)
Total RNA was extracted from 80 % confluent cells grown
in 10-cm plates using 1 ml Tri Reagent Solution (Molec-
ular Research Centre Inc., Cincinnati, OH, USA), quanti-
fied using the Nano Drop 2 000 spectrophotometer
(Thermo Scientific, Wilmington, DE, USA) and the
integrity checked by electrophoresing through a 1 % aga-
rose gel (Supplementary Figs. 1S, 2S). For C2C12 cells,
we treated with DNase (Ambion", Life Technologies Inc.)
20 lg of RNA in a 50-ll total volume, according to the
manufacturer’s instructions, then reverse-transcribed 2 lg
of the DNase-treated RNA using 500 ng OligoDT (Alpha
DNA, Montreal, QC, USA), 10 mM dNTPs (New England
Biolabs, Whitby, ON), 5X First Strand Buffer, 0.1 mM
DTT and 200 U Moloney Murine leukemia virus (MMLV)
reverse transcriptase (Life Technologies) in a 40-ll reac-
tion volume. cDNA was generated by denaturing the RNA
at 65 !C for 5 min, reverse transcribing the RNA into
cDNA for 2 min at 37 !C followed by 50 min at 37 !C,
then terminating the transcription reaction at 70 !C for
10 min. In the case of H9c2 cells, only those time courses
that showed genomic DNA contamination were DNase-
treated. For H9c2 cells, 1 lg of RNA was used in a 20-ll
reaction volume with the above-described RT conditions.
For C2C12 and H9c2 cells, RT negative controls (cDNA
synthesis without the addition of MMLV-RT enzyme) were
also included to confirm the absence of genomic DNA
contamination or the presence of pseudogenes.
End-Point PCR
C2C12 and H9c2 cDNA synthesis and genomic DNA con-
tamination were verified using end-point PCR (Supplemen-
tary Figs. 3S, 4S). For C2C12 cells, we used Gapdh Forward:
50-AACACAGTCCATGCCATCAC-30 and Gapdh Reverse:
50-TCCACCACCCTGTTGCTGTA-30. The PCR reaction
consisted of 100 ng of cDNA template, 0.2 mM dNTPs,
200 nm of forward and reverse oligos (Alpha DNA), 1.25 U
Taq DNA polymerase and 10x reaction buffer in a 50-ll
volume. The template was denatured for 5 min at 95 !C,
amplified with 26 cycles of 95 !C for 30 s, 58 !C for 30 s and
72 !C for 1 min, and extended at 72 !C for 10 min. A 452-bp
amplicon was visualized in a 1 % agarose gel stained with
SYBR" safe DNA gel stain (Life Technologies). For H9c2
cells, we used Actin Forward: 50 TGAGCGCAAGT
ACTCTGTGTGGAT 30 and Reverse: 50 TAGAAGCATT
TGCGGTGCACGATG 30. The PCR reaction consisted of
50 ng of cDNA template, 0.67 mM dNTPs, 0.67 lM of for-
ward and reverse oligos (Alpha DNA), 1 U Taq DNA poly-
merase and 10x reaction buffer in a 15-ll volume. The PCR
conditionswere 95 !C for 10 min, 40 cycles at 95 !C for 30 s,
62 !C for 30 s and 72 !C for 45 s, and an extension at 72 !C
for 10 min. A 129-bp amplicon was visualized in a 2 %
agarose gel stained with SYBR" safe DNA gel stain.
Real-Time Quantitative PCR (qPCR)
Expression levels of Actb, Gapdh, Hprt, Rps12 and Tbp
were determined using qPCR with the primers (Alpha
DNA) listed in Table 1. In silico specificity of these primers
was determined using the NCBI Blast tool and the primers
were confirmed to have 100 % specificity to either the gene
for which it was generated or pseudogenes (which were not
amplified due to DNase treatment [26]). qPCR was carried
out using 12.5 ll of iTaqTM SYBR" Green Super Mix with
ROX (Bio-Rad, Mississauga, ON), 300–400 nM of forward
and reverse oligos and 11 ng (H9c2) and 21 ng (C2C12)
cDNA template in a 25-ll reaction and an ABI Prism 7900T
Thermocycler (Applied Biosystems, Life Technologies
Inc.). For C2C12 cells, four independent differentiation
time courses (D0–D7) with varying numbers of technical
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replicates (n of 2–7) were analyzed. For H9c2 cells, three
independent differentiation time courses with 3 technical
replicates were analyzed. The qPCR conditions were;
denaturation at 95 !C for 3 min, followed by 40 cycles of
95 !C for 30 s and a primer-dependent temperature for
annealing (see Table 1) for 60 s. For H9c2 samples, the
annealing was carried out for 30 s, followed by a 15 s
extension at 72 !C. The annealing temperatures were opti-
mized using gradient end-point PCR performed on pooled
cDNA templates. A melt-curve (dissociation profile), with
data acquisition at 95 !C for 15 s, 60 !C for 15 s and 95 !C
for 15 s, was used to experimentally confirm primer spec-
ificity (Supplementary Figs. 5S, 6S). Standard curves were
generated, using dilutions of the pooled cDNA samples
throughout differentiation (Supplementary Figs. 7S, 8S).
The coefficient of determination (R2) of the standard curves,
used to determine if the Cq of the dilutions are a proper fit to
the standard curve, showed that all were in the range of
0.98–0.99 (Supplementary Figs. 9S, 10S). Reaction effi-
ciencies, calculated from the standard curve slope, were in
the range 1.69–2.26.
Statistical Analysis
RNA expression levels were quantified using the relative
quantification method because of the differing qPCR effi-
ciencies amongst all transcripts [39, 40] using ABI
software (SDS 2.4) based on the formula log 10^[(Cq
(sample)-y intercept)/(-slope)], where Cq is the cycle
threshold value (previously termed Ct value, but now more
accurately referred to as the Cq value) and the y intercept
and slope values are derived from the standard curve [41].
Data analysis was carried out using Microsoft Excel and
Graph Pad Prism". The relative fold-change in reference
gene RNA expression for the time (day) in DM was cal-
culated from the quantity normalized to the reference gene
RNA expression level on day 0. Inter-quartile range (IQR)
analysis was used to identify outliers. IQR was calculated
from the 25th (q1) and 75th (q3) percentile values. Values
with a fold-change[ q3 and\ q1 were considered as
outliers and were eliminated from the analysis.
One-way ANOVA was used to determine if differentia-
tion induced statistically significant changes in the expres-
sion levels of the reference genes. A P\ 0.05 represented a
statistically significant change in expression. Pearson
Table 1 qPCR parameters for 5 candidate reference genes
Gene PubMed ID Function Primer sequence [50 to 30] Annealing
temperature (!C)
Amplicon
length (bp)
Mouse
Actb NM_007393.3 Cytoskeletal protein F: TCCTGACCCTGAAGTACCCCAT 61 131
R: CTCGGTGAGCAGCACAGGGT
Gapdh NM_008084.2 Metabolic enzyme F: ATGTTTGTGATGGGTGTGAA 50 122
R: ATGCCAAAGTTGTCATGGAT
Hprt NM_013556 Enzyme F: ATGGACTGATTATGGACAGGACTG 60 124
R: TCCAGCAGGTCAGCAAAGAAC
Rps12 NM_011295.6 Ribosomal protein F: AAGGCATAGCTGCTGGAGGTGTAA 60 156
R: AGTTGGATGCGAGCACACACAGAT
Tbp NM_013684.3 Transcription factor F: TGCACAGGAGCCAAGAGTGAA 60 132
R: CACATCACAGCTCCCCACCA
Myogenin NM_031189.2 Myogenesis marker F: CAGGAGATCATTTGCTCG 50 122
R: GGGCATGGTTTCGTCTGG
Rat
Gapdh BC059110 Metabolic enzyme F: ATGTTTGTGATGGGTGTGAA 63 122
R: ATGCCAAAGTTGTCATGGAT
Rps12 M18547 Ribosomal protein F: TGAGCCCATGTATGTCAAGCTGGT 67 162
R: ACTACAACGCAACTGCAACCAACC
Myogenin NM_017115.2 Myogenesis marker F: CAACTGAGATTGTCTGCCAGGC 63 165
R: GTCTTATGTGAATGGACGGTGGG
Fig. 1 Confocal immunofluorescence pictures of differentiating
C2C12 and H9c2 cells. Mouse C2C12 (a) and rat H9c2 (b),
myoblasts on D0, differentiating myocytes on D4 and differentiated
myotubes on D7. The nuclei are stained with DRAQ5 (blue), MHC is
detected by Alexafluor-conjugated secondary antibody for the Mf-20
protein (green) and F-actin (showing the cell morphology) is stained
with phalloidin (red). H9c2 cells are also shown using phase contrast.
The mono-nucleated myoblasts on D0 proliferate, elongate and fuse
to become multi-nucleated myotubes by D7 differentiation. Scale bar
100 lm
c
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correlation analysis (r) was used to examine the relationship
between time in DM and reference gene expression changes,
and a two-tailed Student’s t test was used to determine the
level of statistical significance. NormFinder [21], which
determines the stability value based on the intra- and inter-
group variations was used to verify the results obtained from
the statistical analyses. It is a freeware available as an add-in
for Microsoft Excel. Relative expression fold-change values
were used in the analysis.
Results and Discussion
We set out to study gene expression changes during
myoblast differentiation. C2C12 and H9c2 cells were
induced to differentiate by serum withdrawal, resulting in
cell cycle arrest, cell fusion and formation of multinucle-
ated-myotubes. Many expression changes are associated
with this phenotypic change between D0 and D7 as shown
in Fig. 1a (C2C12) and Fig. 1b (H9c2). We ensured that
any change in expression levels was not a result of
decreased efficiency of RNA extraction in the more dif-
ferentiated myotubes, or differences in RNA integrity, by
visually assessing 28S, 18S and 5S RNA degradation using
gel electrophoresis (Supplementary Figs. 1S,2S).
Expression Levels of Candidate Reference Genes
in C2C12 Cells
Actb, Hprt, Gapdh, Rps12 and TbpmRNA expression at each
day of differentiationwas assessed using real-time qPCR. The
box plots in Fig. 2a show the fold-change in expression levels
over time, before and after outlier elimination. (All subsequent
calculations were minus outliers.) By grouping all the differ-
entiation data for a particular gene (Fig. 2a), we see that
expression of all the potential reference genes examined was
less than expression at D0, a phenomenon not attributable to
increased rRNA expression, which decreases during C2C12
differentiation [42].By examining the data according to ‘‘days
in DM’’ (Fig. 2b), we see that decreased expression occurred
for each of the genes by D3; however, expression levels of
Gapdh were closest to D0 and had a much smaller overall
distribution than the other transcripts examined (Fig. 2a, b),
thereby, demonstrating the least expression variability. Rel-
ative expression levels of all the five genes examined were of
the order Gapdh[Actb[Rps12[Hprt[Tbp (Supple-
mentary Fig. 9S).
Expression Levels of Candidate Reference Genes
in H9c2 Cells
During H9c2 skeletal myoblast differentiation, expression
levels of both Gapdh and Rps12 were close to D0 with no
significant variability during differentiation (Fig. 3). We
did not, therefore, evaluate additional reference genes in
H9c2 cells. Expression levels of Gapdh were higher than
those of Rps12 (Supplementary Fig. 10S).
Statistical Analyses
To determine if the observed changes in expression levels
during differentiation were significant (Supplementary
Table 1S), for each day of each time course for each gene,
a one-way analysis of variance (ANOVA) was performed
(Table 2). There was no significant change in expression of
Gapdh, Hprt and Tbp in C2C12 cells, or of Gapdh or Rps12
in H9c2 cells. To determine if a relationship existed
between expression level changes and the length of time in
DM, a Pearson correlation analysis was carried out
(Table 2). In C2C12 cells, Gapdh was the only gene
examined that did not demonstrate a significant correlation
(p = 0.0908, r2 = 0.4030) between expression changes
and days in DM. Combined with the ANOVA analysis,
these results suggest that Actb and Rps12 are unsuitable
individual normalization controls for C2C12 differentiation
studies using our parameters. Though a significant Pear-
son’s correlation was observed for Hprt and Tbp, demon-
strating a relationship between expression levels and the
length of time in DM, the actual change in expression
levels during differentiation was not significant (as deter-
mined by ANOVA), suggesting that Hprt and Tbp
expression is stable during C2C12 differentiation, using
our parameters. In H9c2 cells, no significant change in
expression levels or significant correlations between
expression levels and days in DM were observed for either
Gapdh or Rps12.
Identification of Ideal Reference Genes Using
NormFinder
We used NormFinder software to verify the results
obtained by one-way ANOVA and Pearson’s correlation
analysis. NormFinder ranks the genes using a model-based
approach, the lowest stability value indicating the most
stable gene expression. NormFinder calculates this stability
value using quantified gene expression values and not
simply raw Cq values, as other software programs. This is
important in our study since, as mentioned, certain primer
pairs had lower efficiencies than others (this is taken into
account when quantifying gene expression, but not when
using raw Cq values).
In C2C12 cells, Hprt had the lowest stability value
(0.069) which indicated that its transcript was the most
stable (had the least variable expression) of the five candi-
date reference genes (Fig. 4a). Gapdh (0.142) was the next
most stable, followed by Tbp (0.158), Rps12 (0.196) and
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Actb (0.208). These NormFinder results were consistent
with the results obtained from one-way ANOVA analysis in
that they demonstrated Rps12 and Actb were the least stable
transcripts (most variable). We also examined the stability
values of various groupings of reference genes using the
geometric mean because the geometric mean of multiple
reference genes is another possibility for test gene expres-
sion normalization. Actb/Hprt/Gapdh/Rps12/Tbp, Actb/
Gapdh/Hprt/Rps12, Actb/Gapdh/Rps12/Tbp, Actb/Gapdh/
Hprt/Tbp, Actb/Hprt/Rps12/Tbp, Gapdh/Hprt/Rps12/Tbp,
Gapdh/Hprt/Rps12, Actb/Hprt and Gapdh/Rps12 had lower
stability values (\0.05) than all individual gene stability
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Fig. 2 qPCR expression profiles of five candidate reference genes in
differentiating C2C12 cells. (a) Box plots showing distribution of the
data before and after elimination of outliers. Whiskers represent the
minimum and maximum fold-change values. (b) Individual gene
expression profiles showing the fold-change in expression as
compared to D0. Error bars represent ± SEM from four biological
replicates. Data points are mean values plotted after removal of
outliers
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values (Fig. 4a, b), suggesting that multiple reference genes
are the preferred method for normalizing test gene expres-
sion levels during C2C12 differentiation.
In H9c2 cells, the stability values for Gapdh (0.131) and
Rps12 (0.131) were higher than the geometric mean of both
these genes (0.046) (Fig. 4c), suggesting that the geometric
mean is more suitable than the absolute expression level of
either individual gene as a reference for test gene expres-
sion studies during differentiation.
Verification of the Suitability of the Chosen Reference
Genes
To verify that the selected reference genes (based on
NormFinder analysis) were suitable myoblast differentia-
tion normalization controls, we used them to analyze
expression of the myogenesis marker Myogenin during both
C2C12 and H9c2 differentiation [43]. In C2C12 cells, using
the geometric mean of the expression levels of all five
selected reference genes (the most stable combination), only
Actb/Gapdh/Hprt/Rps12 (the next most stable combination)
or Gapdh/Hprt/Rps12, the fold-change in Myogenin mRNA
expression was assessed, relative to Actb and Hprt (Fig. 5a).
We observed that the geometric mean of five, four and three
genes showed a gradual increase of Myogenin levels to D3,
with a similar expression trend from D3 to D7, as previously
reported by qPCR [44], RT-PCR [45] and Northern blot
[46]. When Actb, the most variable of the five transcripts
examined, was used as a reference gene we observed a dif-
ferent expression profile, with a four-fold greater increase on
D1. Therefore, the geometric mean of the three reference
genes Gapdh/Hprt/Rps12 was a reasonable normalization
factor for Myogenin mRNA expression analysis in differ-
entiating C2C12 cells. In H9c2 cells, using the geometric
mean of Gapdh/Rps12 (Fig 5b), the induction and expres-
sion of Myogenin during differentiation was similar to that
during C2C12 differentiation, suggesting that the geometric
mean of these two transcripts is a suitable normalization
factor for test gene expression analysis during H9c2
differentiation.
General Discussion of Results
The tremendous benefits provided by real-time qPCR
technology for gene expression analysis in myogenic
studies have been hampered by a serious lack of standards,
making data interpretation a monumental task. Standards
relating to data dissemination, including ambiguity in ter-
minologies and experimental procedures, were addressed
by the Minimal Information for publication of qPCR
Experiments (MIQE) guidelines [47]. Standards relating to
data collection, inherent in the experimental protocol,
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Fig. 3 qPCR expression profiles of two candidate reference genes in differentiating H9c2 cells. Individual gene expression profiles showing the
fold-change in expression compared to D0. Error bars represent ± SEM from three biological replicates
Table 2 Results of statistical analyses
Tests performed C2C12 H9c2
Actb Gapdh Hprt Rps12 Tbp Gapdh Rps12
One-way ANOVA 0.022* 0.557 0.1756 0.0001*** 0.1 0.4984 0.1634
Pearson correlation (r) -0.9011 -0.6348 -0.9564 -0.9555 -0.9118 0.3160 -0.5831
p value (two-tailed) 0.0022** 0.0908 0.0002*** 0.0002*** 0.0016* 0.4457 0.1292
Pearson coefficient of determination (r2) 0.8120 0.4030 0.9147 0.9130 0.8314 0.0998 0.3400
Significance: * p\ 0.05; ** p\ 0.01; *** p\ 0.001
Pearson’s correlation values closer to ?1 or -1 indicate strong correlation
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remain to be addressed. This gap in data collection,
accounted for mostly by incorrect normalization strategies,
results in inaccurate quantification and interpretation of
results. We have attempted to address the normalization
issue in two commonly used in vitro models of differen-
tiation and disease, C2C12 and H9c2 myoblasts.
Myoblast differentiation, most notably in C2C12 cells,
is induced by different labs using a range of conditions. We
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grew the C2C12 myoblasts in 10 % fetal bovine serum,
induced differentiation using 2 % horse serum and exam-
ined expression over 7 days. Other labs may vary the
percentage of serum in the GM and/or DM, the serum
species in the DM and the number of days over which
expression is analyzed [8, 48, 49]. It should be noted,
therefore, that our results may not apply to all C2C12
differentiation protocols. Our results do support previous
reports, however, showing that Actb expression decreases
[37, 38] and Gapdh expression remains unchanged during
C2C12 differentiation [37]. No previous reports have
examined the suitability of the geometric mean of the gene
combinations presented in this study as normalization
controls during C2C12 differentiation. For H9c2 differen-
tiation, the most commonly used reference gene is Gapdh
[8, 48, 50]; however, we could find no reference to its
validation as such. Thus, to our knowledge, this is the first
assessment of either Gapdh or Rps12 as a reference gene
for H9c2 differentiation expression studies.
In summary, over seven days of C2C12 differentiation
(from10 %FBS to 2 %HS) andH9c2 skeletal differentiation
(from10 %FBS to 1 %FBS), our statistical andNormFinder
analyses confirmed that a normalization factor obtained from
the geometric averaging of multiple reference genes had the
least expression level variability and was, therefore, the most
suitable normalization control. The normalization data for
C2C12 cells demonstrate that particular combinations of
appropriate reference genes (as demonstrated in Fig. 4b) are
more important than the number of reference genes used. This
highlights the importance of using software programs like
NormFinder, which allow accurate identification of the best
combination of reference genes for a given system. There-
fore, determination of the optimal normalization factor
remains an important aspect of any expression study.
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Figure 1S. Visualization of total RNA extracted from differentiating C2C12 cells (D0 to D7) following 
agarose gel electrophoresis. RNA samples from 4 biological replicates (A),  (B), (C) and (D) from day 0 to 
day 7 visualized in a 1% agarose gel stained with SYBR® safe DNA gel stain. M: 1kb ladder (NEB) 
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Figure 2S. Visualization of total RNA extracted from differentiating H9c2 cells (D0 to D7) 
following agarose gel electrophoresis. RNA samples from 3 biological replicates (A), (B) and (C) 
from day 0 to day 7 visualized in a 1% agarose gel stained with SYBR® safe DNA gel stain. M: 
1kb DNA ladder (NEB) 
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Figure 3S. End-point PCR for Gapdh in C2C12 cells. A) A 452 bp amplified 
fragment from four biological replicates (I, II, III and IV), visualized in a 1% 
agarose gel stained with SYBR® safe DNA gel stain. In case of genomic DNA 
contamination, a 646 bp fragment would be expected. B) Results of +RT enzyme 
and -RT enzyme of day 0 and day 5 samples from biological replicate IV. M: 100 
bp DNA ladder (Life Technologies). NTC: No template control. 
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Figure4S. Actin amplification for genomic DNA contamination verification in H9c2 cells. RNA 
samples from three biological replicates were used to prepare cDNA with and without the addition 
of MMLV-RT reverse transcriptase enzyme. Actin was then amplified from the samples and 
visualized in a 2% agarose gel stained with SYBR® safe DNA gel stain to verify that there was no 
genomic contamination in the RNA samples. A) Results of –RT enzyme cDNA from day 0 to 7 of 
skeletal differentiation for biological replicate 1. Positive control refers to cDNA reaction to which 
the RT enzyme was added. B) Results of –RT enzyme cDNA (I) and +RT enzyme cDNA (II) 
following actin amplification from day 0 to 7 of skeletal differentiation cDNA samples from 
biological replicate 2. C) Results of –RT enzyme cDNA (I) and +RT enzyme cDNA (II) following 
actin amplification from day 0 to 7 of skeletal differentiation cDNA samples from biological 
replicate 3. M: 100 bp DNA ladder (Life Technologies). NTC: No template control. 
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Figure 5S. Primer location, qPCR products and dissociation curve in C2C12 cells. A) The location of forward and 
reverse primer in relationship to exons for i) ActB, ii) Gapdh, iii) Hprt, iv) Rps12 and v) Tbp. B) qPCR products of (1) 
sample and (2) no template control (NTC) stained with SYBR® safe DNA gel stain and visualized in a 2% agarose gel. 
C) Dissociation curves of samples and NTC from one biological replicate showing the melt curve profile. 
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Figure 6S. Primer location, qPCR products and dissociation curve in H9c2 cells. A) The 
location of the forward and reverse primer in relationship to exons for i) Gapdh and ii) Rps12.  
B) qPCR products of (S) sample and (NTC) no template control stained with SYBR® safe DNA 
gel stain and visualized in a 2% agarose gel. C) Dissociation curves of samples and NTC from 
one biological replicate showing the melt curve profile. 
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Figure 7S. Amplification plot and standard curves in C2C12 cells. Amplification plot showing 
the Cq of the standard dilutions for A) ActB, B) Gapdh, C) Hprt, D) Rps12 and E) Tbp. Standard 
curves generated using different dilutions of the pooled cDNA, the Cq values are plotted on the Y-
axis and the logarithmic values of the quantity are plotted on the X-axis. 
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Figure 8S. Amplification plots and standard curves in H9c2 cells. Amplification 
plot showing the Cq of the standard dilutions for A) Gapdh, and B) Rps12. Standard 
curves generated using different dilutions of the pooled cDNA, the Cq values are 
plotted on the Y-axis and the logarithmic values of the quantity are plotted on the X-
axis. 
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Figure 9S. C2C12 qPCR standard curves. Standard curves generated using dilutions of the 
pooled cDNAs for Actb, Gapdh, Hprt, Rps12 and Tbp in C2C12 cells. Y axis represents the Cq 
value and the x axis represents the logarithmic values of the concentration of input cDNA. 
Error bars represent SEM from technical replicates (n=4). The equation indicates the slope, y 
intercept, R
2 
values and the efficiency of the qPCR reaction (E). E is calculated by the formula 
E= POWER (10,-(1/slope)). 
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Figure 10S. H9c2 qPCR standard curves. Standard curves generated using dilutions of the pooled 
cDNAs for Gapdh and Rps12 in H9c2 cells. Y axis represents the Cq value and the x axis represents 
the logarithmic values of the concentration of input cDNA. Error bars represent SEM from technical 
duplicates. The equation indicates the slope, y intercept, R
2 
values and the efficiency of the qPCR 
reaction (E). E is calculated by the formula E= POWER (10,-(1/slope)). 
Supplementary Table 1S. Inter- and intra- assay variations 
C2C12 
 
ActB  D1 D2 D3 D4 D5 D6 D7 
  Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
Biological 
Replicate 
1 1.556 ± 0.152 0.959 ± 0.067 0.937 ± 0.047 0.389 ± 0.035 0.318 ± 0.020 0.231 ± 0.022 0.322 ± 0.023 
2 0.741 ± 0.137 1.217 ± 0.110 0.465 ± 0.052 0.528 ± 0.189 0.630 ± 0.059 0.434 ± 0.108 0.244 ± 0.038 
3 
4 
0.374 ± 0.110 
2.173 ± 0.142 
0.506 ± 0.091 
1.298 ± 0.142 
0.461 ± 0.106 
1.090 ± 0.125 
0.365 ± 0.166 
1.012 ± 0.199 
0.749 ± 0.247 
0.687 ± 0.009 
0.619 ± 0.020 
0.417 ± 0.133 
0.695 ± 0.011 
0.682 ± 0.048 
Overall Average 1.211 ± 0.404 0.995 ± 0.178 0.739 ± 0.161 0.574 ± 0.150 0.689 ± 0.034 0.425 ± 0.079 0.486 ± 0.118 
 
 
Gapdh 
 D1 D2 D3 D4 D5 D6 D7 
  Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
Biological 
Replicate 
1 1.168 ± 0.126 0.953 ± 0.066 0.930 ± 0.081 0.621 ± 0.063 0.618 ± 0.078 0.656 ± 0.059 0.611 ± 0.081 
2 0.907 ± 0.033 1.586 ± 0.102 0.714 ± 0.095 1.284 ± 0.051 1.096 ± 0.079 0.839 ± 0.031 0.631 ± 0.043 
3 
4 
0.324 ± 0.016 
1.836 ± 0.016 
0.952 ± 0.054 
1.507 ± 0.060 
0.886 ± 0.004 
1.581 ± 0.062 
0.462 ± 
0.0006 
1.379 ± 0.087 
0.883 ± 0.064 
1.027 ± 0.004 
1.013 ± 0.073 
0.975 ± 0.080 
0.836 ± 0.034 
1.269 ± 0.251 
Overall Average 1.059 ± 0.313 1.248 ± 0.171 0.843 ± 0.066 0.936 ± 0.231 0.906 ± 0.105 0.871 ± 0.080 0.837 ± 0.152 
         
Hprt  D1 D2 D3 D4 D5 D6 D7 
  Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
Biological 
Replicate 
1 1.198 ± 0.329 0.904 ± 0.586 0.997 ± 0.217 0.972 ± 0.212 0.602 ± 0.139 0.657 ± 0.094 0.527 ± 0.101 
2 0.652 ± 0.208 0.547 ± 0.138 0.629 ± 0.123 0.591 ± 0.073 0.536 ± 0.117 0.744 ± 0.056 0.145 ± 0.007 
3 
4 
0.466 ± 0.080 
1.441 ± 0.053 
0.719 ± 0.079 
1.265 ± 0.046 
0.680 ± 0.087 
0.878 ± 0.157 
0.439 ± 0.105 
0.945 ± 0.050 
0.694 ± 0.250 
0.621 ± 0.053 
1.157 ± 0.279 
0.717 ± 0.047 
0.889 ± 0.261 
0.832 ± 0.060 
Overall Average 0.939 ± 0.228 0.859 ± 0.153 0.796 ± 0.085 0.737 ± 0.131 0.613 ± 0.032 0.706 ± 0.025 0.598 ± 0.170 
 
Rps12  D1 D2 D3 D4 D5 D6 D7 
  Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
Biological 
Replicate 
1 0.849 ± 0.092 0.655 ± 0.016 0.683 ± 0.018 0.655 ± 0.034 0.463 ± 0.017 0.436 ± 0.075 0.376 ± 0.033 
2 0.746 ± 0.003 0.593 ± 0.020 0.598 ± 0.000 0.588 ± 0.037 0.450 ± 0.001 0.463 ± 0.033 0.256 ± 0.003 
3 
4 
0.532 ± 0.013 
0.895 ± 0.046 
1.039 ± 0.029 
0.684 ± 0.024 
0.480 ± 0.014 
0.485 ± 0.006 
0.396 ± 0.006 
0.388 ± 0.011 
0.642 ± 0.006 
0.328 ± 0.009 
0.867 ± 
0.0321 
0.274 ± 0.003 
0.838 ± 0.060 
0.371 ± 0.011 
Overall Average 0.755 ± 0.081 0.644 ± 0.026 0.562 ± 0.048 0.507 ± 0.067 0.414 ± 0.042 0.392 ± 0.059 0.335 ± 0.039 
 
Tbp  D1 D2 D3 D4 D5 D6 D7 
  Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
Biological 
Replicate 
1 1.227 ± 0.162 0.926 ± 0.113 0.933 ± 0.081 0.829 ± 0.088 0.501 ± 0.013 0.542 ± 0.151 0.435 ± 0.024 
2 0.806 ± 0.213 0.546 ± 0.128 0.540 ± 0.198 0.464 ± 0.102 0.473 ± 0.131 0.762 ± 0.084 0.138 ± 0.008 
3 
4 
0.219 ± 0.026 
1.818 ± 
0.0007 
0.476 ± 0.022 
1.204 ± 0.198 
0.369 ± 0.027 
0.894 ± 0.041 
0.212 ± 0.015 
0.720 ± 0.047 
0.520 ± 0.024 
0.325 ± 0.013 
0.800 ± 0.036 
0.336 ± 0.032 
0.594 ± 0.094 
0.467 ± 0.013 
Overall Average 1.015 ± 0.338 0.799 ± 0.170 0.694 ± 0.138 0.565 ± 0.138 0.512 ± 0.012 0.621 ± 0.106 0.407 ± 0.047 
 
H9c2 
 
Rps12  D1 D2 D3 D4 D5 D6 D7 
  Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
Biological 
Replicate 
1 1.433 ± 0.226 1.532 ± 0.269 1.261 ± 0.109 0.721 ± 0.294 0.758 ± 0.092 1.446 ± 0.150 0.942 ± 0.148 
2 0.896 ± 0.072 1.259 ± 0.055 1.057 ± 0.073 1.000 ± 0.089 0.774 ± 0.081 0.863 ± 0.041 0.699 ± 0.048 
3 1.326 ± 0.116 0.928 ± 0.052 0.936 ± 0.101 0.843 ± 0.064 0.850 ± 0.079 0.059 ± 0.041 0.942 ± 0.088 
Overall Average 1.218 ± 0.164 1.240 ± 0.174 1.084 ± 0.095 0.855 ± 0.081 0.794 ± 0.029 1.056 ± 0.195 0.861 ± 0.081 
 
 
Gapdh  D1 D2 D3 D4 D5 D6 D7 
  Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
Biological 
Replicate 
1 2.137 ± 0.184 1.419 ± 0.156 1.660 ± 0.092 1.130 ± 0.066 0.634 ± 0.059 2.443 ± 0.183 1.229 ± 0.336 
2 0.765 ± 0.034 1.763 ± 0.055 2.013 ± 0.024 1.772 ± 0.353 1.787 ± 0.058 2.037 ± 0.038 1.272 ± 0.038 
3 1.777 ± 0.193 1.406 ± 0.133 1.122 ± 0.016 1.045 ± 0.073 1.482 ± 0.126 1.143 ± 0.120 1.487 ± 0.099 
Overall Average 1.560 ± 0.411 1.530 ± 0.117 1.598 ± 0.259 1.315 ± 0.229 1.301 ± 0.345 1.874 ± 0.384 1.329 ± 0.080 
 
